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Abstract
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2020

Targeting DNA has the advantage over proteins for cancer remediation because of the
fewer copies of the ligands required for the desired therapeutic effect. Traditionally, covalent
DNA binders like alkylating agents have been used to induce genetic instability through the
formation of DNA lesions and strand breaks, leading to cellular apoptosis. The primary
drawback of this treatment is the non-specific binding that affects both cancerous and noncancerous cells.
G-quadruplexes are the DNA secondary structures that are present in abundance near the
promoter regions of the oncogenes and are involved in the regulation of their activities. A ligandmediated stabilization of G-quadruplexes in the promoter regions and down-regulation of the
associated oncogenes have been validated. In contrast to alkylating agents, G-quadruplex ligands
induce genetic stabilization through non-covalent interactions. They can be designed to interact
specifically with G-quadruplex DNA over duplex DNA, which reduce side effects arising from
the off-targeting.
G-quadruplex ligands invariably have the large planar aromatic moiety to interact with Gquadruplexes through π- π stacking interactions. For determining the size effect of the aromatic
moiety on stabilization of G-quadruplexes, a series of ligands were synthesized by conjugating
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nucleobases or 1,10-phenanthroline with an aminoglycoside, neomycin. The resulting conjugates
increased the binding affinity synergistically and enabled us to study the effect of the stacking
moiety required for G-quadruplex stabilization. Nucleobase-neomycin conjugates did not show
stabilization stabilize of human telomeric G-quadruplex. 1,10-Phenanthroline-neomycin
conjugate (7b) on the other hand binds to human telomeric G-quadruplex with a Ka of
(8.92.4)×108 M-1 and inhibits telomerase activity at 1.56 µM probably through G-quadruplex
stabilization.
Moving forward, we further enlarged the aromatic moiety by tethering two 1,10phenantholine molecules together through a five-atom linker. The resulting molecule (2-Clipphen) was conjugated with various amino-containing side chains. 2-Clip-phen derivatives
showed at least 30 times weaker binding to duplex DNA over G-quadruplex DNA. In addition,
compounds showed a preference for the antiparallel G-quadruplex conformation over parallel
and hybrid G-quadruplex conformations, as shown in the CD spectroscopy studies. Ligands 11
and 13 induced the formation of an antiparallel G-quadruplex from random coils and stabilize it
to 60 oC (Tm) in a salt-free condition. Mass spectrometry study showed the formation of a twotetrad G-quadruplex with the 2-Clip-phen ligand. Docking study showed that the ligand interacts
most favorably with antiparallel G-quadruplex conformation, which is supported further by the
larger thermal stabilization effect on antiparallel G-quadruplex compared with other Gquadruplex conformations. Our study suggests that 2-Clip-phen can be used as a scaffold for
designing G-quadruplex binding ligands that preferentially bind to antiparallel G-quadruplexes,
which has never been reported before.
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CHAPTER 1: INTRODUCTION

1.1 Cancer Is a Genetic Disease
The central dogma of molecular biology1 (governs the flow of information in the cells.
The genetic code in the DNA is transcribed into the mRNA in the nucleus, which is then
transported into the cytoplasm, where it is translated into the polypeptides through the agency of
ribosomes. Therefore, the information originally stored in the genes (genetic code) is expressed
in the cells through the polypeptides/proteins.

Figure 1.1. The central dogma of molecular biology. Solid arrows present general transfers,
dotted and unfilled arrows represent special transfers.

Three decades ago, the prevalent belief was that some viruses were the source of cancer
in humans; however, Varmus and Bishop’s work2 proved that this phenomenon could only
account for nearly 20% of humans’ cancers. In 1982, evidence was found that single nucleotide
mutation in H-ras (GGC → GTC) leads to the incorporation of valine instead of glycine at the
12th position of p21 protein derived from T24 bladder carcinoma oncogene, resulting in the
conversion of this proto-oncogene to its virulent form3. Wigler and his co-workers published a
similar study on single-nucleotide mutations that lead to the conversion of N-ras proto-oncogene
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a year later4. These pioneering works suggested that changes in the DNA (mutations) could lead
to activation of the proto-oncogenes and inactivation of tumor suppressor genes (TSGs), factors
that might be involved in development of cancer.
1.2. Chemotherapy of the Cancer
Chemotherapy for cancer treatment dates back to the 1950s. The first generation of
chemotherapeutic agents is non-selective with severe side effects. For instance, nitrogen mustard
is recognized as a non-selective DNA alkylating agent and an antimetabolite and tubulin-binding
drug. In recent years, the main focus in this field is to develop targeted cancer therapy.
Understanding the genetic origin of cancer on a molecular level has paved the way for studying
biochemical pathways responsible for diseased states. Targeting these pathways leads to the
development of targeted cancer therapy, one of the most significant milestones achieved in
medical sciences. But this is not without caveats. These biochemical pathways are often
involved in signal transduction, causing drug resistance via activation of the alternative
pathways. In addition, mutations frequently occur in the proteins involved in these pathways,
which changes the binding site of the drug to proteins, making it ineffective. Therefore, there is
always a need for new alternative strategies to combat cancer. The following sections
summarize the different chemotherapy drugs and the problems associated with their use.
1.2.1. Alkylating Agents
Alkylating agents are one of the oldest classes of chemotherapy drugs for the treatment of
cancer. Their therapeutic effect was discovered serendipitously. During World War I and II, the
observations made on the men exposed to mustard gas showed extended depletion of lymph
nodes and bone marrow aplasia. In light of this observation, clinical studies with less toxic
mechlorethamine (Mustragen) showed its remarkable effectiveness against Hodgkin’s disease5.
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However, remissions were short and incomplete. This study is considered the dawn of modern
cancer chemotherapy. Further research for safer analogs led to the development of the less toxic
chlorambucil and cyclophosphamide activated in situ by liver enzymes.
The alkylating agents can be categorized into the following structural classes6 (Figure
1.2)
1. Nitrogen mustards (mechlorethamine (1), chlorambucil (2), and melphalan (3))
2. Oxaphosphorines mustards (cyclophosphamide (4) and ifosfamide (5))
3. Triazenes (dacarbazine (6) and temozolomide (7))
4. Nitrosoureas (N, N’-bis(2-chloroethyl)-N-nitrosourea (BCNU) (8) and N-methyl-Nnitrosourea (MNNG) (9))
5. Mitomycin (mitomycin C (10))
6. Platinum complexes (cisplatin (11), oxaliplatin (12), and satraplatin (13))
Alkylating agents exert their functions by producing DNA cross-links between or within
the DNA strands (except triazenes, which makes the DNA lesions, leading to strand breaks and
apoptosis).
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Figure 1.2. Different structural classes of alkylating agents.

The mechanism of action of mechlorethamine (nitrogen mustard) requires the generation
of a strongly electrophilic aziridium ion through anchimeric assistance, which is then attacked by
a weakly nucleophilic tertiary nitrogen on guanine bases (N-7). Two of such consecutive events
lead to interstrand cross-links of the DNA (Figure 1.3), resulting in cellular apoptosis.
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Figure 1.3. Mechanism of action of mechlorethamine (a nitrogen mustard).

1.2.2. Antimetabolites
In the 1950’s nutritional scientists observed that folic acid was essential for bone marrow
function. Sidney Farber7 used a folic acid antagonist (Methotrexate (14)) (Figure 1.4) to treat
leukemia in the children's medical center in Boston. The result showed temporary remission of
leukemia progression in children. In 1954, Elion and Hitchings8 carried out a series of
experiments on antimetabolites using bacterial models. They observed a synergistic effect of
antimetabolites targeting multiple biochemical pathways simultaneously, which ultimately led to
the development of 6-mercaptopurine (15) and 6-thioguanine (16) (Figure 1.4). These two
drugs were used to treat acute leukemia. In addition, they have been used for the treatment of
herpes viral infection and as immunosuppressive agents. In 1957, fluorinated analogs of
pyrimidines (e.g., 5-fluoro uracil (17) (Figure 1.4) and purines were synthesized and tested to
treat solid tumors. It achieved remarkable tumor suppression in mice models9. These two drugs
became an essential part of the combination of chemotherapy program10 in the late 1970s.
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Figure 1.4. Structural of the different classes of antimetabolites.

1.2.3. Tubulin Binding Drugs
The Discovery of the anticancer activity of plant alkaloids from Vinca rosea viz
Vinblastine, vincristine, vindesine, and vinorelbine was a breakthrough in cancer treatment11.
These alkaloids bind to the tubulin and inhibit the formation of spindle fibers (microtubules)
essential for cell division. Another drug in this class is Paclitaxel from the bark of the Pacific
yew tree Taxus brevifolia, which induces the multipolar division due to the formation of
additional spindle poles. Cell death occurs due to the missing one or more chromosome essential
for growth12.
1.2.4. Targeted Cancer Therapy
Mutations that cause the transformation of proto-oncogenes, disruptions of tumor
suppressor genes, and cell cycle regulatory pathways are crucial factors of cancer development;
therefore, targeting the biochemical pathway/target is a practical approach to suppression of
tumor progression or growth. This approach is different from the conventional non-selective
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cytotoxic chemotherapy treatment. Kinases are one of the largest family of proteins and most
sought after for anticancer drug development. These proteins are involved in important cell
signaling and signal transduction pathways. In the past two decades, the development of kinase
inhibitors as a targeted cancer therapy had an exponential growth. In 2017 there were 201 WHO
registered (INN) small molecule kinase entities13.
Tamoxifen, the first drug developed for targeted cancer therapy, is an anti-hormonal drug
that blocks an oestrogen receptor (OER) on the surface of the OER positive breast cancer cells
and thus controls the growth of cancer. FDA approved the first targeted small molecule kinase
inhibitor, Imatinib (nib = kinase inhibitors) in 2001 for Chronic myelogenous leukemia14. It
executes its functions by inhibiting tyrosine kinase. Tyrosine kinase is over-activated due to
interchromosomal exchange between chromosomes 9 and 22 to form a new shorter chromosome
22 (Philadelphia chromosome). The production of this fusion gene BCR-ABL1 (ABL =
Abelson, BCR = breakpoint cluster) is responsible for a defective protein that renders the
tyrosine kinase always on, causing the cells to divide uncontrollably.
Her2 (human epidermal growth factor receptor 2) proto-oncogene was discovered in
1984, located on chromosome 17, is overexpressed due to its amplification multiple copies15. It
encodes for a transmembrane tyrosine kinase receptor protein overexpressed in HER2 positive
breast cancers. The downstream signal transduction by this kinase leads to a cascade of events
for cell proliferation and inhibition of apoptosis. In 1998, FDA approved trastuzumab
(Herceptin), a humanized monoclonal antibody, to target and downregulate the HER2
overexpression (downregulate the intracellular tyrosine kinase)16. Even though the monoclonal
antibodies (recognizes only one antigen) were first developed in 1975 by the hybridoma method
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(murine origin), this was the first example of using the humanized monoclonal antibodies for
targeted cancer therapy.
In addition to these targeted therapies, other targets such as CAR-T (Chimeric Antigenic
Receptor) (CAR) T-Cell therapy, and immune checkpoint therapy (Nobel prize in 2018) have
attracted extensive research in recent years.
1.3. Side Effects and Challenges in Current Therapies
Conventional cytotoxic alkylating agents are non-selective in their mechanisms of action.
Because their primary target is the DNA, the rapidly dividing cells like bone marrow, hair
forming cells, gonads, intestinal mucosal lining cells, and lymphoid tissues, along with cancer
cells, are the most affected. Cytotoxic alkylating agents also tend to cause a high percentage of
single base-pair mutations in the treated cells. Hence, the dosing regimen of alkylating agents
must be tailored according to the patient response and recovery from the cytotoxic effect on the
bone marrow17.
Similarly, tubulin inhibitors are poised with hematological and neurological side effects
limiting their clinical use18. The side effects associated with antimetabolites are hematological,
including neutropenia, thrombocytopenia, myelosuppression, and mucositis19.
Even targeted therapies are not without side effects, which are not severe most of the
time. The side effects could result from the nature of the targeted pathway or the nature of the
ligand (monoclinal antibodies or small molecules kinase inhibitors). It is noteworthy that offtargeting to other isoforms of the receptor can produce serious side effects20.
Small molecule kinase inhibitors (tyrosine kinase inhibitors) are usually associated with
the skin rash problem. A positive correlation between the response to the treatment and
development of 2-4 grade skin rash has been observed in addition to the hepatotoxicity,
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proteinuria, Hemorrhage, ocular toxicity. Some of these toxicities are the result of primary target
interactions and while others are due to the off-targeting.
1.4. Resistance to the Drugs
1.4.1. Resistance to Conventional Therapies
Drug resistance is the major factor that affects the clinical applicability of the drug. The
resistance of the nitrogen-mustard class of alkylating agents includes two observations. 1)
Increased activity of the Glutathione S-transferases (GSTs) that neutralize alkylating agents via
substitution reactions. 2) Increased expression of the DNA repair enzymes and increased
detoxification of the intermediates.
In the case of oxazaphosphorines, there is an increased expression of aldehyde
dehydrogenase (ALDH1), which neutralizes the side product aldehydes and increases the activity
of the GST and levels of Glutathione (GSH). There is also increased activity of the O6alkylguanine alkyltransferase (AGT), which helps for the repair of damaged DNA.
The resistance of triazenes mainly results from the AGT over-activation leading to
dealkylation of a methyl group at the O6 of guanine.
The resistance to Mitomycin C is associated with its reduction to an inactive form by
two-electron reduction with DT-diaphorase (DTD) or Xanthine dehydrogenase. Additionally,
resistance to mitomycin C has been related to the overactivation of multidrug resistance-1
(MDR1) proteins.
The resistance to cisplatin comes from the overactivation of the enzyme involved in DNA
damage repair ERCC2. Cisplatin also reacts with other nucleophilic species in the blood
(albumin) and in the cytosol, such as glutathione and metallothionein. The resulting products are
actively effluxed out of the cells by glutathione-S-conjugate pumps6.
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The resistance of tubulin-binding drugs results from the overexpression of efflux pumps
such as P-glycoprotein and multidrug resistance-associated protein-1. These are ATP-dependent
family of proteins located in the cell membrane. Mutations in drug binding sites and changes in
tubulin isotypes are also responsible for observed drug resistance to tubulin-binding drugs18.
1.4.2. Resistance to Targeted Cancer Therapy
It includes 1). Resistance to the small molecule kinase inhibitors. 2) Resistance to the
monoclonal antibody (mAbs).
1). Resistance to kinase inhibitors in targeted therapy is primarily due to the mutation at
the active site. For example, Glivec, the first tyrosine kinase inhibitor for targeting
chimeric BCR-ABL1 protein-tyrosine kinase, loses its efficacy due to point mutations
at the ABL tyrosine kinase domain by replacing amino acid 315 threonine with
isoleucince21. Overexpression of multidrug resistance P-glycoproteins is also
responsible for the resistance to the drug observed22.
2). The resistance to mAbs can be divided into three categories23.
a). It can arise due to antibody incompatibility. Some people develop antibodies against
chimeric or murine origin antibodies. In some cases, the binding of the Fc site on
monoclonal antibodies to FcR (Fc receptor) on the killer T cells could be ineffective
due to polymorphism in the FcR (Fc receptor). This interaction is vital to recruiting
killer T cells to kill cancer cells.
b). It can be of tumor-related origins. The tumors may develop resistance after initial
exposure to the antibody. The blocked antigen sites with the antibody are
compensated by decreasing the concentration of the antigen or increasing the number
of pathways on the surface. Some tumors may induce mutation to create an additional
pathway that stops the desired outcome of the events triggered by antibody-antigen
combination. For instance, activation of BCL-2 gene in B cell non-Hodgkin’s
lymphoma stops the apoptotic pathway triggered by the antibody interaction.
Alternatively, drug resistance could result from the generation of mucin in response,
which may mask the potential binding site (epitope masking)24 on the cell surface.
Also, the conformational changes of the binding site (at tumor surface) due to
mutation may significantly reduce the efficacy.
c). It can result from the host-related factors. Drugs may behave differently in people of
different ethnicity. For example, Japanese people have a higher concentration of
circulating CD20 (cCD20). Because CD20 on the cell surface is the natural target of
Rutiximab, the higher concentration of cCD20 may significantly reduce the efficacy
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of mAbs-based drugs. Some ethnic groups can develop human anti-chimeric (HACA)
and human anti-mouse antibodies (HAMA) against therapeutic antibodies. The
development of personalized human mAbs has solved this problem to a significant
extent.
At the current stage, we are not able to target all disease-related biochemical pathways.
Many of the pathways still need further understanding. The combination of different therapies
can effectively sensitize cancer cells to chemotherapy. In addition, simultaneous administrating
drugs with different mechanisms of action increases the probability of remission significantly.10
Therefore, despite the cytotoxic and secondary mutagenic side effects of alkylating agents, they
are still used as popular chemotherapeutic agents against cancer.
There is always an urgent need for new compounds that can match the cytotoxicity of
alkylating agents and the benefits of targeted cancer therapy. In recent years, ligands that target
G-quadruplexes have attracted much attention. They can induce synthetic lethality in cancer
cells deficient in the repair enzymes25, and trigger genetic instability and apoptosis in cells26,27
with minimum toxic effects28. Additional benefits of targeting DNA G-quadruplexes over the
protein targets are described as follows29.
1). Not all the proteins are druggable, but their corresponding genes can be targeted.
2). Point mutations at the drug binding site may make the drug ineffective30 for the
treatment. Targeting at the gene level (promoter region) can circumvent this problem.
3). Targeting at the gene level is an efficient approach instead of targeting the
overexpressing oncogenic proteins. Fewer copies of the target mean less
concentration of the ligand needed.
4). DNA ligands can differentiate between protein and DNA targets. Most of them don’t
follow Lipinksi’s rule of five. DNA ligands can differentiate between the duplex
DNA and tetraplex DNA like G-quadruplex.
The next part of the introductory chapter summarizes the basics of G-quadruplexes and Gquadruplex binding ligands.
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1.5. G-quadruplexes
1.5.1. The Fundamentals of G-quadruplexes
G-quadruplexes are helical, non-canonical, dynamic, and polymorphic nucleic acid
structures. The basic unit of the G-quadruplexes is the G-tetrad, in which four guanine
molecules self-associate through the Hoogsteen hydrogen bonds31 and form a planar structure.
The formation of such a construction was revealed in x-ray diffraction of 5’-guanine
monophosphate (GMP) by Gellert et al in 1962. G-tetrads formed in nucleic acid strand(s) can
stack on top of each other to form a helical structure (G-quadruplex), stabilized through van der
Waals interactions32 (Figure 1.5)

Figure 1.5. Structure of G-tetrad (four strands are labeled in red) (left) and overlap of G-tetrads
due to π- π stacking interaction (right).

The cavity in the middle of G-tetrads is electron-rich, commonly occupied by monovalent
metal ions such as Na+ and K+ under physiological conditions. The interactions between four
oxygen atoms at the 6-position of guanine tetrads and metal ions are the key factor in the
stabilization of G-quadruplexes. Due to its larger ionic radius (1.33 Å), K+ is sandwiched
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between the two G-tetrads and octa-coordinates with the O6 of guanines in the two G-tetrads
(Figure 1.5). Na+ ions (ionic radius 0.95 Å) can move freely along the central cavity33. The
nature of the metal ion can affect the topology of G-quadruplex DNA. For instance, studies
showed that the human telomeric G-rich DNA sequence 5’-AGGG(TTAGGG)-3’ adopts a
hybrid conformation in K+and a basket-type antiparallel conformation in Na+34,35. Detailed
information on G-quadruplex topologies will be discussed in the following sections.
Topology of the G-quadruplexes. G-quadruplexes are highly polymorphic structures.
Typically, a DNA sequence containing more than four consecutive guanine tracks (three or more
guanines in each track) can adopt an ensemble of conformation in dynamic equilibrium with
each other36,37. G-quadruplexes are composed of stacked G-tetrads with negatively charged
phosphate backbones that delimit cavities called grooves. Depending on relative strand
orientations, G-quadruplexes can adopt parallel, antiparallel, and hybrid topologies. Gquadruplex strands can orient in four possible ways38,39. 1). All strands are oriented in the same
direction. 2). Three strands are oriented in one direction, and the fourth is in the opposite
direction. 3). Two neighboring strands are oriented in one direction, and the other two are
oriented in the opposite direction (AABB like arrangement). 4). Two neighboring strands are
oriented in opposite directions alternatively (ABAB like arrangement) (Figure 1.6). The strand
orientations are related to the glycosidic conformation of the guanines, which can be either syn
or anti (Figure 1.7). The relative orientations of the guanines in the three possible strand
orientation is given below in Table 1.141
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Figure 1.6. Four possible type of strand orientations in G-quadruplexes.

Figure 1.7. Syn and anti-glycosidic bond conformations of the guanine nuleoside40.

Table 1.1
The Relationship Between the Relative Strand Orientation and Allowed G-Tetrad Configuration.
Strand orientation
Allowed
G-tetrad Type
configuration
1.
All strands oriented in the same direction
anti . anti. anti . anti
Parallel
syn . syn . syn . syn
2.
Three strands are oriented in direction, and one
syn . anti . anti . anti
Hybrid
is in the opposite direction
anti . syn . syn . syn
(3+1)
3.
Two neighboring strands are oriented in one
syn . syn . anti . anti
Antiparallel
direction, and the other two are in another
direction
4.
Two neighboring strands are oriented in
syn . anti . syn . anti
Antiparallel
opposite directions
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The grooves (3 types) between strands can be narrow (n), wide (w), or medium,
depending on the directionality of the strands. A medium groove is formed between two parallel
strands with the same orientations of guanines (syn . syn or anti . anti ). A wide or narrow
groove is formed between two antiparallel strands with the opposite orientations of guanines (syn
. anti) (Figure 1.841 and 1.940).

Figure 1.8. The cartoon of 3+1 hybrid G4 showing the three types of grooves. The groove
dimensions are mentioned with red double-headed arrow41.

Figure 1.9. Syn and anti-glycosidic bond conformations of the guanine determine the groove
width of G-quadruplexes40.
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G-quadruplexes have three kinds of loops known as the lateral loop, diagonal loop, and
edge reversal loop (propeller loop). Loops have a remarkable effect on the stability of the Gquadruplexes42. Theoretically, a G-quadruplex can have three loops and three loop types, giving
rise to 27 possible loop combinations. The sequence and number of nucleotides in the loops can
affect the type of loop that can formed40. A propeller loop of a G-quadruplex with two or three
tetrads commonly contains a single nucleotide. A single-nucleotide loop is also possible as a
lateral loop, but it is not long enough to form a diagonal loop40 (Figure 1.10).

Figure 1.10. Common loop types in the G-quadruplexes.

The π-π base stacking interactions between G-tetrads play a major role in the stabilization
of the G-quadruplexes. A G-tetrad can overlap with the bottom tetrad in three common ways43
(Figure 1.11) based on the analysis of many G-quadruplexes in the Protein Data40.
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θtet

Figure 1.11. Different ways a G-tetrad can overlap with other G-tetrads. The blue lines are carved
along the C8-H8 bond. The angle between them is relative rotation angle rotation (θtet) from 5’ to
3’.

a). A partial 5/6 ring overlap is found in the Anti/Anti base step, in which the imidazole
ring of one guanine overlaps with the pyrimidine ring of the other guanine.
b). A 5-ring overlap is found in the Syn/Anti base step, in which the imidazole ring of
one guanine overlaps with the imidazole ring of the other guanine.
c). A partial 6-ring is found in the Anti/Syn base step, in which the pyrimidine of one
guanine overlaps with the pyrimidine of the other guanine.
Importance and relative abundance of G-quadruplexes in the genome. The presence
of G-quadruplexes in vitro led to the development of algorithms that can scan the genome for the
putative G-quadruplex (pG4) forming sequences. The algorithms developed can search for the
contiguous stretches of three or more guanines with intervening non-guanines such as GGG3+N1–
7GGG3+

N1–7GGG3+ N1–7GGG3+N1–7. A recent study predicted approximately ~700,000 pG4

sequences present in the human genome44 considering bulges and longer loop regions45 in the Gquadruplexes.
Studies have shown that the pG4 sequences are mostly concentrated near or in the
promoter regions of regulatory genes. These regions are involved in the signal transduction,
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proliferation, cell-cell signaling, growth factor activity, regulation of cell cycles involving other
than the normal housekeeping genes, and tumor suppressor genes46. The pG4 sequences are
typically located in the downstream (transcription starting site +500 base pairs) of the genes with
significant transcriptional activities (Figure 1.12). This phenomenon is conserved throughout
the animal kingdom29, implicating the evolutionary role of the G-quadruplexes in the regulation
of gene expression47,48.

Figure 1.12. Relative abundance of potential quadruplex forming sequences (PQS) in the human
genome near transcription start site29.

Evidence of the role of G-quadruplexes in regulating gene expression also came from the
following experimental data. The concentration of G-quadruplexes in cells is cell-cycle
dependent. The highest concentration of G-quadruplexes was found in the S phase during DNA
replication48. At the S-phase stage, DNA is relaxed from the super helical stress29 allowing for
winding into G-quadruplexes with a physiological concentration of K+. G-quadruplex specific
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helicases have also been discovered, which unfold G-quadruplexes during replication,
transcription, and translation to prevent genomic instability49. Mutations in G-quadruplex
specific helicases like BLM and WRN50 cause the loss of their biological functions, leading to
pathological conditions such as Bloom’s and Werner’s syndromes51. Further studies suggest
these diseases are related to precocious aging, significant DNA damage, and a high propensity
for cancer development. A recent finding of XPD and XPB G-quadruplex specific helicases also
link their role in assisting gene transcription52.
Telomeres structure and their function. The abundance of pG4 sequences in the
telomeric regions and their proximity to the promoter regions of the proto-oncogenes has sparked
considerable interest in G-quadruplexes as a novel class of targets for cancer remediation. The
DNA sequences in the telomeric regions contain the highest GC content and have been found to
fold into G-quadruplexes under physiological conditions as observed with G-quadruplex specific
antibodies44.
Human telomeres at the ends of chromosomes contain double-stranded 5’-AGGGTT
repeats (10-15 kb long) and a single-stranded overhang53 (50-500 nucleotides long) with the
same sequence repeat at the 3’-end. This sequence motif is conserved throughout the eukaryotes.
The 3’ G-rich overhang is folded into the duplex through strand invasion to form a structure
called T-loop54, where it binds to the complementary C-rich strand, displacing the G-rich strand
into a displacement loop (D loop). The size of T-loop varies from species to species, even from
cell to cell. The formation of the T-loop (Figure 1.13) protects the chromosome ends, which
would otherwise be recognized as double-strand breaks (DSBs) by DNA repair pathways. Tloop also prevents the chromosome ends from nonhomologous end-joining (NHEJ) and thus
maintain the chromosome integrity.
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The telomeric region and T-loop are stabilized by a shelterin complex comprising of six
proteins, which associate specifically with the telomeric 5’-TTAGGG repeats.

Figure 1.13. T-loop and its stabilization by shelterin complex55.

The proteins TRF1and TRF2 bind the duplex region of the telomere in a sequencespecific manner. Studies show that TRF2 can promote the formation of T-loop like structures in
telomeric DNA in vitro. POT1 recognizes the single-stranded overhang of TTAGGG repeats
and the D-loop in the T-loop structure. TRF1 and TRF2 are abundant in the telomeres and can
recruit other proteins to the telomeres. Rap1 is recruited to the telomeres by TRF2, but it does
not directly bind to telomere DNA. The TIN2 protein is the central component of the shelterin
complex, bridging TRF1, TRF2, and TPP1. It enables the complex to connect the components
that bind to the single-stranded and double-stranded DNA of telomeres. TPP1 bridges POT1 to
TIN2, which has one oligonucleotide/oligosaccharide-binding fold protein domain (OB) to
interact with the enzyme telomerase. POT1 has two OB folds with which it recognizes ssDNA
at the telomeres and helps maintain the length of the telomeres56. The shelterin complex at the
telomeres plays a central role in maintaining the genomic integrity56, telomere length
maintenance57, and replication regulation55.
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Under normal conditions, a cell loses a part of its DNA at the telomere during each
replication cycle. This is called the end replication problem:
End replication problem. It is an intrinsic property of DNA replication machinery.
DNA polymerase can only synthesize a DNA strand in the 5’ to 3’ direction. It requires a free
hydroxyl group at the 3’-end of the existing RNA or DNA fragment to add additional
nucleotides. DNA replication is semi-conservative. A daughter strand is synthesized on the
template (parent) strand during the replication. One strand known as the leading strand can be
synthesized continuously from 5’ to 3’ by the DNA polymerase. The other strand, known as the
lagging strand, cannot be replicated continuously. It uses RNA primers to initiate the synthesis
of Okazaki fragments (small 150-200 longs pieces of DNA). Later, these Okazaki fragments are
connected with a combined activity of DNA endonuclease and DNA ligase. Because of this
machinery, the lagging strand cannot be fully extended due to the lack of a template strand at the
3’-end of chromosome ends (3’ single-stranded overhang) (Figure 1.14). The loss of the
chromosome ends accumulates after each replication cycle. Such erosion of the telomere
eventually reaches a critical point that triggers DNA damage responses through the shelterin
complex, leading to cellular senescence and apoptosis58.
Germ cells and cancer cells use the same replication machinery, but they are involved in
literally unrestricted replication (immortality). How do they circumvent the end replication
problem associated with telomere shortening? It has been found that these cells overly activate
an enzyme called telomerase, a reverse transcriptase. Telomerase maintains the telomere length
by adding the TTAGGG repeats to the 3’ chromosome ends using its inherent RNA primer.
Telomerase is overexpressed in 85-90% of the cancer cells, and its presence is negligible in
somatic cells. This makes telomerase an attractive therapeutic target. In the early 1990s, it was
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found that the G-quadruplexes are not the substrate of the telomerase59. Therefore, the induction
and stabilization of G-quadruplex at the telomeric regions can inhibit the binding of telomerase
and prohibit its ability to maintain the telomere length. Ultimately, this could trigger cancer
cells’ programmed death60.
To successfully targeting telomeric G-quadruplexes, one needs to differentiate Gquadruplex and duplex DNA. Besides, as mentioned above, G-quadruplexes can adopt various
conformations depending on the DNA sequence and experimental conditions. Methods of
distinguishing G-quadruplexes with different conformations are ideal for potential therapeutic
applications. Using small molecules that specially bind to G-quadruplexes is a promising
approach to target G-quadruplexes. In the next section, I will discuss G-quadruplex binding
ligands and their crucial interactions and structural motifs.

Figure 1.14. An illustration of end replication problem.
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1.6. G-quadruplexes and Their Interactions With Small Molecules
G-quadruplexes are more prevalent than thought before in the gene promoters. Under
physiological conditions, the G-quadruplex sequences can fold into different conformations that
equilibrate between each other. How this interplay37 between different conformations leads to
the difference in gene expression is not fully understood. G-quadruplexes adopt different
topologies; however, there is one inherent similarity between different conformations - the
omnipresence of planar G-tetrads. The planarity of G-tetrads allows ligands with an extended
aromatic surface to stack, a key factor to consider when designing G-quadruplex binding ligands.
Small molecules that stack with G-tetrads increase the thermal stabilization of the G-quadruplex.
However, such a stacking mode often makes it difficult for molecules to bind selectively to Gquadruplexes with different topologies.
In the following sections, different G-quadruplexes and their specific ligands are
reviewed. Common G-quadruplexes with different conformations are shown in Table 1.2. Many
of them are found in the promoter regions of many oncogenes29. They are related to the
regulation of oncogene expression61. Most G-quadruplexes under physiological conditions adopt
parallel conformation except BCL-2, which adopts a hybrid conformation. HRAS1 Gquadruplex adopts antiparallel conformation.

Table 1.2
G-quadruplexes and Conformation Adopted by Them.
Sr. No
Gene/region
Conformation
1
c-MYC
Parallel
2
c-KIT 1
Parallel
3
c-KIT 2
Parallel
4
BCL-2
Hybrid
5
HRAS1
Antiparallel
6
htelo
Hybrid

PDB ID
1XAV
2O3M
2KYP
2F8U
2GKU

Reference
62
63
64
65,66
67,68
69
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1.7. Ligands Targeting Parallel Stranded G4
1.7.1. c-MYC G-quadruplex
The expression of c-MYC in cells is difficult to measure due to the short half-life of cMYC mRNA and low concentrations of c-MYC proteins. Additionally, c-MYC proteins have a
very short half-life in proliferating cells (~20 mins70), and the proteins readily undergo
ubiquitylation and degradation by proteases71. c-MYC proto-oncogene encodes a transcriptional
factor that activates or suppresses a number of other genes. c-MYC also interacts with thousands
of other genes72 through its protein controlling every aspect of cellular functions (Figure 1.15)70.

Figure 1.15. Genes whose expression is affected by overexpression of c-MYC70.

c-MYC is a master regulator for cell growth regulation, increased metabolism73, and
proliferation of cancer cells74. Overexpression of c-MYC gene is observed in nearly 80% of the
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solid tumors of breast, gastrointestinal, and ovarian cancer tumors, making it an attractive
therapeutic target for cancer remediation.
The transcription activity of c-MYC is controlled by multiple promoters such as P1 and
P2 as the predominant ones (Figure 1.16). Located at 142-115 bp upstream of the P1 promoter,
NHE III1 is a highly conserved and guanine-rich element, responsible for 80-95% c-MYC
transcription. The 27 mer G-rich sequence (pu27) is shown in figure 1.15, which contains five
consecutive runs of guanines (3 or more guanines in each run). The pu27 sequence can fold into
a G-quadruplex with a parallel conformation in K+ under physiological conditions75. DNA foot
printing61 and NMR62 showed that the G-quadruplex is composed of the 3’ II, III, IV, and V runs
of guanines in pu27 (Figure 1.16). The formation of this G-quadruplex in NHE III1 promotes
the downregulation of the c-MYC expression76 and has been correlated with antitumor activity.
The c-MYC G-quadruplex formed in vivo can be unwound by theNM23H2, a non-metastasis
family of protein. The resulting single-stranded DNA is stabilized by a nucleic acid-binding
protein (CNBP) and a CCHH zinc-type zinc finger to facilitate further transcription29.

Figure 1.16. Promoter structure of the c-myc gene with pu27 in the NHE III1 of promoter P136.
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Figure 1.17. NMR structure of the c-MYC G-quadruplex (PDB:1XAV).

Stabilization of the parallel G-quadruplex (Figure 1.17) formed in the NHE III1 can
prevent the NM23 from binding and unwinding of the G-quadruplex and thus silence the
expression of the c-MYC gene76. Over the years, several classes of G-quadruplex binding
ligands have been developed to interact with the c-MYC G-quadruplex.

Figure 1.18. TMPyP4 bound by end stacking mode to the c-MYC G-quadruplex (NMR solution
structure, PDB ID 2A5R77).

52
TMPyP4 (18) (Figure 1.18) consists of a planar porphyrin ring with 4-methyl substituted
cationic pyridinium rings as side chains. NMR studies showed that TMPyP4 end stacks on the
terminal G-tetrad of the c-MYC G-quadruplex78 and side chains interact with the loops79.
TMPyP4 has a moderate selectivity for intermolecular quadruplex80 over duplex DNA81,82. Its
binding affinity to G-quadruplex DNA is 0.25 ± 0.1 and 1.9 ± 0.2 µM for 3’ and 5’-tetrad of
23mer htelo human telomeric G-quadruplex83.
The strong binding of TMPyP4 to c-MYC G-quadruplex DNA comes from its shape
complementarity with the G-tetrad. Its large aromatic surface stacks with the G-tetrad via pi-pi
interactions. Four positive charges of TMPyP4 are responsible for its diminished selectivity for
G-quadruplex over duplex DNA. It has been demonstrated experimentally by Ruan et al 84 that a
TMPyP4 analog with only three positive charges has improved selectivity over duplex DNA.
Quindoline (19) derivatives have also been extensively studied for interactions with cMYC G-quadruplex DNA. Quindolines are derived from the parent compound cryptolepine (20)
(Figure 1.19). Cryptolepine is a natural product from Cryptolepis sanguinolenta and has been
used as a traditional Ghanian folk medicine for the treatment of a variety of ailments. It has also
been used as a vasodilator85 and antihyperglycemic medication86.

Figure 1.19. Cryptolepine (left) and Quindoline (right).
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Ou et al87 synthesized a series of quindoline derivatives to target c-MYC G-quadruplex
and its downregulation in vivo (Figure 1.20). The rationale of the design is to optimize the
electronic properties of quindoline. The electron density of the nitrogen at position 5 is increased
by adding an electron-donating substituent at position 11. Hence, the pKa values of the NH
group at the 5-position of quindoline derivatives indeed increase from 4.2 to ~8.288. Under
physiological conditions, this nitrogen could be readily protonated, enhancing its interaction with
the electron-rich center of the G-quadruplex. Compound 29 with an N-diethyl group as an end
moiety at position 11 showed a mild selectivity for parallel c-MYC G-quadruplex over a hybrid
G-quadruplex DNA as determined by competition dialysis assay. It stabilized c-MYC Gquadruplex (wild type Pu27 5µM) by over 25 oC at 5 µM concentration87.

Figure 1.20. 11-substituted Quindoline derivatives.

The G-tetrads at the 3’ and 5’ ends are different depending on their flanking bases89. The
effect of flanking bases on ligand binding was studied on a “truncated c-MYC G-quadruplex
sequence” (Pu22) using solution NMR spectroscopy (Figure 1.21). The DNA sequences used in
the study are shown below. Pu27 is the native sequence of c-MYC. TGA (-3, -2 and -1 to the
first guanine involved in G-tetrad formation, labeled in red) are the flanking bases at the 5’-end
of Pu22, and TAA (+1, +2, and +3 to the adjacent guanine) are the flanking bases at the 3’ end of
Pu22.
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Figure 1.21. Sequence of the wild type c-MYC DNA Pu27 and the truncated version Pu22.

Compound 29 forms a 2:1 ligand to G-quadruplex complex. Its binding to the 5’-end of
the c-MYC G-quadruplex leads to a dramatic rearrangement of the flanking bases (5’-TGA).
The adenine (-1A, A6) is recruited by Compound 29 to form a new plane at the top of 5’-Gtetrad, which is completely by wrapped a guanine residue (-2G, G5) (Figure 1.20). Binding of
the ligand at the 3’ end also showed the involvement of the flanking bases (5’-TAA). Compound
29 recruits the thymine base (+1T, T23) to form a new plane at the 3’ end of the G-quadruplex,
which is capped by the adenine residue (+2A, A24) (Figure 1.22).

Figure 1.22. The ribbon structure of compound 29 bound to the c-MYC G-quadruplex
(PDB:2L&V)(left) and c-MYC bound to the terminal G-tetrad at 5’-position (bottom-right) and
at the 3’end (top right) involving the flanking sequences.
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Compound 29 is protonated at pH 7 (pKa, ~8.3). NOE constrained MD calculations
showed the formation of hydrogen bonding between the O4 of thymine (T23) and the N-H of
Compound 29 (N1H) (Figure 1.23 (right)). The presence of hydrogen bonding interactions is
supported by the increased thermal stabilization of G-quadruplex at low salt concentrations. On
the other hand, binding at the 5’ end is not affected by the salt concentration as dramatically as
that at the 3’ end. The 5’-end is more hydrophobic; therefore, stacking interactions at this end
have more effect on the binding. Mutational analysis showed that guanine (G5) that form the
capping structure at the top of quindoline-i and adenine plane at the 5’ end is more critical for the
binding. The overlapping area at the 5’-end is larger than that at the 3’-end, also suggesting the
importance of hydrophobic stacking interactions (Figure 1.23).

Figure 1.23. Compound 29 overlapped at the 5’ G-tetrad and 3’G-tetrad of the c-MYC Gquadruplex.

To improve the binding selectivity of quindoline derivatives for c-MYC G-quadruplex,
Funke et al90 designed and synthesized phenyl-substituted indolo[3,2-b]quinolines. The
compound 31 (Figure 1.24) with a larger hydrophobic stacking area showed a remarkable
stabilization effect (ΔTm is over 35 oC) on c-MYC G-quadruplex. This compound also showed
an order of magnitude of selectivity for c-MYC G-quadruplex over human telomeric (htelo) G-
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quadruplex. The NMR titrations showed an increased preference for binding to the 5’ G-tetrad
than the 3’ G-tetrad. The better stacking interaction of 31 with the 5’ G-tetrad is believed to be
the driving force.90

Figure 1.24. Structure of 11-phenyl substituted indolo[3,2-b]quinoline (31).

Trisubstituted 11-piperazinylquindoline derivatives (Figure 1.25) were developed for
tight and selective binding to c-MYC G-quadruplex. These compounds contain three
substituents on the quindoline ring. As an example, incorporation of a N, N-dimethyl ethyl
linker at R1 in compound 32 increased its selectivity for c-MYC G-quadruplex over duplex DNA
and other parallel G-quadruplexes. Thermal denaturation monitored by CD showed more than
16.5 oC increase in the Tm of c-MYC G-quadruplex when incubating compound 32 and DNA
with a 1:1 molar ratio. Unfortunately, the ability to stabilize c-MYC G-quadruplex by these
trisubstituted derivatives is not correlated well with their antitumor activity against HCT-116
(colon) and Raji (Lymphoma) cell lines. A CA46 exon-specific test suggested that the
stabilization of c-MYC G-quadruplex is not the sole reason for the inhibition of cancer cell
growth by these derivatives91. It is noteworthy that the stabilization of DNA might not always
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have a positive correlation with the inhibition of c-MYC expression. Similar results were
observed with the famous G-quadruplex binding ligand Quarfloxin29.

Figure 1.25. The general structure of trisubstituted Quindoline derivatives (left) and compound 32
(right).

Ming-Hao Hu and his co-workers reported the development of tetrasubstituted ligands
with excellent binding affinity and selectivity over other parallel stranded G-quadruplexes such
as BCL-2, c-KIT 1, and KRAS. A representative compound IZCZ-3 (33), a 1-methylpiperazine
substituted diaryl imidazole and carbazole conjugate (Figure 1.26), was able to differentiate
between hybrid-type telomeric G-quadruplex DNA and antiparallel HRAS G-quadruplex DNA.

Figure 1.26. The structure of tetrasubstituted clover leaf-like molecule IZCZ-3 (33).
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The compound 33 inhibited cell growth and induced apoptosis by reducing the level of
mRNA and c-MYC proteins. The CA46 exon assay indicated that the observed biological effect
of the compound is correlated with its stabilization of c-MYC G-quadruplex91. This Gquadruplex interacting compound showed comparable activity (effectiveness) with no nonspecific toxicity as compared to the other non-specific DNA binding drug Doxorubicin92.
The binding modes of compound 33 with G-quadruplex were determined by docking
studies (Figure 1.27). Results suggested that compound 33 stacks closely onto the terminal Gtetrads of c-Myc G-quadruplex. The positively charged imidazole ring of compound 33 sits on
top of the central cavity of the G-tetrad and electrostatically interacts with it. The 1methylpiperazinyl side chain makes close contacts with the edgewise reversal loop. In addition,
the flanking bases of c-MYC G-quadruplex are intrinsically flexible, which accommodates a
better ligand fit. As a comparison, in the binding of this compound with htelo G-quadruplex, the
lateral loop of the G-quadruplex can hinder the close contact between the ligand and G-tetrad,
leading to the relatively higher binding energy. The docking data mentioned here can be used to
explain the better binding affinity and selectivity of this ligand towards c-MYC G-quadruplex.89
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Figure 1.27. Top view (upper panel) and side view (lower panel) of the binding models of
compound 33 with (A) the c-MYC G-quadruplex pu22 (PDB ID: 2L7V), (B) the c-KIT Gquadruplex c-KIT 1 (PDB ID: 4WO3), and (C) the telomeric G-quadruplex htg22 (PDB ID:
2MB3).

Other ligands with moderate affinities and relatively better selectivity to c-MYC Gquadruplex DNA include 11-triazole benzofuruquinoline93, bis-triazolylcarbazole94, some natural
products like Fonsecin B95, Berberine derivatives96 and metal complexes like Iridium (III)97 and
Platinum (II) complexes98 (Figure 1.28).
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Figure 1.28. Different classes of c-MYC G-quadruplex ligands.

1.7.2. c-KIT G-quadruplex
The c-KIT gene contains codes for a transmembrane protein product. This protein acts as
a tyrosine kinase receptor that helps to relay signals from the cell surface to the interior of the
cell. Binding of this c-KIT receptor with Stem cell factor (SCF) induces its dimerization and
promotes transphosphorylation. Transphosphorylation triggers a cascade of downstream
reactions affecting hematopoietic cellular differentiation, proliferation, and development.
Mutations in the c-KIT gene produce proteins that have defects in the juxtamembrane region and
kinase domain. Mutant proteins cause SCF independent autophosphorylation and support cell
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proliferation. An abnormal level of c-KIT expression is correlated with small cell lung
carcinona, melanoma, and more than 80% cases of gastrointestinal stromal tumors99 (GISTS). In
recent years, c-KIT pathways have become promising targets for cancer remediation. An FDA
approved drug, Imatinib14, has been used as an effective treatment against c-KIT positive GISTs
by inhibiting the tyrosine kinase activity of c-KIT.
Two potential G-quadruplex forming sequences Kit 1 and Kit 2 are present in the
promoter regions of the c-KIT gene. c-KIT 1 extends from -87 to -109 base pairs, and c-KIT 2
extends from -140 to -160 base pairs located upstream of the transcription initiation site. The
region containing c-KIT 2 was found to be a core regulatory element of transcription100.
Interestingly, this region is highly conserved in the human, rat, mouse, and chimpanzee.
c-KIT G-quadruplexes adopt a parallel G-quadruplex conformation under physiological
conditions63,101–103. The structure of c-KIT 1 G-quadruplex is unusual. A two-nucleotide lateral
loop snaps back another five nucleotide loop, forming a large pocket between the bottom Gtetrad and lateral loop (Figure 1.29, blue arrow)103. Solution NMR studies63 showed the
formation of base pairing between adenine-1 and thymine-12 at the top of 5’-G tetrad and a
Hoogsteen interaction between adenine and guanine in the five-nucleotide lateral loop. Such
interactions contribute to the stability of the c-KIT 1 G-quadruplex.
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Figure 1.29. NMR solution structure of c-KIT 1 (left) and c-KIT 2 solution structure (right).

The c-KIT 2 sequence also adopts a parallel topology containing two one-nucleotide
double chain reversal loops and one five-nucleotide double chain reversal loop. A non-canonical
base pairing between cytidine-1 and adenine-13 at the top of guanine-14/guanine-18G segment
of the 5’ G-tetrad was found.64
To search for specific ligands that bind to c-KIT G-quadruplexes, Rocca et al104 used a
computational method to screen a library of 462,045 molecules against two c-KIT Gquadruplexes (PDB ID: AWO2 and AWO3). All molecules were filtered following Lipinski’s
rule of five and selected for favorable ADME properties. Three compounds (Figure 1.30) were
chosen, all of which can bind to both c-KIT 1 and c-MYC G-quadruplexes. According to the
dock studies, these compounds are groove binders. Circular dichroism studies showed a modest
decrease of the absorption band at 265 nm with increasing ligand concentrations, indicating the
lack of π-π stacking interactions. The primary binding site of the ligands to c-KIT 1 Gquadruplex was in the cleft (Figure 1.29, blue arrow). According to the docking data, the
piperidine residue in all the best-fitted structures is oriented towards the negatively charged
phosphate backbone. Compound 36 forms a salt bridge between the G4 nucleobases and an
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adenine residue (A19). None of the compounds showed the ability to stabilize duplex DNA.
This study showed a new method to target c-KIT 1 by utilizing phosphate backbones bordering
the pocket (Figure 1.29. blue arrow). The ligands bound to the c-KIT 1 G-quadruplex are shown
in figure 1.31.

Figure 1.30. Structure of dual c-KIT and c-MYC binders.

A

B

C

Figure 1.31. Representations of the compounds (A) 34, (B) 35 and (C) 36 docked to c-KIT 1 Gquadruplex104.
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In a separate study, Zorzan et al105 screened an in-house library of compounds based on
five common DNA binding motifs: Anthraquinone (AQ), anthracene (AN), phenanthroline
(Phen), naphthalene diimide (NDI), and heterocyclic diamidines (HAD). Anthraquinone- and
anthracene-based ligands showed the best thermal stabilization and selectivity for the c-KIT 1
and c-KIT 2 G-quadruplex over telomeric G-quadruplex and duplex DNA. The FID assay
revealed three potential binding ligands (37-39), as shown in figure 1.32. Out of the three, AQ1
(37) was the most potent ligand that binds to c-KIT 1 and c-KIT 2 G-quadruplexes.

Table 1.3
FID G4DC50 and Kd Values of the Hits (37-39) Against c-KIT 1 and c-KIT 2.
FID G4DC50
Kd (µM)
Ligand
c-KIT 1
c-KIT 2
c-KIT 1
AQ1 (37)
0.32 ± 0.05
0.35 ± 0.05
1.99 ± 0.15
AQ7 (38)
0.24 ± 0.04
0.25 ± 0.02
3.04 ± 0.43
AN6 (39)
4.11 ± 0.70
3.63 ± 1.00
71.5 ± 20.1

c-KIT 2
1.01 ± 0.15
2.29 ± 0.28
25.5 ± 4.01

Compound 18 showed low cytotoxicity against c-KIT positive cell lines HGC27 (human
gastric carcinoma cell line) and MCF7 (Michigan cancer foundation-7, a breast cancer cell line)
even though it is a potent c-KIT G-quadruplex ligand based on the in vitro studies such as
polymerase stop assay.
Compound 39 did not affect the mRNA level in HGC27 cells but showed a weaker effect
in MCF7 cells. By contrast, Compound 17 reduced the c-KIT expression by 2 to 10 folds in
HGC27 cells and 37 folds in MCF7 cells. Compound 37 showed anti-proliferative activity
against imatinib-resistant cell lines (HMC1.2: Human mast cells), suggesting the potential of this
compound to be effective against any c-KIT mutation in the protein-coding region. The
cytotoxicity of compound 37 was much less against c-KIT deficient cells, implicating that 37
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interacts with the c-KIT G-quadruplex. It is noteworthy that 37 is the best G-quadruplex binding
ligand developed for downregulation of the c-KIT expression.

Figure 1.32. Structure of Anthraquinone derivatives AQ1 (37) (top left), AQ7 (38) (right) and
Anthracene derivative AN6 (39) (bottom). Lys = lysine.

All the ligands mentioned above have limited selectivity for c-KIT G-quadruplex over cMyc G-quadruplex DNA because they have parallel topologies. In fact, till today, many Gquadruplex binding ligands can effectively differentiate between G-quadruplex and duplex DNA
and distinguish G-quadruplexes with different conformations (parallel, antiparallel, and hybrid).
However, reports on targeting G-quadruplexes with parallel conformations (e.g., c-KIT Gquadruplex and c-Myc G-quadruplex DNA) are scarce. Bejugam et al 106 synthesized a series of
trisubstituted isoalloxazines derivatives for selective recognition of c-KIT G-quadruplex DNA.
Impressively, several compounds (Figure 1.33) were able to differentiate between the c-KIT 1
and c-KIT 2 parallel G-quadruplexes and a telomeric hybrid G-quadruplex DNA. Compound 40
was the most potent compound with a Kd value of 3 µM and 6.4 µM for c-KIT 2 and c-KIT 1,
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respectively. By contrast, the Kd values of compound 43 for c-KIT 2 and c-KIT 1 were 9.7 µM
and 31 µM, respectively. The Kd value of compound 40 binding to the hybrid telomeric Gquadruplex was 43 µM, and no meaningful Kd value of compound 43 for telomeric Gquadruplex could be detected. Compound 43 is the only ligand containing a fluorine atom at the
R2 and showed the most selective response against c-KIT 1 and 2 over the telomeric hybrid Gquadruplex. Results also suggested that extra cationic side chains can lead to non-specific
binding interactions, which may lead to loss of selectivity of ligand to different G-quadruplex
species107. Moreover, the presence of fluorine atom would increase the hydrophobicity of the
compound, which may interact better with non-polar G-tetrad better. More detailed binding
process can be investigated using rate of association and dissociation in SPR studies. It is
noteworthy that compound 43 showed the better downregulation of c-KIT expression (31 fold in
6h) in the MCF-7 cell lines.

Figure 1.33. Structures of isoalloxazine ligands 40-45.
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The same group also developed a new c-KIT G-quadruplex binding scaffold,
Benzo[a]phenoxazines108 (Figure 1.34). Both ligands showed greater affinities for c-KIT 2 over
c-KIT 1. In particular, compound 46 binds to c-KIT 2 9.5 times more selectively over c-KIT 1,
and compound 47 binds to c-KIT 2 7.5 times more selectively over c-KIT 1. Both compounds
bind to c-KIT G-quadruplexes more preferentially (about 2-5 times) than c-MYC and telomeric
G-quadruplexes. In addition, both compounds bind more selectively to G-quadruplexes than
duplex DNA. The Kd value of compound 46 binding to G-quadruplex is 10 fold higher than
duplex DNA, and the Kd value of compound 47 to G-quadruplex is more than 50 fold lower than
duplex DNA, as determined using surface plasma resonance (SPR).

Figure 1.34. Structure of benzo[a]phenoxazines ligand 46 (left) and 47 (right).

Other ligands that are developed for recognition of parallel c-KIT G-quadruplexes over
hybrid conformation of telomeric G-quadruplex include triarylpyridines derivatives109,
indolylmethyleneindanone derivatives110, oxazole peptide macrocycles111 shown in Figure 1.35.
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Figure 1.35. Scaffold of various other classes of ligands developed for c-KIT G-quadruplex.

1.8. Ligands Targeting Antiparallel G-quadruplex
1.8.1. HRAS/KRAS
The H-ras, N-ras, and K-ras were the first human oncogenes discovered more than three
decades ago, belonging to the members of the Ras GTPase family. They are crucial in relaying
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signals downstream from the tyrosine kinase membrane receptors to a cascade of parallel
phosphorylation reactions that culminate with nuclear transcription factors. This signal
transduction is involved in normal cell cycle progression, growth, proliferation, apoptosis, and
senescence. Mutations in ras genes have been associated with various developmental disorders
and cancer112. Ras oncogene mutations are primarily concentrated within 2 hot spots, codons
12,13 and codon 61, resulting in 1 in 19 possible point mutations for each RAS isoform113. Val,
ASP, CYS are the dominant mutant alleles of the K-ras gene. These mutations lock the protein
in the active conformation. Currently, the Sanger Center keeps and updates the nature and
frequency of ras mutations in human tumors. About 30% of all human tumors screened carry
some form of mutations in ras genes, and most of these mutations are detected in K-ras oncogene
(25-30% of all the tumors screened)114, along with its involvement in 95% of pancreatic tumors,
50% colon tumors, and 30% of lung adenocarcinomas112. The rates of oncogenic mutations in
N-ras and H-ras family members are much less prevalent (8% and 3% of samples screened,
respectively).
So far, RAS genes are undruggable at the protein level due to the tissue-specific nature of
the up/stream signal transduction pathways. Interestingly, HRAS gene has two G-rich sequences
HRAS1 (-434 to -462) and HRAS2 (-509 to -530) locate at the upstream of the transcription start
site of the HRAS68. HRAS1 was found to adopt an antiparallel conformation in solution68,115.
On the other hand, HRAS2 adopts parallel G-quadruplex conformation. Several classes of
compounds (Figure 1.36) have been developed to target HRAS G-quadruplexes.
Anthrathiophenedione-guanidino derivative (48, ATPD-1) (Figure 1.36) can bind to both
parallel and antiparallel HRAS G-quadruplexes and consequently downregulate the expression of
the gene68.

70
In another report, tetrakis-(diisopropyl-guanidine) phthalocyanine116 (49, DIGP) (Figure
1.36) was shown to stabilize the antiparallel HRAS1 G-quadruplex and strongly halt the
formation of full-length product in a polymerase stop assay. A similar preference for antiparallel
telomeric G-quadruplex was found for this class of compounds by the Balasubramanian group117.
Liu et al118 synthesized a series of para-substituted bis-(vinylquinolinium) benzene
derivatives (50) (Figure 1.36), some of which can increase the Tm of HRAS1 G-quadruplex by
more than 9.3 oC. However, the compounds showed low selectivity for HRAS1 over duplex
DNA (~factor of 2) and limited selectivity toward antiparallel G-quadruplexes. The lack of
selectivity might result from their linear shape, which can fit into the duplex grooves with a
slight twist of the molecules. On the other side, its preference for antiparallel G-quadruplexes
could result from the interactions with the lateral loop residues.
Other quinolinium-based ligands that can selectively bind to HRAS1 G-quadruplex over
hybrid and parallel G-quadruplexes include a fluorescent triphenylamine-quinolinium119 probe
(51) and a series of benzothiazole-substituted benzofuroquinolinium (52) compounds120 (Figure
1.36). These compounds also show good selectivity over dsDNA and ssDNA.
Different G-quadruplex topologies have different groove characteristics. So far, there are
not many ligands121 that can bind into the grooves of G-quadruplexes specifically. A carbazole
based G-quadruplex groove binding ligand (53) for HRAS1 antiparallel G-quadruplex was
developed122 (Figure 1.36). The lead compound showed 6 to 20 times selectivity over other Gquadruplex topologies.
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Figure 1.36. Classes of ligands that target HRAS1 antiparallel G-quadruplex.

1.9. Ligands Targeting Hybrid Conformation of G-quadruplex
1.9.1. BCL-2 G-quadruplex
The BCL-2 gene codes for mitochondrial membrane proteins that facilitate the
oncogenesis by avoiding programmed cell death. BCL-2 gene expression is often significantly
enhanced in pancreatic cancer in addition to the activation of other oncogenes 28, which has led
to inadequate responses to chemotherapy and drug resistance in the treatment of human
pancreatic cancers.
So far, three G-rich sequences upstream of the BCL-2 transcription site have been
identified45,65,66,123, which are Pu 32 [-1875 to -1906 base pairs from the transcription start site
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(TSS)], Pu39 (-1451 to -1489 base pairs upstream of the TSS) and P1G4 (-1412 to -1439 bp
upstream of the TSS) (Figure 1.37). Pu32 can adopt a hybrid G-quadruplex conformation as
observed from spectroscopic data. However, the detailed structural elucidation and its relevance
to BCL-2 biological functions have not been elucidated. Pu39 can adopt multiple conformations
of G-quadruplexes, depending on the sequence tracts used for the G-quadruplex formation. The
most stable G-quadruplex of Pu39, confirmed with DMS DNA footprinting and NMR studies, is
a parallel G-quadruplex conformation45, with an unconventional 13 nucleotide propeller loop. A
loop containing 13 nucleotides is unusual. Its discovery broadens our knowledge on Gquadruplex-folding in solution. Additionally, Pu39 can also adopt a hybrid conformation using
four G-tracts in the middle of the sequence with a 7-nucleotide lateral loop. The latter (PDB ID:
midG4)65 is the key conformation used for research on BCL-2 G-quadruplex. The guanine-rich
P1G4 sequence was recently discovered, which is located immediately above the BCL-2 P1
promoter. The P1G4 G-quadruplex shows a significant effect on the transcriptional regulation of
the BCL-2 gene. It adopts two hairpin-like G-quadruplex conformations with two edge reversal
loops comprising of 12 nucleotides and 11 nucleotides, respectively. Both G-quadruplexes
coexist in equilibrium under physiological conditions.
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Figure 1.37. G-quadruplexes in the promoter P1 of the BCL-2 gene. The guanines used in the
formation of G-quadruplex are underlined. The substitutions in the original loop sequence are
colored in blue.

Figure 1.38. Structure of Naphthalene diimide derivative MM4128.

A G-quadruplex binding agent MM41 (54) (Figure 1.38) has been used for
downregulating the activity of BCL-2 along with the KRAS gene. Thermal denaturation
monitored by fluorescence showed that 54 selectively stabilizes BCL-2 G-quadruplex and two
KRAS G-quadruplexes by more than 20 oC. Molecular dynamics simulations showed 54 stacks
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with the terminal G-tetrad through π-π interactions, and four side chains extend into the grooves.
Guanine-12 of the loop sits at the top of the ligand, forming a sandwich-like structure28 (Figure
1.39). 54 exhibits antitumor activity in the MIA PaCa-2 pancreatic cancer xenograft model.
Interestingly, it did not affect the telomerase activity (TRAP assay) and expression of the c-MYC
gene, suggesting that 54 has a limited stabilization effect on telomeric G-quadruplex and c-MYC
G-quadruplex.

Figure 1.39. A snapshot from MD simulations. Top view of the compound 54 docked onto the
terminal tetrad and interaction with G12 (left), Side chains of ligands interacting with the
grooves of the BCL-2 G-quadruplex28.

In another study, Quindoline (SYUIQ-0187 (55) and SYUIQ-F05124 (56)) and
cryptolepine derivatives (SYUIQ-FM05125 (57)) were used to downregulate the expression of
BCL-2 gene (Figure 1.40). The binding of BCL-2 G-quadruplexes by three compounds was
measured using SPR spectroscopy (Table 1.4). Results suggested that the rates of association of
the ligands to the G-quadruplex and duplex are roughly the same. But the rates of dissociation of
the ligands from the G-quadruplex and duplex are drastically different, especially for compounds
57 and 56. Hence, the low KD (kd /ka) values of these two ligands came from their relatively low
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rate of dissociation from the G-quadruplex. 57 is a more potent G-quadruplex binding ligand,
with an impressive kd value of 3.18 × 10−8 M-1. Due to similar molecular structures, the
hydrophobic interactions of compounds 56 and 57 with the BCL-2 G-quadruplex DNA is
roughly the same. The major difference is the quaternary nitrogen in compound 57. This
positively charged atom sits above the G-tetrad center and interacts with four oxygens (O6) of
guanines via electrostatic attractions (acts as a pseudo potassium ion). Such ionic interactions
could decrease the observed dissociation constant of compound 57. It is necessary to point out
that the positive charge(s) of a ligand must be placed at a specific location in G-quadruplex DNA
to achieve binding specificity. Otherwise, non-specific interactions of a positively charged
ligand with DNA could occur, reducing binding selectivity. Ligand 57 was also found to reduce
the production of mRNA and induce apoptosis in HL-60 (human leukemia-60) cells126.

Figure 1.40. Structure of Quinoline derivatives SYUIQ-01 (55) (left), SYUIQ-F05 (56) (middle)
and Cryptolepine derivative SYUIQ-FM05 (57) (right).
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Table 1.4
Kinetic Parameters of the Ligands (57-59) Determined by SPR Spectroscopy.
SYUIQ-FM05 (57)
SYUIQ-F05 (56)
SYUIQ-01 (55)
BCL-2
duplex
BCL-2
duplex
BCL-2
duplex
ka (M−1 s−1) 2.29 × 105
2.23 × 105
1.20 × 105
1.66 × 105
8.65 × 104
5.92 × 103
−3
−1
kd (s )
7.28 × 10
0.06
0.02
0.08
0.13
0.02
−8
−7
−7
−7
−6
KD (M)
3.18 × 10
2.69 × 10
1.67 × 10
4.82 × 10
1.50 × 10
3.38 × 10−6
ka is association constant, kd is dissociation constant, KD (kd/ka) is equilibrium dissociation
constant

Giusiniano127 et al synthesized a series of ligands for selectively targeting BCL-2 and cMYC G-quadruplex using nucleobases as synthons. Three nucleobase-oriented scaffolds are
shown in Figure 1.41.

Figure 1.41. Structure of cytosine, guanine and adenine-based scaffolds for G4 stabilization.

An initial survey of compounds 58, 59, and 60 showed that 58 and 59 were ineffective in
stabilizing any G-quadruplex conformations. Compound 60 did show thermal stabilization of
the c-MYC, BCL-2, and human telomeric G-quadruplexes. Based on the scaffold of compound

77
60, a library of 16 compounds was synthesized. Compound 61 (Figure 1.42) was the most
potent and selective ligand for BCL-2 (hybrid) and c-MYC (parallel) G-quadruplex topologies in
the series.

Groove

Figure 1.42. Compound 61 (left) Compound 61 docked on BCL-2 G-quadruplex, the
electrostatic interaction is circled in red. PDB:2F8U (right).

Compound 61 showed selective inhibition of BCL-2 positive Jurkat cell growth (human
leukemia cell line) without having any effect on the cell viability of melanoma cells, MCF-7
cells, HCT-116 cells, and non-cancerous cells.
An NMR titration study showed that the binding of compound 61 only causes slight
perturbation of the guanines in the 3’ G-tetrad and has no effect on the guanines in the 5’ Gtetrad. By contrast, docking studies showed that the compound interacts with the N-H of
guanines pointing in the grooves (top and middle tetrad) in the grooves. The amino side chains
of the ligand interact with the phosphate backbones (Circled in red in Figure 1.42).
1.9.2. Human Telomeric G-quadruplex
The ends of the chromosome consistently shorten after each replication cycle, known as
the end replication problem. When a cell’s chromosome ends reach a critical point, it will trigger
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cellular senescence. Theoretically, each cell can have around 50-70 replication cycles. On the
contrary, cancer cells are immortal, having unrestricted replication cycles. Cancer cells
overcome the end replication problem by overexpressing a reverse transcriptase, human
telomerase. Telomerase extends the chromosome ends by adding 5’-TTAGGG repeats and thus
maintain their length. It requires a single-stranded DNA (3’-G rich overhang) to pair with its
embedded mRNA template to execute its function. Telomerase is overexpressed in 85-95% of
cancer cells, making it a promising anticancer target. As discussed before, the guanine-rich
telomeric region can fold into G-quadruplexes in vivo. Because the G-quadruplexes are not the
native substrate of telomerase; therefore, the formation of G-quadruplex in the telomeric region
can prevent the binding of telomerase and thus inhibit its biological activity. The use of small
molecules to induce telomeric G-quadruplex is an effective approach for the inhibition of
telomerase activity.
The first evidence of ligand-mediated G-quadruplex stabilization responsible for
telomerase inhibition was reported in 1997. A G-quadruplex binding ligand 2,6diamidoanthraquinone (62) (Figure 1.46) thermally stabilizes telomeric G-quadruplex and
inhibits telomerase activity with an IC50 value of 23 µM.
Until today, the design of G-quadruplex binding ligands mainly focuses on two factors,
aromatic surface and charged side chains. Ligands containing extended and fused aromatic rings
can maximize π-π interactions with the planar nature of G-tetrads. Ligands with positively
charged moieties can enhance their binding with and negatively charged G-quadruplex grooves
and electron-rich G-tetrads. Porphyrin derivatives79,128 (63) and PIPER129 (64) are examples of
G-quadruplex ligands with extended aromatic rings and charged side chains (Figure 1.46).
When designing G-quadruplex ligands, one needs to consider the ligand's selectivity for G-
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quadruplex over duplex DNA. The charged side chains are also a favorable factor for duplex
binding ligands. Several synthetic and natural G-quadruplex binding ligands are listed below.
Neidle et al130 synthesized a series of disubstituted and trisubstituted acridine molecules.
The side chains were judiciously placed to interact with the grooves to maximize the binding
affinity. The derivatives with three side chains showed a much weaker dissociation constant in
the SPR (surface plasmon resonance) study. The acridine ring nitrogen aligns along the channel
of negative electrostatic potential above the top G-tetrad (Figure 1.43). The compound showed
40 times selectivity over duplex DNA. One of the trisubstituted derivatives, BRACO-19 (65),
showed the inhibition of telomerase activity with an impressive telIC50 value of 95 nM. It inhibits
the telomerase-mediated telomere extension in vivo by displacing hTERT (catalytic subunit of
telomerase) from telomeres. In addition, it colocalizes with ubiquitin in the cytoplasm for
proteasomal destruction131. Cancer cells treated with BRACO-19 showed an increased incidence
of chromosome fusion132, a hallmark of genetic instability.

Figure 1.43. BRACO-19 (yellow color) bound to htelo G-quadruplex130 (red color).
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Pyridostatin (PDS, 66) is another potent ligand for telomerase inhibition by displacing
POT1 from telomeres54. This displacement triggers the DNA damage response in cells. The
appearance of nuclear foci of phosphorylated histone gH2AX (an early damage response marker)
has been observed in the cells treated with PDS26. Although PDS does not have a fused aromatic
ring structure, its flexible structure can make intramolecular hydrogen bonds to result in a planar
structure for binding (Figure 1.46). The side chains containing amine groups have electrostatic
interactions with negatively charged phosphate backbones133.
Phen-DC3 (67), a 1,10-phenanthroline analog, is one of the most potent telomerase
inhibitors134 via the G-Quadruplex approach135. It induces genetic instability in the yeast through
G-quadruplex stabilization27. Phen-DC3 induces the conformation change of the hybrid Gquadruplex to two-tetrad antiparallel G-quadruplex or hybrid-3136, leading to the unfavorable
entropy change during binding137. The primary mode of binding of Phen-DC3 is stacking
interactions at the outer tetrad (Figure 1.44) (image shown is for c-MYC G-quadruplex).

Figure 1.44. Phen-DC3 (67) stacked on the G-tetrad (left), Phen-DC3 bound to the Gquadruplex138 (PDB:2MGN).
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Substituted Naphthalene diimides are another class of ligands extensively developed to
target telomeric G-quadruplexes. The ligands have a fused aromatic core and preferentially bind
through end-stacking mode. One of the advantages of these ligands is to decorate the
naphthalene diimide core with up to 4 basic/hydrogen bonding moieties stabilizing ranges of
conformation in solution depending upon the nature of side chains as determined from the CD
spectra, for example, a parallel conformation with N-methyl piperazine139 (68), antiparallel with
morpholine and N-methyl piperazine (2+2) side chains140.
The basic side chains have a pronounced effect with the one of the most potent analogues
so far can thermally stabilize telomeric G-quadruplex for over 28.3 oC (Figure 1.46). The telIC50
of the compound is 50 nM. It has shown a potent POT1 in displacement activity, which act as
the DNA damage response. The compound showed potent anticancer against pancreatic cancer
cell lines both in vitro139 and in vivo141.
The compound is positively charged under physiological conditions and has a suggested
binding mode similar to the MM41142 (54). It prefers to binds to the parallel stranded
conformation htelo conformation, which is the most common binding mode for this class of
ligands139,142,143 except a few140.
Telomestatin (69), a natural product from the bacterium Streptomyces annulatus 3533SV4144, is one of the most potent G-quadruplex ligands, inhibits telomerase at 0.64nM using
traditional TRAP assay (58 ± 17nM, according to direct primer assay)134. The compound has a
macrocyclic structure, which is in perfect congruity with the outer G-tetrad (Figure 1.45). The
compound has over 70-fold selectivity over the duplex DNA80. It inhibits the activity of
telomerase at 0.64nM using traditional TRAP assay. The telomestatin derivative (70, L2H)
showed binding to the 5’-G tetrad of the (3+1) human telomeric hybrid conformation145. The
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compound stabilizes the G-quadruplex through the pi-pi interaction and side chains maintain
close contacts with the nucleobases in the backbone of G-quadruplexes (Figure1.45).

Figure 1.45. Telomestatin analogue L2H2-6M(2)OTD (70) (left), and its bound state to (3+1)
htelo hybrid G-quadruplex.
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Figure 1.46. Ligands targeting hybrid G-quadruplexes.

In summary, all the G-quadruplex ligands developed so far share several common
features.
1). Positively charged side chains increase the binding affinity by interacting with
negatively charged G-quadruplex backbones. However, the presence of multiple
charges can reduce selectivity over duplex DNA
2). An extended aromatic surface is required for enhanced G-quadruplex stabilization.
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3). The presence of positively charged nitrogen either may enhance interactions of the
ligand with the cavity center of G-quadruplexes.
4). The ligand with biaryl or flexible linkages can readily fit in the grooves of Gquadruplexes.
5). Increase in hydrophobicity may increase the binding affinity to the G-quadruplex to a
certain extent.
6). The G-quadruplex structures have water ribbons in the grooves. The binding
interaction between the basic side chain and negatively charged backbone can occur
through the intermediacy of water bridges.
In light of these findings, my research focuses on developing potent ligands that bind to
G-quadruplexes via a dual recognition mode (extended aromatic surface and side chains). Two
classes of aromatic molecules, nucleobases and 1,10-phenanthroline, are used. Neomycin and
polyamines will be used as cationic side chains. The synthesis and biochemical evaluations of
these molecules will be discussed in the following chapters.
-

In chapter 2, four novel nucleobase-neomycin conjugates are synthesized, and their
binding to triplex DNA and telomeric G-quadruplex DNA is evaluated. Also, the
anti-bacterial effect of these conjugates is determined.

-

In chapter 3, several 1,10-phenanthroline-neomycin conjugates are synthesized and
characterized. Their binding to telomeric G-quadruplex DNA and duplex DNA are
studied using various biophysical methods. In addition, the inhibition of telomerase
activity by these compounds is determined using the TRAP assay. In chapter 4, a
series of 2-clip-phen (a 1,10-phenanthroline dimer) derivatives with amino side
chains are synthesized and characterized. The binding of these compounds with three
different G-quadruplexes is studied using various biophysical methods.
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CHAPTER 2: NUCLEOBASE-MODIFIED NEOMYCIN TO TARGET A-FORM OF
NUCLEIC ACID

2.1. Introduction
Aminoglycosides are potent antibiotics that have widely used in bactericidal infection.
The mechanism of action of most aminoglycosides is binding to RNA targets and creating
fissures in the outer membrane of bacterial cells. For instance, neomycin, an aminoglycoside,
binds to the 16S ribosomal A-site, which causes misreading of the genetic code and inhibition of
translocation146,147, leading to protein synthesis disruption and cell death. They are effective
against aerobic, gram-negative bacteria and certain gram-positive bacteria. Aminoglycosides are
ototoxic and have acute nephrotoxicity associated with them. They accumulate in kidney cells
with a long half-life and damage kidneys over time148. A recent report showed that a Ru(II)
arene-neomycin conjugate has moderate antiproliferative activity against MCF-7 cells (human
breast adenocarcinoma) at low micromolar concentrations with low selectivity over normal
cells149.
Recent studies revealed that neomycin has a binding preference for the A-type nucleic
acid structures like triplex DNA, duplex RNA, and DNA-RNA hybrid150. The specificity of
neomycin to these structures is due to the flexible glycosidic linkages and structured amino
groups, which are positively charged under physiological conditions151. Over the past years,
several neomycin conjugates have been synthesized to modulate its binding to several nucleic
acid structures. The C5”-position of the ring III is a common site for tethering another moiety
because the chemical modification at this site has a minimal effect on the binding of neomycin to
its substrates. Using this approach, Tor group synthesized an acridine-neomycin conjugate that
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binds with high affinity to the HIV-1 Rev-Response Element152. Several intercalator-neomycin
conjugates have been developed by tethering an aromatic moiety at the C5”- position, showing
enhanced binding to the triplex DNA over the unmodified neomycin153. In addition, a peryleneneomycin conjugate has been found to increase the binding affinity of the intercalator (perylene)
to G-quadruplex DNA154. In all the cases mentioned here, the enhanced binding of these
conjugates to their nucleic acid substrates result from a synergistic effect, in which neomycin
binds into the groove and the intercalator moiety stacks with aromatic bases of the nucleic acid
structure simultaneously. Neomycin has become a promising scaffold for the development of
ligands that binds unique nucleic acid structures specifically.
On the other side, due to the over and indiscriminate use of aminoglycosides, the
emergence of resistant strains, especially those containing aminoglycosides modifying enzymes
has become a global concern for public health155. Modifications of existing aminoglycosides to
circumvent the resistance while keeping their antibiotic potential is one of the useful approaches
to quickly tackle this problem as the therapeutic and toxicity profiles of these aminoglycosides
are already known. Zhang et al156 synthesized a series of 5”-acetylated neomycin derivatives
and found two lead compounds that were effective against methicillin and vancomycin-resistant
bacterial species. In another study, bisubstrate derivatives of neamine (truncated neomycin) and
adenosine were synthesized as the competitive inhibitors of the enzyme aminoglycoside 3’-Ophosphotransferases157.
In this chapter, we present the synthesis of four novel nucleobase-neomycin conjugates
containing a triazole linker. The binding of these conjugates with duplex, triplex, and Gquadruplex DNA was studied. The goal of the study was to explore the size limitation of the
intercalator moiety in an intercalator-neomycin conjugate on its binding with DNA. In addition,
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the cytotoxicity of these novel conjugates against HeLa and MCF-7 cancer cells and their
antibacterial effect were determined.
2.2. Experimental Section
2.2.1. Material and Methods
Chemicals for synthesis were purchased from Fisher Scientific (Pittsburgh, PA) and used
without further purification. Reactions were carried out under Argon using dry solvent unless
otherwise noted. IR spectra were collected on a Shimadzu (Pleasanton, CA) IR Prestige-21 FTIR spectrophotometer. 1H spectra were collected on a JEOL (Peabody, MA) ECA 600 MHz FTNMR spectrometer. HRMS (ESI) spectra were collected on an Agilent 1290 UHPLC connected
to an Agilent 6230 Time-of-Flight mass spectrometer through an electrospray ionization source
at Chevron, Richmond, California. UV spectra were collected on a Varian Cary 100 Bio UV-Vis
spectrophotometer equipped with a thermoelectrically controlled 6 x 6 cell holder (Walnut
Creek, CA). The MTT read-outs were measured by a TriStar LB 941 multimode microplate
reader. Dulbecco’s modified Eagles medium (DMEM) was purchased from Sigma (St. Louis,
MO). Advanced MEM, glutaMAX, penicillin, and streptomycin were purchased from
Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from Tissue Culture
Biologicals (Seal Beach, CA).
2.2.2. Synthesis of Nucleobase-neomycin Conjugates
Compounds 2-4 and 11-14 have been synthesized according to the published
procedure158–160. The synthesis scheme is described in Scheme 2.1.
Synthesis of 2. To the solution of neomycin B (1.0g, 1.1 mmol) in water (7ml),
triethylamine (2ml, 14.43 mmol) was added, and the reaction mixture was stirred for 10 mins at
rt. Di-tert-butyl dicarbonate (2.1g, 9.756 mmol) in DMF (20ml) was added dropwise into the
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flask over a period of 10 mins. The reaction mixture was stirred at 60 oC for 5 h. The
completion of the reaction was monitored with TLC (Rf = 0.414, CH2Cl2: CH3OH = 9:1 (v/v),
silica gel 60 F254, EMD Millipore]. The residue was precipitated with water (200 ml) and
filtered. Flash chromatography of the residue [silica gel, CH3COOC2H5, Rf = 0.19] yielded
compound 2 (700 mg and 52.4 %) as a white solid. 1H-NMR (600 MHz, CD3OD) δ 1H-NMR
(600 MHz, CDCl3) δ 6.18 - 4.57 (m, 7H), 4.54 - 4.03 (m, 4H), 4.00 - 2.89 (m, 16H), 1.65 - 1.05
(m, 54H).
Synthesis of 3. In a 50-ml round-bottomed flask, 2,4,6-triisopropylbenzene sulphonyl
chloride (7g, 23 mmol) and 2 (1g, 0.83mmol) were dissolved in anhydrous pyridine (20ml). The
reaction mixture is stirred at rt for 48 h under N2 and then concentrated under vacuum. The
crude compound was in two stages. In stage one, all the unreacted 2,4,6-triisopropylbenzene
sulphonyl chloride was removed using CH2Cl2 as eluent. The column was then flushed with
CH3OH:CH2Cl2 (2:8 v/v), [Rf = 0.487 in a 9:1 (v/v) CH2Cl2: CH3OH = 9:1 (v/v), silica gel 60
F254, EMD Millipore]. Residue was concentrated and flash chromatography of the residue [silica
gel, CH3OH:CH2Cl2 (2 - 5 % v/v)] yielded compound 3 (971.5 mg, 79 %) as white solid. 1H NMR (600 MHz, CD3OD) δ 7.27 (s, 2H), 5.42 (s, 1H), 5.16 (s, 1H), 4.85 (s, 1H), 4.01 - 4.42 (m
7H), 3.86 (s, 1H), 3.65 - 3.79 (m, 3H), 3.31 - 3.63 (m, 9H), 3.09 - 3.25 (m, 1H), 2.85 - 3.00 (m,
2H), 2.67 - 2.79 (m, 2H), 1.90 - 2.00 (m, 1H), 1.32 - 1.57 (m, 54H), 1.15-1.29 (m, 18H).
Synthesis of 4. To the solution of 3 (330mg, 0.22 mmol) in DMF (5ml), was added
NaN3 (110 mg, 1.687 mmol). The reaction mixture was stirred at 90 oC for 24h. The reaction
completion was monitored with TLC [Rf = 0.26, CH3OH:CH2Cl2 = 0.625:9.375 (v/v), silica gel
60 F254, EMD Millipore]. The reaction mixture was concentrated under vacuum. Flash
chromatography of the residue [silica gel, CH3OH:CH2Cl2 = 0.625:9.375 (v/v)] yielded
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compound 4 (223mg, 82 %) as a white solid. The yield is 223 mg, 82 % as a white solid. 1HNMR (600 MHz, CD3OD) δ 5.46 (s, 1H), 5.15 (s, 1H), 4.91 (s, 1H), 4.23 - 4.39 (m, 2H), 3.99 4.09 (m, 1H), 3.67 - 3.96 (m, 5H), 3.42 - 3.63 (m, 8H), 3.10 - 3.21 (m, 1H), 1.89 - 2.00 (m, 1H),
1.39 - 1.53 (m, 54H).
Synthesis of 5a. Adenine-9-prop-2ynyl (11) (12.5 mg, 0.072 mmol) was added to an
anhydrous DMF solution (6 mL) of sodium ascorbate (13.7 mg, 0.069 mmol), copper (II) sulfate
(2.0 mg, 0.008 mmol), and compound 4 (71.0 mg, 0.058 mmol). The reaction mixture was
stirred at room temperature overnight. The completion of the reaction was monitored by TLC
under UV [Rf= 0.23, CH3OH:CH2Cl2 0.8:9.2 (v/v), silica gel 60 F254, EMD Millipore]. The
reaction mixture was concentrated under vacuum. Flash chromatography of the residue [(silica
gel, CH3OH:CH2Cl2 1:9 (v/v)] yielded compound 5a (67.5 mg, 82.0%) as a pale white solid. IR
(KBr) (cm-1) 3343, 2976, 2938, 1644, 1649, 1631, 1367, 1248, 1165, 1043. 1H NMR (CD3OD,
600 MHz) δ 8.32 (s, 1H), 8.22 - 8.29 (m, 2H), 6.47 - 6.83 (m, 2H), 5.58 - 5.70 (m, 1H). 5.33 5.44 (bs, 1H), 5.01-5.11 (m, 1H), 4.97 (s, 1H), 4.78 - 4.86 (m, 1H), 4.66 - 4.76 (m, 1H), 4.07 4.41 (m, 3H), 3.98 (t, 1H, J = 5.8 Hz), 3.90 (s, 1H), 3.66 - 3.83 (m, 3H), 3.50 - 3.65 (m, 2H),
3.41 - 3.49 (m, 2H), 2.9 8- 3.08 (m, 1H), 1.90 - 2.01 (m, 1H), 1.15 - 1.56 (m, 54H). HRMS (ESI)
calcd. for C61H100N14O24 [M+ H]+ = 1413.7113, found 1413.7090.
Synthesis of 5b. Guanine-9-prop-2ynyl (12) (14.0 mg, 0.074 mmol) was added to an
anhydrous DMF solution (6 mL) of sodium ascorbate (15.0 mg, 0.075 mmol), copper (II) sulfate
(3.0 mg, 0.012 mmol), and compound 4 (46.0 mg, 0.037 mmol). The reaction mixture was
stirred at room temperature overnight. The completion of the reaction was monitored by TLC
under UV [Rf= 0.275, CH3OH:CH2Cl2:NH4OH 1.25:8.75:0.1 (v/v/v), silica gel 60 F254, EMD
Millipore]. The reaction mixture was concentrated under vacuum. Flash chromatography of the
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residue [(silica gel, CH3OH:CH2Cl2:NH4OH 1.25:8.75:0.1 v/v/v)] yielded compound 5b (25.0
mg, 47.3%) as a pale white solid. IR (KBr) (cm-1) 3408, 1689, 1633, 1516, 13676, 1251, 1167,
1043, 856. 1H NMR (CD3OD, 600 MHz) δ 8.36 (s, 1H), 7.83 (s, 1H), 6.62 - 6.84 (m, 1H), 5.56
(d, J = 14.4 Hz, 1H), 5.36 (s, 1H), 5.28 (d, J = 15.6 Hz, 1H), 5.01 (s, 1H), 4.96 (s, 1H), 4.6 - 4.73
(m, 1H), 3.90 - 4.15 (m, 4H), 3.87 (s, 1H), 3.68 - 3.79 (m, 2H), 3.38 - 3.59 (m, 7H), 3.28 - 3.37
(m, 1H), 3.04 (br s, 1H), 1.84 - 1.96 (m, 1H), 1.2 5- 1.49 (m, 54H). HRMS (ESI) calcd. for
C61H100N14O25 [M+ H]+ =1429.7062, found 1429.7042.
Synthesis of 5c. Cytosine-1-prop-2ynyl (13) (24.0 mg, 0.161 mmol) was added to an
anhydrous DMF solution (6 mL) of sodium ascorbate (14.6 mg, 0.0738 mmol), copper (II)
sulfate (2.0 mg, 0.008 mmol), and compound 4 (64.0 mg, 0.054 mmol). The reaction mixture
was stirred at room temperature overnight. The completion of the reaction was monitored by
TLC under UV [Rf= 0.435, CH3OH:CH2Cl2:NH4OH 1.5:8.5:0.05 (v/v/v), silica gel 60 F254,
EMD Millipore]. The reaction mixture was concentrated under vacuum. Flash chromatography
of the residue [silica gel, CH3OH:CH2Cl2 1.25:8.75 (v/v)] yielded compound 5c (30.0 mg,
42.0%) as a pale white solid. IR (KBr) (cm-1) 3369, 2978, 2932, 1701, 1647, 1524, 1394, 1367,
1280, 1251, 1169, 1043, 865. 1H NMR (CD3OD, 600 MHz) δ 8.07 (s, 1H), 7.73 (d, J = 7.26 Hz,
1H), 5.85 (d, J = 7.26 Hz, 1H), 5.47 (s, 1H), 5.41 (s, 1H), 5.00 - 5.13 (m, 3H), 4.92 (d, J = 1.56
Hz, 1H), 4.66 (dd, J = 13.02 Hz, 4.38 Hz, 1H), 4.58 (s, 1H), 4.07 - 4.36 (m, 3H), 3.95 (m, 1H),
3.88 (s, 1H), 3.69 - 3.79 (m, 2H), 3.57 - 3.67 (m, 1H), 3.39 - 3.55 (m, 4H), 3.31 - 3.38 (m, 2H),
3.09 (m, 1H), 1.86 - 1.97 (m, 1H), 1.25 - 1.49 (m, 54H). HRMS (ESI) calcd. for C61H100N14O25
[M+ H]+ = 1389.7001, found 1389.6990.
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Synthesis of 5d. Thymine-1-prop-2ynyl (14) (13.7 mg, 0.0836 mmol) was added to an
anhydrous DMF solution (6 mL) of sodium ascorbate (15.8 mg, 0.079 mmol), copper (II) sulfate
(2.0 mg, 0.008 mmol), and compound 4 (55.0 mg, 0.0442 mmol). The reaction mixture was
stirred at room temperature overnight. The completion of the reaction was monitored by TLC
under UV [Rf= 0.2125, CH3OH:CH2Cl2 0.75:9.25 (v/v), silica gel 60 F254, EMD Millipore]. The
reaction mixture was concentrated under vacuum. Flash chromatography of the residue [silica
gel, CH3OH:CH2Cl2 0.75:9.25 (v/v)] yielded compound 5d (60.0 mg, 96.7%) as a pale white
solid. IR (KBr) (cm-1) 3371, 2978, 2934, 1690,1514, 1458, 1392, 1367, 1267, 1250, 1167,
1043, 862, 781. 1H NMR (CD3OD, 600 MHz) δ 8.10 (s, 1H), 7.56 (s, 1H), 6.55 - 6.67 (m, 1H),
6.37 - 6.53 (m, 1H), 5.47 (s, 1H), 5.41 (s, 1H), 4.89 - 5.14 (m, 3H), 4.54 - 4.68 (m, 1H), 4.04 4.47 (m, 3H), 3.95 (t, J = 6.6 Hz, 1H), 3.70 - 3.80 (m, 2H), 3.60 - 3.69 (m, 1H), 3.36 - 3.59 (m,
3H), 3.08 (t, J = 8.4 Hz 1H), 1.87 - 1.95 (m, 1H), 1.85 (d, J = 1.3 Hz, 3H), 1.25-1.48 (m, 54H).
HRMS (ESI) calcd. for C61H101N11O26 [M+ H]+ = 1404.6997, found 1404.6971.
General procedure for the synthesis of 6a–6d. Hydrochloric acid in dioxane (4M, 1
mL) and ethanedithiol (3 μL) were added into a dioxane solution (1 mL) of compound 5a (17.0
mg), 5b (24.0 mg), 5c (12.0 mg), or 5d (24.0 mg) in a 15-mL conical vial. The reaction mixture
was swirled for 5 min and became turbid. The deprotected pro- duct was further precipitated by
adding ether and hexane (1 mL each). The solid was collected by centrifugation (3000 rpm),
decanted, washed with ether (3 × 1 mL) and hexane (3 × 1 mL), and dried overnight under
vacuum. The residue was re-dissolved in milli-Q water and lyophilized to give a pale-white
fluffy solid.
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Compound 6a. Yield: 11.6 mg, 93.5%. IR (KBr) (cm-1) 3396, 3058, 2948, 1685, 1601,
1491, 1144, 1044, 1018, 769, 638. 1H NMR (D2O, 600 MHz) δ 8.32 (s, 1H), 8.30 (s, 1H), 8.17
(s, 1H), 5.94 (d, J = 4.2 Hz, 1H), 5.56 (s, 2H), 5.31 (d, J = 3.6 Hz, 1H), 5.21 (d, J = 1.8 Hz, 1H),
4.76 (dd, J = 15.0 Hz, 5.0 Hz, 1H), 4.68 (m, 1H), 4.45 (m, 2H), 4.23 (m, 1H), 4.12 (t, J = 6.0 Hz,
1H), 4.05 (t, J = 9.6 Hz, 1H), 3.82 -3 .93 (m, 4H), 3.72 (s, 1H), 3.62 (t, J = 9.6 Hz, 1H), 3.21 3.51 (m, 9H), 2.38 (m, 1H), 1.82 (m, 1H). HRMS (ESI) calcd. for C31H53N14O12+ [M+ H]+ =
813.3962, found 813.3945.
Compound 6b. Yield: 14.7 mg, 84.0%. IR (KBr) (cm-1) 3383, 2922, 1701, 1637, 1604,
1500, 1490, 1369, 1143, 1047, 1024, 781, 605. 1H NMR (D2O, 600 MHz) δ 8.16 (s, 1H), 8.05
(s, 1H), 5.52 (d, J = 4.2 Hz, 1H), 5.34 (s, 2H), 5.23 (d, J = 4.2 Hz, 1H), 5.19 (d, J = 1.2 Hz, 1H),
4.71 - 4.75 (m, 1H), 4.65 (s, 1H), 4.43 (q, J = 4.2 Hz, 1H), 4.38 (t, J = 4.8 Hz, 1H), 4.20 (t, J =
4.8 Hz, 1H), 4.09 (t, J = 3 Hz, 1H), 3.74 - 3.90 (m, 4H), 3.70 (s, 1H), 3.17 - 3.51 (m, 11H), 2.35
(dt, J = 8.4 Hz, 4.2 Hz, 1H), 1.75 - 1.86 (m, 1H). HRMS (ESI) calcd. for C31H53N14O13+ [M+
H]+ = 829.3911, found 829.3909.
Compound 6c. Yield: 6.7 mg, 77.0%. IR (KBr) (cm-1) 3392, 1676, 1497, 1144, 1053,
1018, 797. 1H NMR (D2O, 600 MHz) δ 8.08 (s, 1H), 7.83 (d, J = 7.8 Hz, 1H), 6.04 (d, J = 7.2
Hz, 1H), 5.93 (d, J = 3.0 Hz, 1H), 5.30 (d, J = 2.4 Hz, 1H), 5.22 (s, 1H), 5.02 (s, 2H), 4.55 - 4.84
(m, 2H), 4.45 (s, 2H), 4.24 (t, J = 3.6 Hz, 1H), 4.12 (s, 1H), 4.05 (t, J = 9.6 Hz, 1H), 3.77 - 3.99
(m, 4H), 3.73 (s, 1H), 3.60 (t, J = 10.2 Hz, 1H), 3.19 - 3.55 (m, 9H), 2.38 (m, 1H), 1.83 (q, J =
12.0 Hz, 1H). HRMS (ESI) calcd. for C30H53N14O12+ [M+ H]+ = 789.3850, found 789.3859.
Compound 6d. Yield: 14.7 mg, 84.0%. IR (KBr) (cm-1) 3387, 2918, 1701, 1601, 1244,
1220, 1143, 1049, 1026, 773. 1H NMR (D2O, 600 MHz) δ 8.03 (s, 1H), 7.51 (d, J = 1.2 Hz, 1H),
5.82 (d, J = 3.6 Hz, 1H), 5.28 (d, J = 3.6 Hz, 1H), 5.21 (d, J = 1.2 Hz, 1H), 4.94 (d, J = 2.4 Hz,
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2H), 4.75 (dd, J = 15.0 Hz, 3.0 Hz, 1H), 4.56 - 4.72 (m, 1H), 4.39 - 4.48 (m, 2H), 4.20 - 4.25 (m,
1H), 4.11 (t, J = 3.0 Hz, 1H), 3.84-3.96 (m, 3H), 3.74 - 3.83 (m, 2H), 3.69 - 3.73 (m, 1H), 3.54
(t, J = 10.2 Hz, 1H), 3.47 - 3.51 (m, 1H), 3.20 - 3.46 (m, 8H), 2.32 (m, 1H), 1.70 - 1.82 (m, 4H).
HRMS (ESI) calcd. for C31H54N11O14+ [M+ H]+ = 804.3846, found 804.3850.
2.2.3. Measurements of High-resolution Mass Spectra
Samples were introduced by flow injection analysis (FIA) in positive-ion mode. The
mobile phase was 90% H2O and 10% MeOH with 0.1% formic acid. The nebulizer pressure was
50 psi with 12 L/min of nitrogen (drying gas) at 325 °C for desolvation. The capillary voltage
was set at 3500 V, the fragmentor voltage was set at 150 V, the skimmer voltage was set at 65 V,
and the octopole voltage was set at 750 V. Spectra were collected from 300–1500 Da at a rate of
2 spectra/sec with 4962 transients/spectrum.
2.2.4. Preparation of Triplex DNA for Thermal Denaturation
The oligonucleotides dA22 (1 μM) and dT22 (2 μM) were mixed with a solution (1 mL,
pH 7.0) of sodium cacodylate (10 mM), EDTA (1 mM), and sodium chloride (200 mM) in the
absence or presence of a ligand (10 μM). The mixtures were heated at 90 °C for 5 min, slowly
cooled at 25 °C, and incubated at 4 °C overnight before use.
2.2.5. Preparation of G-quadruplex DNA for Thermal Denaturation
The G-quadruplex sequence 5′-AGG(TTAGGG)3T(1 μM) was mixed with a solution (1
mL, pH 7.0) of lithium cacodylate (10 mM), EDTA (1 mM), and potassium chloride (50 mM) in
the absence or presence of a ligand (10 μM). The mixtures were heated at 90 °C for 5 min,
slowly cooled at 25 °C, and incubated at 4 °C overnight before use.
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2.2.6. Thermal Denaturation of Triplex DNA or G- quadruplex DNA
UV melting spectra were recorded at 260 nm for triplex DNA and 295 nm for Gquadruplex DNA as a function of increasing temperature (4-80 °C, heating rate: 0.5 °C/min).
The melting temperatures (Tm) were determined using the first derivative method.
2.2.7. The MTT Assay
All the experiments were carried out in triplicate. MCF-7 (human breast
adenocarcinoma) and HeLa cells were maintained in advanced DMEM medium supplemented
with 5% fetal bovine serum (FBS), L-glutamine, and anti-mycotic (antibiotic) at 37 °C in a
humid atmosphere containing 5% CO2. Neomycin and nucleobase-neomycin conjugates (6a–
6b) were pre-dissolved in sterilized water. The cells (3000 cells/well, 200 μL) were seeded in a
96-well microtiter plate and incubated for 24 h. The supernatant in each well was removed,
followed by adding neomycin or conjugates in FBS-free media (200 μL) to reach a final
concentration of 500 µM. After incubation at 37 °C for 24 h, an MTT solution (20 μL, 0.5
mg/mL) was added to each well and incubated again for 4 h. The formazan product was
dissolved in 150 μL of DMSO, and the absorbance of each well was measured at 590 nm using a
plate reader. Untreated cells and media without cells were used as controls. To calculate the
viability (%), the following equation was used.
Viability % =

A treated − (A media)
× 100 %
(A untreated) − (A media)

Atreated: The absorbance of the solution containing treated cells. Amedia: The absorbance of the
media. Auntreated: The absorbance of the solution containing untreated cells.
2.2.8. Statistical Analysis
Minitab software was used to determine statistical significance. Two-sample student’s ttest was performed to show statistically significant (p < 0.05) and insignificant (p > 0.05) data.
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2.2.9. Kirby-Bauer Test Protocol (Disk Diffusion Zone Determination)
Neomycin or conjugate (50 nmol) impregnated paper discs were placed onto the surface
of Müller Hinton agar plates (70191 Fluka) that were pre-seeded with bacteria (Bacillus subtilis,
Escherichia coli, Proteus vulgaris, and Serratia marcescens) and incubated aerobically at 37 °C
for 24 h. The diameters of inhibition zones were measured using a ruler to the nearest 1 mm.
2.2.10. Determination of Minimum Inhibition Concentrations (MICs)
Bacterial species were grown overnight in the Müller Hin- ton broth at 37 °C. A dilution
of the overnight culture was made in broth to an approximate concentration of 106 cfu/ mL. A
Müller Hinton broth (100 µL) solution containing the desired antibacterial reagent (neomycin or
compound 6a–6d) was inoculated with a freshly diluted bacterial suspension (5 µL) in a 96-well
plate and incubated at 37 °C overnight. The OD600 value in each well was recorded to determine
the bacterial growth. The OD600 value of the broth was used as a reference to determine the
complete inhibition of bacterial growth, and the OD600 value of the bacterial solution without any
reagent was used as a positive control.
2.3. Results and Discussion
2.3.1. Synthesis of Nucleobase-neomycin Conjugates via Click Chemistry
Synthesis of nucleobases with a propargyl group (11-14 containing adenine, guanine,
cytosine, and thymine, respectively) was reported previously159,160. The C5”-azido neomycin
precursor (4) were synthesized separately for the click reaction based on a previously published
procedure152. The modification at the C5”-position ring III of neomycin does not alter its
conformation for binding with nucleic acids154,158. All the six amino groups of neomycin (1)
were protected using di-tert-butyl decarbonate to yield compound 2. The C5”-hydroxyl group of
2 was converted into a good leaving group using 2,4,6- triisopropylbenzenesulfonyl chloride.
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The use of this bulky reagent enabled us to selectively protect the C5” primary hydroxy of ring
III of neomycin with a Boc group. Replacement of 2,4,6- triisopropylbenzenesulfonylate in 3
with azide via an SN2 mechnism yielded compound 4. Compound 4 and nucleobase precursors
(11-14) were finally coupled in the presence of Cu (I) via a click reaction to yield the compounds
5a to 5d containing a 1,4 substituted161 1,2,3-triazole linker. The boc-protected amino groups
were protected using 3M HCl/dioxane to produce final nucleobase-neomycin derivatives 6a to
6b (6a: adenine-neomycin; 6b: guanine-neomycin; 6c: cytosine-neomycin; 6d: thymineneomycin) with a yield ranging from 77.0-93.5%. All the target compounds were characterized
by IR, 1H NMR, and high-resolution ESI mass spectrometry.
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Scheme 2.1. Synthesis of nucleobase-neomycin conjugates (6a-6d), reagents and conditions: (i)
(Boc)2O, DMF-H2O, 60 °C; (ii) 2,4,6-triisopropylbenznenesulfonyl chloride, pyridine, r.t.; (iii)
NaN3, DMF, 90 °C; (iv) 11–14, sodium ascorbate, CuSO4, DMF, r.t.; (v) 4M HCl in Dioxane, r.t.

2.3.2. Nucleobase-neomycin Conjugates Stabilizes DNA-triplex Significantly
The stabilization of neomycin-nucleobase conjugates on triplex DNA was ascertained
using thermal denaturation studies monitored by UV at 260 nm. The observed change (increase)
in absorbance as a function of temperature is plotted, as shown in (Figure 2.1a). The melting
curve of an oligonucleotide DNA triplex (dA22•2dT22) is biphasic, including two distinct
transitions. The first transition (increase in hyperchromicity) represents the dissociation of the
triplex into a DNA duplex (dA22•dT22) and a single strand (dT22). In the absence of the ligand,
this transition is shown at 8.7 oC (Tm3→2) using the published protocol162. The second
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hyperchromic event (Tm2→1) at 54.1 oC corresponds to the dissociation of the duplex DNA
(dA22•dT22) to two single-stranded random coils (dA22 and dT22). In order to compare the effect
of various ligands on triplex stabilization, we chose a fixed concentration, 10 μM, to conduct the
experiments. As shown in figure 2.1b, and Table 2.1, neomycin significantly stabilizes the
DNA triplex (Tm3→2 = 39.3 oC), an increase in melting temperature of 30.6 oC (ΔTm3→2) while
having no stabilization effect on the DNA duplex, which is consistent with the previously
published reports.

Figure 2.1. a) UV melting of a 22 mer T.A.T triplex (1 μM) in the absence and presence of
neomycin (neo) and compound 6a-6d (10 µM). b) Bar graph showing the melting temperature of
(Continued) triplex to duplex (Tm3→2) and duplex to random coil (Tm2→1). Buffer conditions: 10
mM sodium cacodylate, 200mM NaCl, 1mM EDTA at pH 7.0.

Neomycin snuggly fits into the Watson-Hoogsteen groove of the neomycin due to
charge/shape complementarity to the binding site151. Similar results were obtained with the
nucleobase-neomycin conjugates. All the compounds showed an increase in the triplex DNA
melting temperature (Tm3→2) with a negligible effect on the duplex melting temperature (Tm2→1).
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Based on increase in the ΔTm3→2, the order of triplex stabilization effect of these conjugates is
guanine-neomycin (6b) > neomycin (neo) > adenine-neomycin (6a) > cytosine-neomycin (6c) >
thymine-neomycin (6d).

Table 2.1
Melting Temperatures (Tm3→2) of Triplex DNA to Duplex DNA and (Tm2→1) Duplex to Single
Strand Random Coil. 22 mer T.A.T triplex (1µM) in the Absence and Presence of Neomycin
(neo) and Compounds 6a-6d (10uM).
Compound
No Ligand
Neo
6a
6b
6c
6d

T(m3→2)
8.7 ± 0.5
39.3 ± 1.8
36.9 ± 1.0
43.4 ± 2.4
35.1 ± 1.7
28.7 ± 3.2

ΔT(m3→2)
n/a
30.6
28.2
34.7
26.4
19.7

T(m2→1)
54.1 ± 0
54.1 ± 0.5
54.1 ± 0.2
54.0 ± 0.5
53.9 ± 0.3
53.8 ± 0.8

ΔT(m2→1)
n/a
0
0
-0.1
-0.2
-0.3

Interestingly, three conjugates (thymine-neomycin, adenine-neomycin, and cytosineneomycin) could not stabilize the triplex DNA as efficiently as neomycin. The increment in
Tm3→2 values by these three conjugates was a few degrees lower than that by neomycin. This
observation could result from the increased non-favorable steric crowding at the binding site of
neomycin due to the conjugation of a nucleobase. It is known that the binding pocket of
neomycin can be affected by the surrounding structural geometry163. On the other hand,
compound 6b (guanine-neomycin) increased the Tm3→2 melting temperature 4.1 °C more than
neomycin. The order for stacking surface area of nucleobases is guanine (G) > adenine (A) >
cytosine (C) > thymine (T). Adenine, cytosine, and thymine in the conjugates have a smaller
aromatic surface, which may not be sufficient for stacking. These three nucleobases could
become a steric hindrance factor in the binding of neomycin to triplex DNA. By contrast, the
guanine moiety of 6b has the largest surface area that could efficiently intercalate with the base
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triplets while neomycin occupies the groove of the triplex DNA. However, the observed
stabilization of triplex DNA by 6b is relatively less efficient than that of other neomycinconjugates with a much larger surface area of the intercalator moiety such as pyrene-neomycin164
and BQQ-neomycin153. As a comparison, at 4 μM concentration, a pyrene-neomycin conjugate
has ΔTm of 26 oC for triplex melting. BBQ-neomycin conjugate binds the triplex DNA so tightly
that the triplex DNA directly dissociates into random coils without the biphasic transitions. The
other difference between 6b and these compounds is the linker. The linker of 6b includes a
triazole ring. Both pyrene-neomycin and BQQ-neomycin conjugates contain an aliphatic linker
that is more flexible than the triazole ring. This study implicates that the nature of the linker in a
conjugate could be an essential factor of binding in addition to the aromatic stacking surface.
The stabilization of a telomeric G-quadruplex by these four conjugates was determined
using thermal denaturation studies monitored by UV at 290 nm in the presence and absence of a
conjugate. In a typical experiment, CD signals at 290 nm were monitored as a function of
temperature ranging from 20-90 oC. G-quadruplex dissociates into random coils at higher
temperatures with concomitant hyperchromicity at 290 nm. The temperature at which 50% of
the G-quadruplex dissociates into random coils is called melting temperature (Tm). As indicated
in figure 2.2, none of the conjugates could increase the dissociation temperature of the telomeric
G-quadruplex. In K+, the G-quadruplex DNA used in the experiments adopted the hybrid type
conformation165.
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Figure 2.2. Bar graph showing G-quadruplex DNA (1µM) melting temperature in the presence
of neomycin (10 µM) and compounds 6a-6d. Buffer conditions: 10mM LiCaco, 50mM KCl,
1mM EDTA, pH 7.0.

The surface area of a G-tetrad is much larger than that of a base triplet. Stacking with a
guanine nucleobase with a G-tetrad via π- π interactions may not be strong enough to obtain a
noticeable increase in the melting temperature. In addition, only one or two conjugate molecules
are able to end stack with a G-quadruplex, while more molecules can interact with a triplex
DNA. Arya et al reported a similar result on a perylene-neomycin154, which binds efficiently
with G-quadruplex DNA, and a larger thermal stabilization effect was observed. The large
stacking surface of perylene of the conjugate is believed to be a crucial factor for these
observations. It is noteworthy that neomycin does not thermally stabilize G-quadruplex DNA.
At most, it is a relatively weaker G-quadruplex groove binder166. In addition, the triazole ring in
the linker might be too rigid for the two moieties to interact synergistically with G-quadruplex
DNA. Taken together, we can conclude that the aromatic surface area of guanine could be the
minimum for binding of the triplex DNA with an intercalator-neomycin conjugate via a
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synergistic effect. A larger aromatic surface is required if one designs an intercalator-neomycin
conjugate for targeting G-quadruplex DNA.
2.3.3. Nucleobase-neomycin Conjugates Are More Cytotoxic Than Neomycin
The cytotoxicity of the conjugates was checked for two cancer cell lines, MCF-7 and
HeLa, using the MTT assay. This assay measures a cellular metabolic activity that reflects cell
viability. As a general procedure, cells are incubated with a chemical reagent, 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). NAD(P)H-dependent
oxidoreductase in live cells' mitochondria reduces MTT to produce insoluble, purple-colored
formazan (Figure 2.3).

Figure 2.3. The conversion of MTT to formazan with mitochondrial reductase.

The color of the latter can be measured using colorimetry at 500-600 nm. Neomycin has
relatively low toxicity towards MCF-7 cells (IC50 > 250 µM) as previously reported149; therefore,
we chose a concentration of 500 µM for all the compounds as the initial study. As shown in
Figure 2.4, the cell viability values of neomycin toward MCF-7 and HeLa cells were 94.6 ± 12.5
and 96.4 ± 1.5 %, respectively, showing expected low toxicity. All nucleobase-neomycin
conjugates showed better cytotoxicity against the two cells in a statistically significant manner.
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All the conjugates (except 6d) were more cytotoxic towards MCF-7 cells than HeLa cells. The
order of increasing toxicity towards MCF-7 cells and HeLa cell lines was neo < 6d < 6a < 6c <
6b and neo < 6a < 6d < 6c < 6b, respectively.

Figure 2.4. Cytotoxic effects of neomycin and compounds 6a-6d (500 µM) in MCF-7 and HeLa
cell lines. Cell viability was determined by the MTT assay.

The guanine-neomycin conjugate (6b) was the most cytotoxic compound against both
cell lines. The cell viability of HeLa cells in the presence of 500 µM 6b was 15.4 ± 0.8 %,
which is 5-fold better than neomycin and at least 2-fold better than the other conjugates in the
series. The cell viability of MCF-7 cells in the presence of 6b under identical conditions was
47.6 ± 6.7 %. The cytotoxicity range of the conjugates towards MCF-7 cells ( 47.6 - 61.9%) was
smaller than that of HeLa cells (15.4-68.3%). This disparity might arise from different cellular
uptake of the conjugates by the two cell lines. 6b contains the largest stacking moiety and
showed the best cytotoxic effect against the cancer cells lines. It is possible that the larger
guanine moiety can have more interactions with certain substrates, but the clear correlation
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between the stacking moiety and cytotoxicity can not be drawn. The observed toxicity could
also result from the binding of these conjugates to the cellular RNA150,152 as neomycin is known
to bind to the A form of the nucleic acids. We did not conduct concentration-dependent studies
as IC50 values of these conjugates would be higher than the 250 µM, which is considered
inactive149. Because nucleobases are not cytotoxic, the increased cytotoxicity of the conjugates
should result from the structural modification at the C5” position of neomycin. Therefore,
tethering a moiety to the C5”-position of the neomycin can be used to develop novel neomycinbased cytotoxic agents. Grau-Campistany and coworkers149 have recently reported a Ru(II)neomycin conjugate that showed enhanced cytotoxicity towards two cancer cells used in our
studies.
2.3.4. Nucleobase-neomycin Conjugates Showed a Weaker Antibacterial Effect Than
Neomycin
The antibacterial effect of nucleobase neomycin conjugates was assessed on both
aminoglycoside resistant and non-resistant bacterial strains. Four antibiotic susceptible strains
including Serratia marcescens (S. marcescens, Gram-negative), Escherichia coli (E. coli, Gramnegative), Bacillus subtilis (B. subtilis, Gram-positive), and Proteus vulgaris (P. vulgaris, Gramnegative) were first tested against 50 nmol of nucleobase-neomycin conjugates using the KirbyBauer (Agar-disk-diffusion) test167. Neomycin with the same concentration was used as a
control. The size of an inhibition zone on the Agar disk reflects the inhibitory potency of a
compound on bacterial growth. The larger the inhibition zone, the stronger the inhibition effect
of the compound is. The diameter of an inhibition zone can be measured with a ruler (Figure
2.5). The size of the inhibition zone (cm) for neomycin was 1.5 for S. marcescens, 2.2 for E.
coli, 1.9 for B. subtilis, and 2.0 for P. vulgaris. The median values of inhibition zones by four
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conjugates were calculated for each bacterial strain. The values (cm) are 1.2 for S. marcescens,
1.3 E. coli, 1.6 for B. subtilis, and 0.7 for P. vulgaris. (Figure 2.5)
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Figure 2.5. Petri-dish images of the Kirby-Bauer test. a) The zone of inhibition for compounds
6a-6d (50 nmol) is a light circle around the disk. Neomycin is used as a positive control. b). Bar
graph depicting the relative size (cm) of the inhibition zone for each compound against a bacterial
species.

By subtracting these median values from the corresponding values of neomycin, we
interpreted the effect of conjugation on the antibacterial activity of neomycin. Neomycin
showed the best antibacterial effect against all the four bacterial strains as compared to
nucleobase-neomycin conjugates. Conjugation of a nucleobase to the C5”- position of neomycin
reduced the antibacterial effect of neomycin. It is possible that modifications at the C5”-position
could interfere with the binding of neomycin to its RNA target site. The observed reduction is
bacterial strain-dependent. Conjugation of nucleobases to neomycin has less reduction effect on
S. marcescens (Gram-negative) and B. subtilis (Gram-positive) than E. Coli (Gram-negative) and
P. vulgaris (Gram-negative). Such a difference could result from a different inhibitory
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mechanism or a different mechanism of cellular penetration between the Gram-positive and
Gram-negative bacteria species. Amongst all the conjugates, guanine-neomycin (6b) is the most
potent against all four bacterial species. Adenine-neomycin (6a) was the least potent against all
the Gram-negative bacterial species. It is noteworthy that 6a did not show any measurable effect
on the inhibition of P. vulgaris at the concentration we used.
The minimum inhibitory concentration (MIC) of the conjugates against the four bacterial
species was determined on 96-well microtiter plates. The absorbance of the well at 600 nm
(OD600) in the absence of bacteria was taken as a control, representing the complete inhibition
effect of bacterial growth. As shown in figure 2.6, the order of bacterial species based on
decreasing inhibitory effect by all compounds was B. subtilis > E. coli > S. marcescens > P.
vulgaris.

Figure 2.6. Minimum inhibition concentration of the compounds 6a-6d against four bacterial
species (S. marcescens (Gram positive), E. coli (Gram negative), B. subtilis (Gram negative) and
P. vulgaris (Gram negative).
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All the conjugates inhibited the growth of Gram-positive B. subtilis better than that of the
other Gram-negative bacteria (Figure 2.6). 6b is the most potent inhibitor amongst four
conjugates against bacteria species used in the study. The MIC value of 6b against Grampositive B. subtilis was 2 µM, which is about twice higher than the value for neomycin. By
contrast, 6b had a MIC value of 32 µM against Gram-negative S. marcescens, which is about 8
times higher than the value for neomycin. The reduced activity against Gram-negative species
could be attributed to the factors related to:
1. Bacterial anatomy- whether Gram-positive or negative.
2. Altered drug structure/conformational restraints.
Gram-negative bacteria have an additional outer membrane (OM) composed of a bilayer
including glycolipids lipopolysaccharides (LPS), glycerol phospholipids, and periplasm, which
provide protection against a wide range of antibiotics168. The hydrophobic drugs can diffuse
through the outer membrane, but the intake of hydrophilic drugs like aminoglycosides is
maintained through special protein gated channels called porins in the outer membrane169. The
addition of nucleobase moiety may have altered the polarity of the molecule, which could result
in the altered transport of conjugates into the cell to affect the target site. This is supported by
the fact that both neomycin and its conjugates showed comparative inhibition of gram-positive
bacteria species B. subtilis, as evident from the MIC values and Kirby-Bauer test. In addition,
covalent tethering of nucleobase moiety at the C5” may introduce steric interactions at the
binding site. A previous study suggested that the tethering of a moiety at the C5” position of
neomycin could affect its interaction with the G1491 base at the binding site of 16S
rRNA(Figure 2.7a and Figure 2.7b), which may lower the affinity of the conjugate to the target
site with concomitant loss in antibacterial activity170.
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Figure 2.7. a) Neomycin bound in the A site of 16S rRNA170 (point of nucleobase attachment is
labelled in red). b) Critical contacts between paromomycin (differ from neomycin in one amine
group in ring II) and residues at the binding site171 (right).

Moreover, tethering a moiety at the C5” position of neomycin could reduce the
conformational freedom of neomycin170. It is known that the ring I and II of neomycin are
involved in making conserved (similar among different aminoglycosides of this class)172 critical
connections (with A1408, G1494, U1495 at the decoding A site of the 16S ribosomes170,171
(Figure 2.7). Subtle changes in conformation may reduce the efficiency of neomycin binding to
its target.
The different responses of the Gram-negative bacterial species to the conjugates could be
due to different permeability/efflux and possible off-targeting. However, it is difficult to
pinpoint the exact reason due to the limitation of the study. In addition, no direct correlation was
found between the antibacterial activity and the size of conjugated aromatic moiety although the
polarity of nucleobases could play a role.
All four nucleobase-neomycin conjugates were also analyzed for their antibacterial
activities against an aminoglycoside-resistant E. coli strain. This E. coli strain is transfected with
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an aminoglycoside 3’-O-phosphotransferase (APHs) Ia gene. APHs transfer a phosphate group
to the 3’ or 5” hydroxyl group of the aminoglycoside molecule. Addition of a phosphate group
changes the electronic property of the aminoglycoside and dramatically alters its ability to bind
to the target rRNA171 (Figure 2.8), increasing to the survival of the bacteria. This strain is
known to have a resistance profile, including kanamycin, neomycin, and a few other
aminoglycosides.

Figure 2.8. APH (3’) I modifies neomycin at 3’OH (ring II) or at 5” OH at the ring III labelled
with red circle.

Tethering a nucleobase moiety to the 5” position of neomycin could change the
antibacterial profile of neomycin to the resistant E. Coli strain. It will be interesting to see if
nucleobase-neomycin conjugates can act as better antibiotics against aminoglycoside-resistant
strains. In our study, the MIC value of neomycin for this E. coli strain was 64 µM, which is 8
times higher than that of the non-resistant E. Coli strain, showing the presence of drug resistance
against neomycin. The effect of resistance to kanamycin and four conjugates were much
stronger than that to neomycin. No meaningful MIC value was observed for kanamycin at the
concentration up to 512 µM. Amongst all four conjugates, only 6b showed a detectable MIC
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value of 512 µM, which is 32 times higher than that (16 µM) toward the non-transfected species.
These results suggest that none of nucleobase-neomycin conjugates can overcome the bacterial
resistance because all the MIC values are much higher than that of neomycin.
2.4. Conclusion
We have successfully completed the synthesis and characterization of four novel
nucleobase-neomycin conjugates. The thermal denaturation studies showed that the size of the
intercalator moiety has a large impact on the thermal stabilization of DNA triplex and Gquadruplex DNA. The aromatic surface size of guanine could be a minimal requirement for the
synergistic binding effect on DNA triplets, but it is not sufficiently large for stacking with Gtetrad. The modifications at the C5” position of the neomycin is an efficient approach to
enhance the cytotoxicity of the aminoglycoside (neomycin) against HeLa and MCF-7 cancer
cells. The antibacterial activity of the conjugates behaves differently between the Gram-positive
and Gram-negative bacteria. It is possible that addition of a nucleobase to the C5” position of
neomycin may affect the binding of neomycin to its rRNA, but this modification may not affect
the function of 3”-O-phosphotransferase. The study presented here has provided important
insights into developing aminoglycoside-based compounds with better DNA binding affinities,
altered cytotoxicities, and better antibacterial activities.
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CHAPTER 3: PHENANTHROLINE-NEOMYCIN CONJUGATES, A POTENT G4 LIGANDS

3.1 Introduction
Binding of a drug to its substrate with high potency and selectivity is one of the
requirements to prevent off-targeting and achieve a desired therapeutic effect with low doses if
other pharmacokinetic parameters of the drug are favorable. Possible side effects associated with
the drug could be reduced as well.
As explained previously, G-quadruplexes are important regulatory elements in the
cellular processes. The Nobel laureate Aaron Klug had a famous quote over 30 years ago, “If Gquadruplexes form so readily in vitro, Nature will have found a way of using them in vivo”.
Recently, RNA G2-quadruplexes have been found to regulate the polyamine biosynthesis in the
cells in a negative feedback loop manner173. Many recent reports have suggested the role of Gquadruplex in the maintenance of cellular processes. Targeting G-quadruplex is a viable
approach to disrupt the processes involved in pathological conditions.
G-quadruplexes are macro structures, and all of them share a common feature, a planar G
tetrad. In general, the G-quadruplex ligands contain a planar aromatic moiety(s) to stack on, and
the G-tetrads through π- π interactions and consequently stabilize the corresponding Gquadruplex. This feature is crucial to the binding selectivity for G-quadruplex over duplex
DNA80,174. In addition, most of the G-quadruplex ligands have a permanent positive charge or a
basic moiety that is charged under physiological conditions. The positively charged groups
increase the binding affinity of the ligands to G-quadruplex DNA by electrostatic interactions
with the negatively charged phosphate backbones. The relative number and disposition of the
side chains have a profound effect on the binding affinity of the ligand to the G-quadruplexes.
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Ligands with multiple positive charges have higher binding affinities to G-quadruplex
DNA125,142, for example, trisubstituted acridine (BRACO-19) containing four positive charges is
a much stronger G-quadruplex binder than a di-substituted acridine derivative130 containing three
positive charges (Figure 3.1). However, there is one caveat. Positively charged groups, if not
judiciously placed on the molecule, could decrease the binding selectivity for G-quadruplexes
over duple DNA28,107. For example, TmPyP4, a potent, selective G-quadruplex ligand, has an
extended aromatic surface for favorable π- π stacking interaction with the G-quadruplex but has a
poor selectivity over duplex DNA175 due to the presence of four positive charges. Replacing one
charge with a neutral moiety has been shown to improve selectivity for G-quadruplex over
duplex DNA84. Our group has also previously reported a potent G-quadruplex binding ligand (a
thiazole orange-spermine conjugate) that inhibits human telomerase activity at sub-micromolar
concentrations176. It binds tightly to telomeric G-quadruplex DNA but with limited selectivity
for G-quadruplex over duplex DNA, probably due to its highly charged polyamine side chain.

Figure 3.1. Structure of disubstituted acridine (top) and trisubstituted acridine (bottom).
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On the other hand, a judicious disposition of positively charged side chains in a ligand
can enhance its binding affinity without compromising the selectivity79,92,105. By positioning
positively charged groups in a structured fashion, one can reduce non-specific binding between
the ligands and DNA backbones. In search of such side chains, we came across the
aminoglycoside (neomycin) scaffold. Neomycin has six amino groups on four rings spatially
separated by the saccharide linkages between the rings (Figure 3.2). The amino groups are
positively charged or partially positively charged under physiological conditions177. Previous
reports have suggested that neomycin binds preferentially to the A form of the nucleic acids150
such as RNA and triplex DNA with a minimal affinity to duplex DNA even at significantly high
concentrations178. In addition, neomycin binds to G-quadruplex DNA as a groove binder166 with
a relatively low binding affinity. The apparent binding selectivity of neomycin towards A-form
nucleic acids should result from its unique spatial arrangement of multiple positive charges. We
believe that by utilizing neomycin as the structured amino-containing side chain, we can develop
novel and stronger G-quadruplex binding ligands.

Figure 3.2. Structure of neomycin.
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Previous studies from our lab reported several 5-substituted 1,10-phenanthroline
derivatives as potent G-quadruplex ligands (Figure 3.3). In particular, derivatives with an amino
side chain (piperidine, dimethylamine) showed enhanced binding affinity to G-quadruplex
DNA179. The 1,10-phenanthroline moiety most likely binds with the end G-tetrad via π-π
stacking interactions. Results from molecular modeling180 and solution NMR spectroscopy by
other groups have shown that 5 and 6 positions of 1,10 phenanthroline are located close to the
grooves of G-quadruplexes when it stacks at the end G-tetrad of a G-quadruplex138. Therefore,
the side chains at the 5 position of 1,10-phenanthroline derivatives should readily fit into the
groove of G-quadruplex, enhancing the binding affinity of the ligand via a dual recognition
mode.

Figure 3.3. 5-substituted phenanthroline derivatives with piperidine, dimethylamine and 4methylphenyl side chains.

Encouraged by these findings, we decided to develop novel ligands by tethering
neomycin to the 5 position of 1,10-phenanthroline as a structured amino group side chain. The
tethering position on neomycin was the 5” position of the ring III. Previous studies suggested
that modification at this position has minimal influence on the binding affinity of neomycin to
secondary nucleic acid structures152.
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In the present work, two phenanthroline-neomycin conjugates were synthesized, which
differ in the length of the linker between the groove binder moiety (neomycin) and end stacking
moiety (1,10-phenanthroline) (Figure 3.4). Their binding affinity and selectivity to Gquadruplex were determined with biophysical methods, including fluorescence intercalator
displacement assay (FID), isothermal titration calorimetry (ITC), and thermal denaturation
monitored by circular dichroism (CD) or UV. The binding stoichiometry was determined by ESI
mass spectrometry, and plausible binding modes were estimated using molecular docking. In
vitro telomerase inhibition of the ligands was investigated using a modified Telomerase
Repeated Amplification Protocol (TRAP) assay.

Figure 3.4. Structure of the proposed compounds, with longer linker between 1,10phenanthroline and neomycin (7a), with longer linker between 1,10-phenanthroline and
neomycin (7b).

3.2. Experimental Section
3.2.1. Materials and General Methods
All the chemicals for synthesis were purchased from Sigma-Aldrich or Fisher Scientific
and used without further purification. DNA oligonucleotides were synthesized on an ABI 392
DNA/RNA synthesizer using standard phosphoramidite protocols and purified using
polyacrylamide gel electrophoresis. All reagents and solid-support columns for DNA synthesis
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were purchased from Glen Research. The concentrations of DNA solutions were determined by
UV spectroscopy, using the molar extinction coefficients (in units of mol of strand/L-1 cm-1)
obtained from OligoAnalyzer (www.idtdna.com). ε260 = 237,000 for G1 [5’AGGG(TTAGGG)3T-3’]; ε260 = 259,100 for S1 (5’ATGAAGGACGTAACCGGCTCTGAACG-3’); ε260 = 167,400 for S2 (5’CGTTCAGAGCCGGTTACGTCCTTCAT-3’); ε260 = 238,300 for TS primer (5’AATCCGTCGAGCAGAGTT-3’); ε260 = 261,000 for RP (5’GCGCGGCTTACCCTTACCCTTACCCTAACC-3’); ε260 = 151,800 for NT (5’ATCGCTTCTCGGCCTTTT-3’); ε260 = 370,100 for TSNT (5’AATCCGTCGAGCAGAGTTAAAAGGCCGAGAAGCGAT-3’). 1H NMR and 13C NMR
spectra were collected on a JEOL ECA 600 MHz FT-NMR spectrometer. Mass spectra of the
synthesized compounds were analyzed on an Agilent 1290 UHPLC coupled to an Agilent 6230
Time-of-Flight mass spectrometer at Chevron, Richmond, California. Mass spectra of ligandDNA complexes were collected on a Thermo Fisher Orbitrap Fusion Tribrid Mass Spectrometer.
UV spectra were recorded on a Varian Cary 100 Bio UV-Vis spectrophotometer equipped with a
thermoelectrically controlled 6 × 6 cell holder. Circular dichroism spectra were recorded on a
JASCO J-810 spectropolarimeter using a quartz cuvette with a 1 mm or 1 cm optical path length.
Isothermal microcalorimetric measurements were performed on a TA Instruments Affinity ITC
LV. T4 polynucleotide kinase was obtained from New England Biolabs. [-32P]-ATP was
purchased from MP Biochemicals. Quantification of 5’ 32P-labeled oligonucleotides was carried
out using a Storm 860 phosphorimager and ImageQuant 5.1 software. Cell medium and
supplements (fetal bovine serum, L-glutamine, antimycotic) were acquired from Invitrogen.
HeLa cells were maintained in advanced DMEM/F12 medium supplemented with 5% fetal
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bovine serum, L-glutamine, and antimycotic at 37 °C in a humid atmosphere containing 5% CO2.
DNA labeling was performed by incubating [-32P]-ATP (30 Ci) and T4 polynucleotide kinase
(20 units) in the presence of an oligonucleotide (10 pmol) at 37C for 30 min. Unreacted [γ-32P]ATP was removed using a MicroSpin G-25 column.
3.2.2. Synthesis of Phenanthroline-neomycin Conjugates
The final compounds 7a and 7b are synthesized as described in the scheme 3.1 and 3.2.
The synthesis of compounds 2-4 was described in chapter 2.
Synthesis of 5a-L. In a 50-ml round-bottomed flask, freshly cut sodium metal (0.648 g,
28 mmol) was added to anhydrous ethanol (20 ml) and stirred at 0 oC for 30 mins. 2aminoethanthiol hydrochloride (1.518 g, 13.4 mmol) was added to the flask, and the reaction
mixture was stirred for 5 mins at rt. Compound 3 (460 mg, 0.31 mmol) dissolved in dry ethanol
(10 ml) was added to the flask using a syringe. The reaction mixture was stirred at rt for 5 h.
The competition of the reaction was monitored with TLC [ Rf = 0.43 (CH3OH:CH2Cl2:NH4OH =
10:90:0.5 (v/v/v), silica gel 60 F254, EMD Millipore]. The reaction mixture was concentrated
under vacuum. Flash chromatography of the residue [silica gel, CH3OH:CH2Cl2:NH4OH =
5:95:0.5 (v/v/v)] yielded compound 5aL (324mg, 82.3 %) as a white solid.
Synthesis of 5b-S. In the hydrogenation flask, compound 4 (160 mg, 0.129 mmol) was
dissolved in 15ml of anhydrous ethanol. 40mg of the Pd/C catalyst was added to the flask, and
the reaction mixture was shaken overnight under 40 Psi H2 pressure. The completion of the
reaction was monitored for the disappearance of compound 4 using TLC. The mixture is filtered
through celite, and the residue is concentrated under vacuum to yield (130mg, 83 %) compound
5bS as a white solid.
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Synthesis of 9. In a 25-ml round-bottomed flask, β-aminoethanthiol hydrochloride (68
mg, 0.6 mmol) was dissolved in freshly prepared sodium ethoxide in ethanol (0.1M, 4 ml). 1,10Phenanthroline epoxide 8 (100 mg, 0.510 mmol) dissolved in anhydrous ethanol (4 ml) was
charged into the flask with a syringe. The reaction mixture was stirred at 50 oC for 10 h, and the
residue was concentrated under vacuum. [Rf =0.22, CH3OH:NH4OH = 20:1 (v/v), silica gel 60
F254, EMD Millipore]. Flash chromatography of the residue [silica gel, CH3OH:NH4OH (20:1)]
yielded 9 (110 mg, 84.6 %) as a slightly yellow oily liquid.
Synthesis of 9NCS. In a 25‐mL round‐bottomed flask, compound 9 (80.0 mg,
0.314 mmol) and DMAP (catalytic amount) were dissolved in DMF (10 ml) under N2. A DMF
solution (1 ml) of TCDP (109 mg, 0.471 mmol) was added dropwise into the flask using a
syringe, and the resulting mixture was stirred overnight at room temperature. The completion of
the reaction was monitored by TLC [Rf = 0.52, CH3OH:CH2Cl2:NH4OH = 8:92:0.5 (v/v), silica
gel 60 F254, EMD Millipore] under UV. The reaction mixture was concentrated under vacuum.
Flash chromatography of the residue [silica gel, CH3OH:CH2Cl2 = 5:95 (v/v)] yielded
compound 9NCS as a pale yellow oil (52.0 mg, 55.5%). IR (KBr, cm−1) 3,173, 3,018, 2,924,
2,187, 2,122, 2086, 1674, 1652, 1,590, 1,560, 1,502, 1,418, 1,344, 1,292, 1,284, 1,240, 1,142,
1,103, 1,079, 942, 874, 824. 1H NMR (600 MHz, CD3OD): δ 9.1 (dd, J = 4.2, 1.8 Hz, 1H), 9.03
(dd, J = 4.8, 1.8 Hz, 1H), 8.89 (dd, J = 7.8, 4.2 Hz, 1H), 8.38 (dd, J = 7.8, 4.2 Hz, 1H), 8.11 (s
1H), 7.82 (q, J = 4.2 Hz, 1H), 7.73 (q, J = 4.2 Hz, 1H), 3.79 (t, J = 6 Hz, 2H), 3.40 (t, J = 6.6 Hz,
2H).

13

C NMR (150 MHz, CD3OD) δ 151.16, 151.10, 146.91, 146.14, 137.35, 135.20, 133.55,

132.34, 130.36, 129.92, 125.13, 124.79, 45.48, 35.21. HRMS (ESI) calcd for
C15H13N3S2 [M + H]+: 298.0473, found 298.0459.
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Synthesis of 6a-L. In a 25‐ml round‐bottomed flask, 5a-L (50 mg, 0.0385 mmol) was
dissolved in anhydrous pyridine (5 ml). An anhydrous pyridine solution (1 ml) of
compound 9NCS (9 mg, 0.0302 mmol) was added dropwise into the flask with a syringe. The
reaction mixture was stirred overnight at room temperature under N2 and concentrated under
vacuum. [Rf = 0.24, CH3OH:CH2Cl2:NH4OH = 8:92:1 (v/v/v), silica gel 60 F254, EMD
Millipore]. Flash chromatography of the residue [silica gel, CH3OH:CH2Cl2:NH4OH = 8:92:1
(v/v/v)] yielded compound 6a-L (26.5 mg, 56 %). IR (KBr, cm−1) 3430, 2976, 2930, 1691,
1515, 1423, 1367, 1248, 1168, 1038. 1H NMR (600 MHz, CD3OD): ): δ 9.07 (dd, J = 4.2, 1.8
Hz, 1H), 8.97 (dd, J = 4.2, 1.8 Hz, 1H), 8.76 (dd, J = 8.4, 1.8 Hz, 1H), 8.36 (dd, J = 7.8, 1.8 Hz,
1H), 8.25 (s, 1H), 7.78 (q, J = 4.2 Hz, 1H), 7.70 (q, J = 4.2 Hz, 1H), 6.41 - 6.75 (m, 2H), 5.40 (s,
1H), 5.12 (s, 1H), 4.91 (s, 1H), 4.13 - 4.37 (m, 2H), 3.99 - 4.11 (m, 1H), 3.63 - 3.98 (m, 6H),
3.36 - 3.62 (m, 6H), 2.67 - 2.99 (m, 4H), 1.87 - 2.00 (m, 1H), 1.12 - 1.54 (m, 54H). HRMS (ESI)
calcd for C68H107N10O24S2 [M + H]+: 1571.6935, found 1571.6856.
Synthesis of 6b-S. In a 25‐ml round‐bottomed flask, 5b-S (46.8 mg, 0.0385 mmol) was
dissolved in anhydrous pyridine (5 ml). An anhydrous pyridine solution (1 ml) of
compound 9NCS (10.4 mg, 0.0350 mmol) was added dropwise into the flask with a syringe.
The reaction mixture was stirred overnight at room temperature under N2 and concentrated under
vacuum. [Rf = 0.30, CH3OH:CH2Cl2:NH4OH = 8:92:0.8 (v/v/v) silica gel 60 F254, EMD
Millipore], Flash chromatography of the residue [silica gel, CH3OH:CH2Cl2:NH4OH = 8:92:0.8
(v/v/v)] yielded compound 6b-S (23.7 mg, 40.7%). IR (KBr, cm−1) 3,340, 2,976, 2,920, 2,851,
1685, 1521, 1,384, 1,252, 1,174, 1,031. 1H NMR (600 MHz, CD3OD): 1H NMR (600 MHz,
CD3OD): δ 9.11 (dd, J = 4.2, 1.8 Hz, 1H), 9.00 (dd, J = 4.2, 1.8 Hz, 1H), 8.83 (dd, J = 8.4,
1.8 Hz, 1H), 8.41 (dd, J = 7.8, 1.8 Hz, 1H), 8.35 (s, 1H), 7.82 (q, J = 4.2 Hz, 1H), 7.76 (q, J
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= 4.2 Hz, 1H), 6.59 - 6.94 (m, 2H), 5.51 (s, 1H), 5.03 (s, 1H), 4.24 - 4.55 (m, 2H), 3.68 - 4.21
(m, 8H), 3.69 - 3.79 (m, 2H), 3.45 - 3.64 (m, 6H), 3.06 - 3.22 (m, 3H), 1.88 - 1.99 (m, 1H), 1.27 1.57 (m, 54H). HRMS (ESI) calcd for C68H107N10O24S2 [M + H]+: 1511.6901, found 1511.6894.
Synthesis of 7a and 7b. 5-10 mg of 6a-L (10 mg) or 6b-S (6mg) is dissolved in
trifluoroacetic acid (2 ml) in a small RBF and stirred for 15 mins. The reaction mixture was
concentrated under vacuum. The residual was dissolved in water, and the aqueous solution is
washed with DCM (3 x 3 ml). Lyophilization of the aqueous layer yielded compound 7a (92.4
%) and 7b (78.9 %).
7a. IR (KBr pellet, cm-1) 3436, 2919, 2847, 1623, 1503, 1412, 1043. 1H NMR (600
MHz, D2O) : δ 9.03 (d, J = 4.2 Hz, 1H), 8.84 - 8.99 (m, 2H), 8.69 (d, J = 7.8 Hz, 1H), 8.07 (s,
1H), 7.99 (dd, J = 8.4, 4.8 Hz, 1H), 7.93 (dd, J = 8.4, 4.8 Hz, 1H), 5.89 (d, J = 4.2 Hz, 1H), 5.24
(d, J = 3 Hz, 1H), 5.12 (s, 1H), 4.56 - 4.69 (m, 2H), 4.10 - 4.36 (m, 4H), 4.05 (t, J = 3 Hz, 1H),
3.93 (t, J = 9.6 Hz, 1H), 3.85 (t, J = 9.6 Hz, 1H), 3.60 - 3.81 (m, 4H), 3.53 (t, J = 9.6 Hz, 1H,),
3.15 - 3.49 (m, 12H), 3.09 (q, J = 7.2 Hz, 1H), 2.91 - 3.01 (m, 1H), 2.65 (dd, J = 15, 7.8 Hz, 1H),
2.42 - 4.62 (m, 2H), 2.33 (dt, J = 12.6, 4.2 Hz, 1H), 1.74 (q, J = 12.6 Hz, 1H). HRMS (ESI)
calcd for C40H64N10O12S3 [M+2H]2+: 486.1910, found 486.1933.
7b. IR (KBr pellet, cm-1) 3431, 2920, 2850, 1624, 1500, 1384, 1040. 1H NMR (600
MHz, D2O): δ 9.09 (d, J = 4.3 Hz, 1H), 8.89 - 9.03 (m, 2H), 8.76 (d, J = 8.4 Hz, 1H), 8.18 (s,
1H), 8.02 (dd, J = 8.4, 5.4 Hz, 1H), 7.97 (dd, J = 8.4, 4.8 Hz, 1H), 5.90 (d, J = 3 Hz, 1H), 5.27
(d, J = 3 Hz, 1H), 5.12 (s, 1H), 4.65 (s, 2H), 4.31 (t, J = 4.8 Hz, 1H), 4.02 - 4.26 (m, 3H), 3.97 (t,
J = 10.2 Hz, 1H), 3.50 - 3.92 (m, 7H), 3.05 – 3.50 (m, 11H), 2.35 (dt, J = 8.4, 2.4 Hz, 1H), 1.75
(q, J = 13.2 Hz). HRMS (ESI) calcd for C38H60N10O12S2 [M+H]+ : 911.3755, found 911.3754.
Yield was 5.00 mg, 78.9 %.
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3.2.3. MS Analysis Procedures of Synthesized Compounds
The samples were diluted in methanol to approximately 1 M concentration. A sample
solution (1 µL) was introduced by flow injection analysis (FIA) without a chromatographic
column except for compound 7a/7b where 2 µL was injected. The solvent system was 1:1
methanol:water with 0.1% formic acid. Ions were delivered to the mass spectrometer with an
electrospray ionization (ESI) source. The nebulizer pressure was 50 psig. at 325 °C and nitrogen
drying gas flow was 12 mL/min. The capillary voltage was 3000 V for all samples. For
compound 6 (Boc protected), the fragmentor voltage was 150 V. Data were collected in the m/z
range of 100-3200. Spectra were collected at a rate of 2 spectra/s allowing for 4903
transients/spectrum. For compound 7, the fragmentor voltage was 70 V. Data were collected in
the m/z range of 500-2000. Spectra were acquired at a rate of 1 spectra/s allowing for 9978
transients/spectrum.
3.2.4. Preparation of G-quadruplex DNA and Duplex DNA for CD and UV Experiments
The G-quadruplex DNA strand (G1, 100 M) was dissolved in a mixture (100 L) of
lithium cacodylate buffer (10 mM, pH 7.0) and KCl (50 mM) and incubated at 90 °C for 10 min,
slowly cooled to 25°C, and incubated at 4 C overnight. Similarly, duplex D1 (complementary
strands of S1 and S2, 100 M each) was dissolved in a mixture of lithium cacodylate buffer (10
mM, pH 7.0) and KCl (150 mM) and incubated at 90 °C for 10 min, slowly cooled to 25°C, and
incubated at 4 C overnight. All solutions were stored at 4 C for further use.
3.2.5. Preparation of G-quadruplex DNA for ESI Mass Spectrometry Experiments
G1 (100 µM) in 150 mM NH4OAc solution was heated to 95 °C for 5 min followed by
cooling slowly to room temperature and incubated at 4°C overnight.

122
3.2.6. Thermal Denaturation Analysis Monitored by CD
The mixture solutions (200 μL) of G1 (5 µM) in lithium cacodylate buffer (10 mM, pH
7.0) and KCl (50 mM) in the absence or presence of a ligand (Phen, neomycin, and 7a/7b, 10
µM) were prepared. The CD spectra were recorded at 290 nm as a function of increasing
temperature (25-85 ˚C) at a heating rate of 0.5 ˚C/min. Melting profiles were converted into a
folded faction based on a published procedure, and the melting temperatures were determined at
the 0.5 folded fraction.
3.2.7. CD Titration
Aliquots of a stock solution containing compound 7a/7b were gradually added into a
solution (2 mL) of G1 (5 M) in lithium cacodylate (10 mM, pH 7.0) and 50 mM KCl at 20 C.
The final molar ratios of 7 to G1 were varied from 0 to 5. After each addition, the solution was
gently mixed and incubated for 5 min for equilibrium before collecting the spectrum. The
overall volume change during the titration was kept less than 1% of the initial volume. CD
spectra were recorded as a function of wavelength (200-400 mm, 100 nm/min scan speed, 0.5 nm
data pitch) using a 1 cm pathlength quartz cuvette. Each spectrum was averaged over three
scans.
3.2.8. Thermal Denaturation Analysis Monitored by UV
The mixture solutions (1 mL) of D1 (1 µM) in lithium cacodylate buffer (10 mM, pH 7.0)
and KCl (150 mM) in the absence or presence of a ligand (Phen, neomycin, and 7a/7b, 10 µM)
were prepared. The UV melting curves were recorded at 260 nm as a function of temperature
(20-85 C, heating rate: 0.5 C/min). Melting profiles were converted into a folded faction, and
the melting temperatures were determined at the 0.5 folded fraction.
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3.2.9. Fluorescent Intercalator Displacement Assay
A reaction solution containing 0.25 μM DNA (G-quadruplex (G1) or duplex (D1) in
lithium cacodylate (10 mM, pH 7.0) and KCl (50 mM) was incubated with 0.5 μM thiazole
orange (TO) for 30 min in the dark. Aliquots of a ligand were added to this mixture solution and
equilibrated for 5 min in the dark before measurement. The fluorescence spectra (Ex: 501 nm,
slit width: 5.0 nm, scan speed 120 nm/min) were recorded from 510-650 nm after each addition.
The percent fluorescence displacement (%F) was calculated at λmax by using the formula %FI.
displacement=100-[(FA/FA0)×100], where FA0 is the initial fluorescence intensity in the absence
of a ligand, and FA is the fluorescence intensity upon addition of a ligand.
3.2.10. Isothermal Titration Calorimetry (ITC)
In a typical experiment, 2 µL aliquots of compound 7b (200 μM) were injected from a
264 µL rotating syringe (125 rpm) into an isothermal sample cell containing 185 μL of a
telomeric G-quadruplex (G1) (20 µM/strand) or a duplex DNA (D1) solution (10 µM/strand) at
25 °C. The corresponding control experiment was carried out by injecting 2 µL aliquots of
compound 7b (200 μM) into a solution of buffer alone. The duration of each injection was 4 s,
and the delay between injections was 120 s. The initial delay prior to the first injection was 100
s. A heat burst curve (microcalories per second vs. seconds) was generated from each injection.
The area under each curve was calculated using the NanoAnalyzer software (Version 3.8.0) to
yield a measure of the heat associated with that injection. The heat of ligand binding to DNA
associated with that injection was obtained by subtracting the heat associated with each ligandbuffer injection from the corresponding heat associated with each ligand-DNA injection.
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3.2.11. Preparation of Cell Lysate for TRAP Assay
Approximately 1 x 107 HeLa cells were suspended in CHAPS buffer (1 mL) and
incubated on ice for 30 min. The supernatant was collected after spinning the sample at 12,000 x
g for 10 min and stored at -80℃.
3.2.12. TRAP Assay
The 5′-[32P] end-labeled TS primer (0.1 μg) was incubated in a reaction mixture (50 μL)
[buffer: Tris-HCl (20 mM, pH 8.3), MgCl2 (1.5 mM), KCl (63 mM), 0.05% Tween 20, EGTA (1
mM)] with cell lysate (1 μL), RP (0.1 μg, reverse primer for telomerase extended products), NT
(0.1 μg, primer for polymerase as internal standard), TSNT (0.01 amol, template for NT primer),
2 units of Taq polymerase, dNTP mix (50 μM), and ligand (3.125-100 μM) at 30℃ for 30 min
and 94 ℃ for 2 min to deactivate telomerase. The reaction mixture was then incubated using a
3-step PCR method (94 ℃ for 20 s, 59 ℃ for 30 s, and 72 ℃ for 30 s) with a total of 25 cycles.
The residues were concentrated and resuspended in formamide loading buffer (7 μL). Analytical
separation was carried out using 10% denaturing polyacrylamide gel [5% crosslink, 45% urea
w/w].
3.2.13. Docking Procedure
The geometry optimization of compound 7b was carried out at the hybrid density
functional B3LYP level with 6-31G(d) basis set using the Gaussian’09 program package. The
Natural bond order (NBO) analysis was carried out to calculate the atomic charges on the
optimized geometries. G1 structure for docking simulation was modeled after the solution
structure of the complex of platinum (II) based ligand with human telomeric G-quadruplex (PDB
id: 5Z80) whose structure was obtained from RCSB protein data bank. In the complex structure,
the bound ligand molecule was removed. The resulting template has two more A residues at the
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5’-end and one additional A at the 3’-end in comparison to G1. In the NMR structure, Adenine25 was mutated to thymine, and residues adenine-1, 2, and 26 were truncated to yield the
structure of G1 for docking studies. The flexible ligand docking experiments were carried out
using the DOCK 6.9 program. Analyses of docked structures and docked image creations were
carried out using the UCSF Chimera program.
3.2.14. ESI-MS Analysis of Complex Formation Between G1 and 7a/7b
G1 (20 µM) and compound 7a/7b at various concentrations (0, 20, 40, 60, and 80 µM)
were mixed as 50% methanol-water solutions. The mixed solutions were injected into a Thermo
Fisher Orbitrap Fusion Tribrid Mass Spectrometer at a rate of 5 µL/min. The ion spray voltage
was set to -2,250 V and ion transfer tube temperature to 300 °C. Nitrogen sheath and auxiliary
gas flows were 45 and 0 arbitrary units, respectively. MS spectra were recorded in the m/z range
from 1400 to 1800 with an average of 150 scans. Data were collected and analyzed using the
Xcalibur 4.0 software.
3.3. Results and Discussion
3.3.1. Synthesis of Phenanthroline-neomycin Conjugates
As shown in the synthesis scheme 3.1 and 3.2, neomycin precursors were synthesized
based on the published procedures158,164. The C-5’’ position of the ribofuranose ring of
neomycin was used for conjugation as this site has a minimal effect on the structure of the
neomycin and its ability to bind to nucleic acids154,158. The six amino groups of neomycin were
protected with di-tert-butyl dicarbonate in 1:1 DMF-H2O to yield compound 2. Only the 5’’
position of ribofuranose ring of neomycin has a primary hydroxyl group, which was selectively
tosylated using 2,4,6-triisopropylbenzenesulfonyl chloride (TIPS-Cl) in dry pyridine at room
temperature to yield 3. The TIPS group was replaced with sodium azide via an SN2 reaction

126
mechanism in DMF at elevated temperature to yield compound 4, which was further converted
to 5b-S via catalytic hydrogenation utilizing Pd/C as the catalyst. The other analogue 5a was
synthesized by reacting compound 3 with β-mercaptoethanamine hydrochloride using sodium
ethoxide in ethanol at room temperature. Compound 9 was synthesized by reacting 5,6-epoxy5,6-dihydro-[1,10]phenanthroline 8 with β-mercaptoethanamine hydrochloride using sodium
ethoxide in ethanol181. Reaction of compound 9 with 1,1’-thiocarbonyldi-2(1H)-pyridone
(TCDP) in DMF yielded compound 9NCS. Compound 9NCS was coupled with compound 5a-L
and 5b-S through a thiourea linkage to yield a boc-protected phenanthroline neomycin
conjugates 6a-L and 6b-S, respectively. Deprotection of amine groups of 6a-L and 6b-S was
accomplished successfully with trifluoroacetic acid to yield final compounds 7a and 7b.

Scheme 3.1. Synthesis of neomycin amine at C5” of ring III. Reagents and conditions: (i)
(Boc)2O, DMF-H2O, 60 °C; (ii) 2,4,6-triisopropylbenznenesulfonyl chloride, pyridine, r.t.; (iii)
NaN3, DMF, 90 °C; (iv) Sodium ethoxide, ethanol, β-mercaptoethanamine; (68%) (v) Pd/C, H2,
r.t.

127

Scheme 3.2. Synthesis of phenanthroline derivatives 9NCS, 7a and 7b. Reagents and conditions:
i-iv: (i) Sodium ethoxide, ethanol, β-mercaptoethanamine. (ii) TCDP, DMF, r.t., overnight stir
(iii) dry pyridine (iv) TFA, 15 mins.

3.3.2. Phen-neo Conjugates Bind With High Affinity to G-quadruplex (G1) DNA
The binding of a telomeric G-quadruplex (G1) or a duplex (D1) with phenanthrolineneomycin conjugates 7a and 7b, phenanthroline (Phen), and neomycin was first assessed using
the Fluorescence Intercalator Displacement (FID) Assay182. This assay is based on the
phenomenon that binding of thiazole orange (TO) with nucleic acids can drastically increase its
quantum yield of dye from 2 × 10-4 to 0.1, about 1000 times. Free TO in solution does not
fluoresce. In a typical FID experiment, TO is first incubated with DNA to turn on fluorescence.
Addition of a ligand of interest into the TO-DNA solution can gradually displace TO out of
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DNA, resulting in the loss of fluorescence. The concentration of the ligand required to displace
50% of pre-bound TO from DNA is defined as DC50. Low DC50 values represent the high
binding affinity of the ligand towards DNA. For G-quadruplex and duplex DNA, this value is
designated as G4DC50 and dsDC50, respectively. It is noteworthy that TO is non-specific DNA
binding dye; therefore, it does not selectively bind to different types of nucleic acids183. The FID
assay has been used for the detection of ligands binding to non-canonical structures in the
genomic DNA184 in conjunction with other biophysical methods182. Over the years, it has been
successfully used to determine potent and selective G4 ligands that inhibit human telomerase
activity176.
Initial studies were carried out by incubating 7a or 7b with Ni2+ ion because coordination
of phenanthroline with metal ions can drastically enhance the stacking surface of the ligand. Our
results did not show enhanced binding of 7a and 7b to G1 compared with that of 7a and 7b alone
(Figure 3.5b). Neomycin is known to coordinate with metal ions185. It is possible that Ni2+
could not effectively coordinate with the Phen moiety of 7a and 7b due to the interference of
neomycin at the concentration range used. Therefore, due to this uncertainty, we only report the
binding of 7a and 7b (without Ni2+) with G-quadruplex DNA in the following section. As
shown in figure 3.5a, the corresponding rank order of the G4DC50 values was 7b < 7a <
neomycin << Phen. The G4DC50 value for 7b (0.9 µM) was impressively low, 50-fold less than
that of neomycin (49.8 µM) and at least 500-fold less than that of phenanthroline alone (> 500
μM). On the other hand, 7a, a longer linker analog of 7b, had a G4DC50 value of 1.32 µM. The
low G4DC50 values for 7b showed a stronger displacement of TO from G1 by 7b, suggesting that
the structured amino-containing binding motif (neomycin) can significantly enhance the binding
with G-quadruplex DNA. Using the same conditions, the dsDC50 values for these compounds
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were also measured with a DNA duplex (D1). The dsDC50 values for 7a, 7b, and neomycin are
2.78, 3.4 µM, and 5.7 µM, respectively. The relative selectivity of G-quadruplex over duplex
DNA was determined by the ratio of dsDC50/G4DC50. The rank order for such selectivity was 7b
(3.8) > 7a (2.0) > neomycin (0.11). It is clear that compound 7b binds more preferentially to G4
than duplex DNA as compared to 7a. Interestingly, neomycin has a smaller dsDC50 value (5.7
µM) than its G4DC50 value (49.8 µM). Phen binds to both duplex and G-quadruplex DNA very
weakly based on the FID data. Both of the G4DC50 and dsDC50 values for Phen are over 500 μM;
therefore, its selectivity of G4 over duplex DNA is negligible. An FID experiment of a mixture
of neomycin and Phen (1:1 molar ratio) was also carried out. The G4DC50 value for the mixture is
9.0 µM, much smaller than those of neomycin (49.8 µM) and Phen (> 500 µM), indicating that
the simultaneous binding of neomycin and Phen with G-quadruplex DNA has a synergistic
effect. As a comparison, this value is 10-fold greater than that of 7b (0.9 µM) and 6.8-fold
greater than that of 7a. Hence, conjugation of neomycin with Phen via covalent bonds provides
a more significant enhancement of binding with G-quadruplex DNA than merely mixing two
ligands. It is noteworthy that 7b shows more significantly enhanced binding with G-quadruplex
DNA than duplex DNA. The dsDC50 value (4.5 µM) of the mixture of neomycin and Phen is
similar to the values of neomycin (5.7 µM) and 7 (3.4 µM). The binding of duplex DNA by 7b
could mainly result from the non-specific binding by electrostatic interactions of cationic charges
of the neomycin moiety.

130

Figure 3.5. a) dsDC50 and G4DC50 values for compounds 7a and 7b, neomycin (neo), Phen, a
mixture of Phen and neomycin (1:1 molar ratio). b) the G4DC50 values of 7a, 7a-Ni, 7b, and 7bNi from the FID assay. 7a-Ni and 7b-Ni represent a mixture of Ni2+ with 7a and 7b in a 1:2
ratio, repectively. Buffer: 10 mM lithium cacodylate, 50 mM KCl, pH 7.0.

3.3.3. Compound 7b Binds and Stabilizes Telomeric Hybrid G-quadruplex Without
Producing Any Change in Conformation of the G-quadruplex
Circular dichroism spectroscopy is a useful technique to study the conformations of
biomolecules. For instance, it has been extensively used to study the conformation186 and
handedness of the G-quadruplexes187. Human telomeric G-quadruplex can adopt a variety of
conformations depending upon the metal ion165. In the presence of K+ ions, a hybrid topology188
is observed, which typically shows a maximum (+) around 290 nm, a shoulder (+) centered
around 260 nm, a weak band (+) with a maximum around 250 nm, and a band (-) with a
maximum around 240 nm. Whereas in Na+ it adopts a basket shape topology with a maximum
band (+) around 290 nm and a maximum (-) band at 260 nm. The change in intensity of the
bands along with their red or blue shift on ligand binding can provide useful information about
the process of ligand binding.
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Thermal denaturation monitored by CD is used to study the stabilizing influence of a
ligand on G-quadruplex DNA189. The ability of 7b to stabilize G1 was confirmed using thermal
denaturation of G1 monitored by circular dichroism at 290 nm. As shown in figure 3.6a and 2b,
the representative folded fractions of G1 in the absence and presence of a ligand (10 μM) are
plotted as a function of temperature. The melting temperature (Tm) of G1 was measured to be
61.0  0.6 °C. In the presence of neomycin or Phen at 10 μM, the Tm values were 60.6  0.3 °C
and 60.8  0.5 °C, respectively. Both neomycin and Phen could not stabilize G1 under this
condition. Phen did not increase the Tm value of G1, which is consistent with the previous
studies179. On the other hand, 7a destabilizes G1 by 4 oC. In the presence of 7b at 10 μM, a
shorter linker analog of 7a, the Tm value was 66.6  0.3 °C, a 5.6 °C increment as compared with
that of G1. Further increase in the concentration of 7b did not increase the Tm of G1
significantly (Figure 3.6c). When incubating G1 with neomycin (10 μM) and Phen (10 μM), no
increment of Tm (61.0  0.8 °C) was observed. Because both neomycin and phenanthroline
alone were ineffective in stabilizing the G1, therefore, the stabilization effect of 7b toward G1
must be resulting from a synergistic enhancement of binding affinity by conjugating neomycin
and phenanthroline together. Similar results were obtained from thermal denaturation monitored
by UV at 295 nm (Figure 3.6d).
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Figure 3.6. a) CD thermal denaturation of G1 in the presence of phen-neo conjugates,
phenanthroline, neomycin, and phen:neo (1:1). b) Tm of G1 in the presence of the ligands. c)
Effect of molar concentration of 7b on Tm of G1. d) UV thermal denaturation of G1 in the
presence of phen-neo conjugates, phenanthroline, neomycin, and phen:neo (1:1).

The difference in thermal stabilization of G1 by 7a and 7b prompted us to investigate
their interactions with CD titration experiments. As shown in Figure 3.7b, G1 in K+ adopts a
hybrid-type topology with a maximum (+) around 292 nm, a shoulder (+) centered around 270
nm, a weak band (+) with a maximum around 250 nm, and a band (-) with a maximum around
235 nm, which is consistent with previous reports.
In general, titration of G1 with 7b did not lead to an overall topological change of G1. A
hybrid conformation was conserved even at the 5:1 ligand to DNA ratio. When the ligand to
DNA molar ratio was below 3, a gradual increase in the intensity of the band (-) at 235 nm, the
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band (+) at 250 nm, and the band (+) around 292 nm was observed, respectively, suggesting that
a further stabilization of the folded hybrid conformation. When the ligand to DNA molar ratio
was above 3, a slight decrease in the intensities of these three bands occurred. A redshift of the
band (+) at 293 up to 300 nm was clearly observed. It is known that the lateral or diagonal loops
of G-quadruplexes greatly affect the shape of their CD spectra. At high ligand to DNA molar
ratios, it is plausible that the neomycin moiety of 7 could interact with the loops of G1 via nonspecific interactions, causing the observed shift in band maxima (Figure 3.7b).
By contrast, titration of 7a with G1 showed a distinct difference (Figure 3.7a). At the
ligand to DNA ratio of 0.5, an increase in the intensity of band (+) around 292 nm along with the
loss of shoulder peak at 270 nm and a slight dip of the peak at 260 nm was observed. At the
ligand to DNA molar ratio of 3, the intensity of the band around 292 nm increased along with the
redshift of the band, and the intensity of the peak (-) at 260 nm also deepened, suggesting the
topology of G1 was more close to the antiparallel G-quadruplex [the maximum (+) around 292
nm and a band (-) with a maximum around 260 nm]. When the ligand to DNA molar ratio was
above 3, a decrease in the intensity of the band (+) around 300 nm and concomitant increase in
the maximum (-) around 260 nm was observed probably due to the non-specific interactions
between the ligand and DNA at higher concentrations. The transient increase in the antiparallel
topology character observed in the CD titrations might be due to the unfolding pathway of the
G1.
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Figure 3.7. a) CD titrations of compound 7a against G1. b) CD titrations of compound 7b
against G1.

Based on kinetic studies of folding and unfolding pathways of the human telomeric Gquadruplexes, Chaires et al190 proposed the following folding/unfolding mechanism for htelo Gquadruplexes (Figure 3.8). The unfolding of the G-quadruplex was proposed to be sequential190,
which can be used to explain the Tm difference observed for 7a and 7b in our studies.
Non-specific binding of 7a with random coil destabilizes the established equilibrium in
solution. More hybrid G-quadruplex unfolds sequentially through a triplex like intermediate, an
antiparallel intermediate, and finally a hairpin-like intermediate. The observation of the
antiparallel signature by CD at the ligand to DNA molar ratio of 3 and higher and the observed
destabilization of (ΔTm = - 4 oC) could fit for this explanation. It is noteworthy that we observed
turbidity in solution when titrating 7a into G1 at the ligand to DNA molar ratio more than 3.
Turbidity could come from the precipitation of DNA because of the non-specific binding of 7a
with G1. In the FID experiments, the unfolding of G1 by 7a could release TO of G1, leading to
a concomitant decrease in fluorescence.
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Figure 3.8. Folding and unfolding pathway of the htelo G-quadruplexes190.

The stabilization effect of neomycin, 7a and 7b, and Phen on a duplex DNA (D1) was
investigated using thermal denaturation monitored by UV (Figure 3.9). None of them showed a
noticeable stabilization effect on the melting of D1, suggesting a weak binding of phen-neo
conjugates with duplex DNA.

Figure 3.9. UV thermal denaturation of dsDNA in the presence phen-neo conjugates,
phenanthroline and neomycin.
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3.3.4. Compound 7b Binds to G1 in a 1:1 Binding Stoichiometry
The electrospray-ionization mass spectrometry (ESI-MS) is a highly sensitive analytical
technique for the analysis of small molecule-DNA interactions. The use of ESI-MS for the Gquadruplex structure analyses136, relative binding affinity calculations82, and binding
stoichiometry176 is well documented. Compared with other analytical techniques like NMR and
x-ray crystallography, which are also used for G-quadruplex-ligand binding interactions, ESI-MS
requires simple sample preparation or less sample consumption due to its high sensitivity. In
addition, studies have documented that G-quadruplexes maintained their solution-phase structure
in the gas phase191,192.
Because of the possible ion suppression effect of non-volatile alkali metals, ammonium
acetate was commonly used for studying G-quadruplex DNA in ESI-MS. Ammonium ions assist
in the folding of G-quadruplex just as K+ ions do. As shown in figure 3.10, G1 in NH4+ adopts a
hybrid topology determined by CD spectroscopy. Because NH4+ ions are present between the
adjacent G-tetrads; therefore, the number of NH4+ associated with the G-quadruplex structure
indicates the number of G-tetrads in the topology. For example, the observation of two NH4+
ions in a G-quadruplex complex suggests that it contains three G-tetrads.136,193
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Figure 3.10. CD spectrum of the human telomere DNA (5 µM) annealed in 150 mM ammonium
acetate and 10 mM LiCaco buffer.

In our study, the complexation of a ligand (7a, 7b, or neomycin) with G1 in NH4+ was
investigated with electrospray ionization (ESI) mass spectrometry. All the spectra shown here
are normalized relative to the most abundant ion peak (base peak) in the spectrum. Mixtures of a
ligand (7a or 7b) and G1 at a molar ratio ranging from 1:1 to 1:4 in 150 mM NH4+ were prepared
and analyzed. A solution of G1 under the same condition in the absence of a ligand was used as
a control. A mass spectrum representing a mixture of G1 and 7b ([G1]:[7] = 1:2) is shown in
figure 3.11b. The formation of the G-quadruplex structure was confirmed by the peak at m/z
1459.85, representing the ion [G1+2NH4+-7H+]5-. The inclusion of two NH4+ ions is a distinct
indication of the presence of three G-tetrads in the G-quadruplex. Compound 7b was found to
form a 1:1 complex with G1, indicated by the ion [G1+2NH4++7b-7H+]5- at m/z 1642.13. The
relative abundance of the complex is higher than those of free intact G-quadruplex when the
molar ratio of 7b to G1 is larger than 1 suggesting the strong tenancy of 7b to bind with the G-
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quadruplex. It is noteworthy that varying the molar ratios of 7b and G1 did not lead to different
binding stoichiometries (Figure 3.11c and 3.11d)

Figure 3.11. Mass spectrum of a mixture solution of G1 and 7b at different molar ratio. The peak
with the maximum intensity was set as the base peak (100%).

Interestingly, mixtures of 7a and G1 did not show any complexation in ESI mass
spectrometry, even with the molar ratio of 7a to G1 at 4 (Figure 3.12b). It is noteworthy that
precipitation was observed when the ratio of 7a to G1 was above 3. Failing to observe the
complexation of 7a with G1 suggested a relatively weak interaction between the two, which is
consistent with our thermal stabilization studies. Because of this, in the following sections, we
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will only pursue further biochemical and biophysical characterization of 7b with telomeric Gquadruplex DNA.

Figure 3.12. Mass spectrum of a mixture solution of G1 and 7a at [7a]:[G1] = 1 (left) and at
[7a]:[G1] = 4 (right). The peak with the maximum intensity was set as the base peak (100%).

3.3.5. 7b Binds With a Much Higher Binding Affinity to G1 as Compared to Neomycin and
Phenanthroline
Isothermal titration calorimetry (ITC) was used for the analysis of the thermodynamics of
binding. ITC is a gold standard for measuring binding affinity, and it is the only technique that
measures the binding enthalpy directly. It allows for the dissection of the free energy of binding
into the relative contribution of the entropy and enthalpy components, providing indispensable
information about the kinds of forces involved in binding and ligand optimization194. A
complete thermodynamic characterization provides more information on the nature of driving
force for the binding process if they are enthalpic or entropic in origin.
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In a typical ITC experiment, a series of aliquots of a ligand are injected into a sample cell
containing the binding substrate. The heat released or gained during each injection is integrated
and plotted against the molar ratio of ligand to substrate. The resulting thermogram is then fitted
with a binding model that can describe the binding event. The fitting provides crucial
parameters, including the number of binding sites, enthalpy, entropy, and free energy of the
binding event (Figure 3.13)194.

Figure 3.13. Basic principle of isothermal titration calorimetry194.

In the present study, ligands (7b and neomycin) were analyzed for their thermodynamics
of binding to a telomeric G-quadruplex (G1) and a 26-mer duplex (D1). Figure 3.14 shows the
representative ITC profiles (upper panels) resulting from a series of injections of 7b (200 µM)
into a solution (20 μM) of G1 (A) and D1 (B) in K+ at 25 °C. Each injection of the ligand to the
G1/D1 is accompanied by the heat burst from the binding event and heat of dilution. The area
under the thermogram peak is calculated with Nano Analyze software (version 3.8.0) and plotted
against the molar ratio of ligand to DNA in the calorimetry cell. Calorimetric data from
injections of 7b into K+ phosphate buffer under the same experimental conditions is used as
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blank for the heat of dilution (black peaks in the thermograms). The blank data was deducted on
the peak by peak basis from the heat of interaction between ligand 7b and G1/D1.
The dotted lines (Figure 3.14, lower panels) show the resulting corrected injection heats
(by subtracting the blank data for corrections of dilution effects) plotted as a function of the
[7b]/[DNA] molar ratio.

a

b

Figure 3.14. upper panel: ITC profiles of G1 (20 µM) (A) and D1 (10 µM) (B) titrated with 7b
(200 µM) in a 10 mM potassium phosphate buffer with a total of 150 mM K+, pH 7.0 at 25 °C.
The black peaks represent the heat of dilution. lower panel: The dotted line represents the
integrated corrected injection heats plotted as a function of the [7b]/[G1] (A) and [7b]/[D1] (B)
molar ratio. The smooth solid line reflects the calculated fit of the data using the binding models
(multiple-sites for G4 and independent for duplex) from the software NanoAnalyze. Upward
peaks represent an exothermic event.

Two slopes in the graph (Figure 3.14a, lower panel) are indicative of two primary
binding events (there could multiple-binding sites with equal binding affinities). The data best
fit a multiple-sites model with a 90% confidence level and result in the two association constants
(Kas), (8.92.4)×108 M-1 and (3.5 0.5)×105 M-1. Based on the Ka values, the first binding event
is a tight binding with a sharp transition, and the second binding event shows a gradual slope
towards the binding saturation of G1 by 7b, suggesting a relatively weak binding. Neomycin is
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positively charged under the conditions used in the study, so it is reasonable to expect weak nonspecific electrostatic interactions between the charged molecules. A similar low-affinity second
binding event at higher concentrations was also found in the study of G-quadruplex ligands such
as BRACO-19195 and Se2SAP196 by other groups, which have permanently charged side chains.
Binding enthalpies for the two events were determined to be ΔH1 [-(37.31.6) kJ/mol] and ΔH2 [(32.30.5) kJ/mol], indicative of highly enthalpically favored binding for both events. The first
binding event is entropy favorable with a TΔS value of +13.8 kJ/mol, which means the binding
process is accompanied by favorable release of small molecules (e.g., water, ions). Just like
duplex DNA, G-quadruplexes also have organized water molecules (hydration of spine) in the
grooves197. The neomycin moiety of 7b binds into the grooves of G1 could release water
molecules and/or metal ions. According to a survey of thermodynamic signatures for ligandDNA binding mode, groove binding is predominantly entropically driven, while intercalation is
enthalpically driven. Our observation suggests that the tight-binding event could involve both
groove-binding and π-π stacking, implying a synergetic binding effect between Phen and
neomycin. The second binding event is slightly entropy unfavorable with a TΔS value of -0.7
kJ/mol, which might be coming from non-specific interactions with the loop nucleotides or
backbones without the release of relative equivalents of the water or ions. The presence of the
first strong binding event was highlighted by a separate ITC titration experiment in which a
series of injections of 7b (200 µM) was titrated into a solution (40 μM) of G1 to reach a final
mole ratio of approximately 3 (Figure 3.15a).
The overall stoichiometry for binding of 7b to G1 in the K+ solution was determined to
be approximately five ligands per G-quadruplex DNA. The sizeable binding stoichiometry also
suggests the second (weak) binding event may be associated with non-specific binding. It is
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noted that only a 1:1 binding stoichiometry was obtained from the ESI/MS experiments, as
mentioned above. This discrepancy could result from the stability variations of ligand-DNA
complexes in the solution phase and the gas phase of experimental conditions; therefore, the
binding of 7b to weaker binding sites (non-specific binding) might not be observed in the
ESI/MS experiments. The binding selectivity of 7b for G1 was analyzed by performing another
experiment at 25 °C with D1. The binding isotherm of 7b with D1 (Figure 3.14b, lower panel)
best fits with an independent (single-site) model with a 90% confidence level and result in an
association constant of (5.90.3)×104 M-1 as evident from the gradual slope. It is evident that the
binding of 7b with D1 is much weaker than both binding events of 7b with G1 when comparing
Ka values. The results obtained here are consistent with the aforementioned biophysical studies,
in which compound 7b binds preferentially to telomeric G4 over duplex DNA. As a comparison,
the titration of neomycin to G1 at 25 oC was performed under the same condition. The binding
of neomycin to G1 showed a much lower association constant of (6.10.2)×103 M-1 (Figure
3.15b). Given that Phen does not bind to G4s and weak binding of neomycin with G1, the
strong binding of 7b with G1 must come from covalently tethering neomycin and phenanthroline
together.
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a

b

Figure 3.15. upper panel: ITC profiles of G1 (40 µM) titrated with 7b (200 µM) (A) and G1 (20
µM) titrated with neomycin (400 µM) (B) in a 10 mM potassium phosphate buffer with a total of
150 mM K+, pH 7.0 at 25 °C. The black peaks represent the heat of dilution. lower panel: The
dotted line represents the integrated corrected injection heats plotted as a function of the
[7b]/[G1] (A) and [Neomycin]/[G1] (B) molar ratio. The smooth solid line reflects the
calculated fit of the data using the binding models (Independent model for 7b and multiple sites
for neomycin) from the software NanoAnalyze. Upward peaks represent an exothermic event.

3.3.6. 7b Binds to G1 With a Dual Recognition Mode
Plausible binding modes of 7b with human telomeric G-quadruplex DNA was
investigated using the DOCK 6.9 program. Because the G4 structure of the exact sequence used
this work is not available in the data bank, we modeled G1 structure using the NMR solution
structure (PDB id: 5Z80) of the complex formed by a platinum ligand and a human telomeric Gquadruplex as the initial point. It is noted that the G-quadruplex-forming regions of G1 and
5Z80 are the same. Upon manual removal of the platinum ligand and modification of a few
residues at the 5’ and 3’-positions, the resulting G4 structure has the same sequence as G1 and is
a hybrid-type topology. The simple docking results show that compound 7b can bind in the
original binding site of the hybrid G-quadruplex, where the platinum ligand was found in the
solution NMR structure. The most energetically favorable binding mode (Figure 3.16a) of 7b
has the phenanthroline ring stack on top of the base pair in the G-quadruplex through π-π
stacking and the neomycin moiety in the groove of the G-quadruplex. Further analysis shows π-
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π stacking between the phenanthroline ring of 7b and residues of adenine-7 and guanine-8
(Figure 3.16b) and hydrogen bonding interactions of the neomycin moiety with guanine-21
amino group in the groove with the primary amine group on idopyranose ring of neomycin.
Similarly, one of the amine groups in the glucopyranose ring of neomycin (circled) interacts with
the guanine in the upper G-tetrad. In addition, neomycin was found to have hydrogen bonding
interactions with the phosphate backbone of residues 19-21 (Figure 3.16c). The proposed
binding mode is cohesive with the synergistic effect observed from biophysical studies. Using
docking simulation, we also found several binding modes that do not interfere with each other.
A representative binding mode of G1 with three molecules of 7b is presented in (Figure 3.16d).
These binding modes could represent plausible non-specific interactions between G1 and 7b due
to the electrostatic interactions of the neomycin moiety with DNA backbones.
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Figure 3.16. a) Docked structure of compound 7b with a human telomeric G-quadruplex (G1).
G-quadruplex is represented as surface colored by electrostatic potential, and the ligand is
represented as ball and stick. b) π-π stacking interactions of the phenanthroline moiety with the
top G-tetrad of G1. c) Binding interactions of the neomycin moiety with the groove of G1. The
distances are in Å. d) A plausible binding mode of three molecules of 7b at higher concentration
to G1.3.3.6. 7b inhibits the telomerase activity at low micromolar concentrations.

Upon confirming the favorable interactions between 7b and the telomeric G4, we
investigated their inhibition of human telomerase activity in vitro using a modified (Telomerase
Repeat Amplification Protocol) TRAP assay.
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3.3.7. 7b Inhibits Telomerase at Low Micromolar Concentration as Determined by TRAP
Assay
TRAP assay was originally developed by Kim et al198 to study the relationship between
cancer cell immortality and telomerase concentration (above a certain threshold). It includes
three steps (Figure 3.17):
1. Extension: Telomeric repeats are added to the radiolabeled telomerase substrate (TS
Primer). In humans, a 6-mer repeat 5’-TTAGGG-3’ is added by the telomerase during
each round of addition.
2. Amplification: Extension of extended DNA by PCR with reverse primer RP and
forward primer TS.
3. Detection of telomerase products: The presence and absence of telomerase activity is
analyzed by gel electrophoresis. Typically, a ladder-like pattern reflects the activity of
telomerase because it adds different units of 5’-TTAGGG-3’ during the process.
The compound may inhibit the DNA polymerase during the amplification step, which
would give false-positive results. We used an internal standard to distinguish if a compound
inhibits telomerase activity (through G-quadruplex stabilization) and not DNA polymerase
(directly or by binding to duplex) from amplifying the telomerase extended product because
either event will give a positive result.
An internal standard TSNT, a non-G-rich oligonucleotide primer, is used in the assay,
which is amplified with its own reverse primer NT during the amplification step. With the
addition of the internal standard, the results can be interpreted in the following ways. First, if
both the ladder pattern and internal standard are observed, then the ligand has no effect on both
the telomerase and polymerase activity. Second, if the telomerase extended products are reduced
or disappeared and the product of the internal standard is still present, the compound inhibits
telomerase activity while having no effect on the polymerase activity. Therefore, the use of the
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internal standard helps in predicting ligand selectivity for G-quadruplex (telomerase) over duplex
DNA (polymerase).

Figure 3.17. Schematic presentation of a TRAP assay.

Two control compounds, BIBR (50 µM) and TmPyP4 (100 µM ), were employed in the
assay. BIBR199 is a telomerase translocation inhibitor which inhibits the telomerase activity
without interacting with DNA. TMPyP4 is a known G-quadruplex DNA binding ligand82,175.
As shown in figure 3.18, Lane 1 is the negative control Lane with no telomerase. Only
the product of the internal standard (IS) band was observed at the bottom. Lane 2 is a positive
control Lane with telomeres in the absence of any ligand. The latter pattern indicates the
telomerase activity, and the product of the internal standard (IS) at the bottom shows the
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polymerase activity. Lane 3 represents the reaction with BIBR. The extension product bands
were negligible, while the band for the internal standard was clearly observed, suggesting that
BIBR inhibited telomerase but not polymerase in the reaction. In contrast to BIBR, TMPyP4, a
potent non-selective G-quadruplex ligand, fully inhibited the activities of both telomerase and
polymerase. No telomerase extension and PCR product bands (IS band disappeared) could be
observed (Lane 4). The large stacking surface of TMPyP4 could intercalate into duplex DNA at
this high concentration (50 μM) and thus inhibit the polymerase activity. These results were
consistent with previously reported data. Compound 7b (Lanes 5-8) selectively inhibited the
telomerase activity while it has no effect on the polymerase activity in the concentration range of
1.6 to 12.5 µM. The inhibition of telomerase activity by 7b could be unambiguously observed at
3.1 µM. Such inhibition is clearly concentration-dependent. At 12.5 µM, the activity of
telomerase is greatly inhibited while the polymerase activity remains unaffected (IS band
observed). Lane 9-11 represent the reactions in the presence of a mixture of phenanthroline and
neomycin (1:1 molar ratio). Even at 25 µM, the mixture could not inhibit the telomerase activity
because no extension products were observed. This observation further suggests a synergistic
enhancement of the G-quadruplex mediated telomerase inhibition by phenanthroline-neomycin
conjugation.
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Figure 3.18. 32P-TRAP reactions in the presence of 7b (left) at concentrations of 12.5, 6.25,
3.125 and 1.56 µM in Lanes from 5 to 8, respectively. 32P-TRAP reactions in the presence of
phen:neo (1:1) (right) at concentrations of 25, 12.5, and 6.25 µM in Lanes from 9 to 11,
respectively. Reactions in the presence of BIBR (50 µM) and TMPyP4 (50 µM) were carried
out as controls. IS: PCR product as the internal control.

3.4. Conclusion
In summary, the data here demonstrate that structured amino-containing side chains such
as neomycin can be used as a suitable binding motif for 5-substituted phenanthroline based G4
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ligands and telomerase inhibitors. Phenanthroline-neomycin conjugates can bind to telomeric Gquadruplex selectively over duplex DNA. The binding of conjugates to telomeric G-quadruplex
DNA depends on the linker length between two moieties. Phenanthroline-neomycin conjugates
bind to G-quadruplex in a synergistic fashion, in which phenanthroline stacks with the end Gtetrad while neomycin binds into the groove. Phenanthroline-neomycin conjugates can inhibit
telomerase activity at low micromolar concentrations. The research presented in this chapter
suggests that a structured amino group side chain can be used as a motif for designing selective
G-quadruplex ligands and telomerase inhibitors.
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CHAPTER 4: 2-CLIP-PHEN DERIVATIVES AS G4 LIGANDS TARGETING
ANTIPARALLEL G-QUADRUPLEXES

4.1. Introduction
G-quadruplexes are dynamic DNA secondary structures, which have received much
attention due to their direct involvement in the regulation of proto-oncogenes. The Gquadruplexes are formed in a stretch of G-rich strands, and many G-quadruplex conformations
are in a dynamic equilibrium36,37. The interplay of these conformations may control gene
expression in various ways; however, the understanding of such relationships is still in infancy.
Efforts are usually spent on targeting the most stable conformation under physiological
conditions studied by solution-phase NMR63,101,200, molecular dynamics simulations, along with
a variety of biochemical and biophysical techniques201. Most of the ligands have good
selectivity for G-quadruplex over duplex DNA195. Examples of selective ligands toward Gquadruplexes with different conformations are scarce. Hundreds of thousands of putative Gquadruplexes forming sequences are present in the human genome. Without efficient ligands to
target different G-quadruplexes, off-targeting side effects202 could occur in therapeutic
applications. There are more than 1000 G-quadruplex ligands in the G4 database. Most of them
have extended aromatic surface to end-stack a G-quadruplex and contain cationic side chains to
enhance the binding with electron-rich G-quadruplex grooves.92,105 As mentioned in the
previous chapters, extended aromatic rings could increase the selectivity of a ligand for Gquadruplex over duplex DNA, while cationic side chains often decrease the ligand’s selectivity
to some extent. Two drugs CX-5461203 and CX-3543204 (Quarfloxin) have entered clinical trials,
which can induce selective lethality in DNA repair-deficient cancer cells by stabilizing G-
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quadruplexes in vivo203. Both drugs cannot selectively target G-quadruplex conformations as
found in vitro studies. In fact, most of the G-quadruplex binding ligands developed so far have
limited conformational selectivity61,87,175,205.
In our effort to develop more potent G-quadruplex ligands, we came across a novel class
of molecules that show good selectivity for antiparallel G-quadruplexes over parallel and hybrid
G-quadruplexes. In chapter 3, I reported phenanthroline-neomycin conjugates as G4 ligands.
Previous studies in our group showed when 5-substituted 1,10-phenanthroline derivatives
coordinate with Ni2+ ions, the resulting complexes have enhanced binding affinity towards Gquadruplexes179. The enhancement comes from forming a larger aromatic surface by
coordinating two phenanthroline molecules with a Ni2+ ion. In light of this finding, we initially
tried to complex phenanthroline-neomycin conjugates (Chapter 3) with Ni2+ to develop more
potent G4 ligands; however, our attempt was unsuccessful because the interference of neomycin
with metal ions made the study complicated. So, we sought to covalently link two 1,10phenanthroline moieties with a serinol bridge that can mimic the phenanthroline-Ni2+ planar
structure (Figure 4.1). The proposed molecule known as 2-Clip-phen was previously developed
by Pitie et al206. 2-Clip-phen coordinated with Cu2+ has been used as an artificial endonuclease,
which cleaves deoxyribose units from the minor grooves of DNA207–209. Efforts have been made
to improve the DNA binding affinity by conjugating 2-Clip-phen with spermine208. 2-Clip-phen
was tethered with acridine210 and poly N-methylpyrrole209 to increase its cellular uptake and
DNA cleavage efficiency. 2-Clip-phen has also been linked to cis-platin, and the resulting
complex showed dual functionality – DNA cleavage and DNA crosslinking26,211 (Figure 4.2).
Ozalp-Yaman et al212 synthesized bis-Clip phen platinum compounds for better DNA cleavage
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and cytotoxicity. Recently, conjugation of clip-phen with a triplex-forming oligonucleotide
(TFO) for site-specific DNA cleavage has reported213.
From the structure viewpoint, 2-Clip-phen has a very large extended aromatic surface
that in theory, should stack with G-tetrads well. We believe it could be used as a lead to develop
G-quadruplex ligands. Surprisingly, to the best of our knowledge, no studies using 2-Clip-phen
as a G-quadruplex ligand scaffold have been reported in the literature. Only one similar
structure, a bis-phenanthroline derivative with a single-nitrogen-atom linker, was reported by
Bianco et al214 for recognition of G-quadruplexes (Figure 4.3), which has a weak-to-moderate
G-quadruplex binding ability. Given the ability of 2-Clip-phen to cleave DNA, we believe that it
can be used as a promising scaffold for developing G-quadruplex binding ligands and for Gquadruplex specific cleaving agents (future direction).

Figure 4.1. A) 5-substituted phenanthrolines B) 2-Clip-phen design.
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Figure 4.2. The complex of the Clip-phen with cis-platin.

Figure 4.3. Bis-phenanthroline ligand with a three-carbon linker between two 1,10phenanthroline rings.

Our multiple attempts to synthesize the 2-Clip-phen and neomycin conjugates were
unsuccessful. The 2-Clip-phen moiety was degraded under the acidic deprotection condition for
Boc groups (Scheme 4.2). Hence, we replaced neomycin with various amino-containing side
chains and synthesized a series of conjugates. To our surprise, these conjugates can specifically
target antiparallel G-quadruplexes over hybrid and parallel G-quadruplexes. This discovery is
exciting, and it allows us to add novel G-quadruplex ligands that can distinguish conformations
to the G4 ligand library. The structures of the 2-Clip-phen conjugates also provide future
directions to develop novel G4 ligands. The synthesis and biophysical evaluations of these
ligands will be presented in Chapter 4.
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4.2. Experimental Section
4.2.1. Materials and Methods
All the chemicals for synthesis were purchased from Sigma-Aldrich or Fisher Scientific
and used without further purification. DNA oligonucleotides were synthesized on an ABI 392
DNA/RNA synthesizer using standard phosphoramidite protocols and purified using
polyacrylamide gel electrophoresis. All reagents and solid-support columns for DNA synthesis
were purchased from Glen Research. The concentrations of DNA solutions were determined by
UV spectroscopy, using the molar extinction coefficients (in units of mol of strand/L-1 cm-1)
obtained from OligoAnalyzer (www.idtdna.com). ε260 = 237,000 for G1 [5’AGGG(TTAGGG)3T-3’]. ε260 = 248200 for G3 (5’-TGG GGA GGG TGG GGA GGG TGG
GGA-3’). ε260 = 259,100 for S1 (5’-ATGAAGGACGTAACCGGCTCTGAACG-3’); ε260 =
167,400 for S2 (5’- CGTTCAGAGCCGGTTACGTCCTTCAT-3’). 1H NMR and 13C NMR
spectra were collected on a JEOL ECA 600 MHz FT-NMR spectrometer. Mass spectra of the
synthesized compounds were analyzed on an Agilent 1290 UHPLC coupled to an Agilent 6230
Time-of-Flight mass spectrometer. Mass spectra of ligand-DNA complexes were collected on a
Thermo Fisher LTQ Mass Spectrometer. UV spectra were recorded on a Varian Cary 100 Bio
UV-Vis spectrophotometer equipped with a thermoelectrically controlled 6 × 6 cell holder.
Circular dichroism spectra were recorded on a JASCO J-810 spectropolarimeter using a quartz
cuvette with a 1 mm or 1 cm optical path length.
4.2.2. Synthesis of 2-Clip-phen (2-CP) Derivatives
Compounds 2-CP-1 and 2-CP-2 were synthesized according to the scheme 4.1. 5a-NCS
was synthesized using the published procedure154. Compound 5b-NCS was synthesized from
5b-S, which was synthesized as described in chapter 3. We were not able to deprotect the 2-CP-
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1 and 2-CP-2 to get the final compounds even when we used the mildest conditions possible215
for deprotection. The synthesis of 2-CP-1 and 2-CP-2 is described below (Scheme 4.1 and
Scheme 4.2). We also synthesized a series of novel 2-Clip-phen derivatives (10-18) by
decorating 2-Clip-phen scaffold with potent G-quadruplex binding side chains88,130 (scheme 4.3
and scheme 4.4).
Synthesis of 2-Clip-phen (2-CP). Synthesis of this compound was done following the
published procedure206 with some changes. To the solution of sodium hydride (232 mg, 5.8
mmol) in dry DMF (4ml) at 0oC in two neck flask were added 2-bromo-1,10-phenanthroline
(200 mg, 0.77 mmol) and serinol (35mg, 0.386 mmol). The reaction mixture was stirred at 0oC
for 24 h and then allowed to warm to room temperature. The crude product was dissolved in 10
ml of DMF and 3.4 ml of ethanol and precipitation was done with 33 ml of water. The
precipitates were collected with vacuum filtration and re-dissolved in 18 ml of hot methanol and
precipitated again with water. Finally, the precipitates were dissolved in dichloromethane and
precipitated with hexane. The compound has Rf value of 0.17, CH3OH:CH2Cl2:NH4OH =
6:94:0.6 (v/v/v), silica gel 60 F254, EMD Millipore. Yield = 143 mg (32 mmol, 41.4%).1H NMR
(600 MHz, CDCl3): δ 9.15 (dd, J = 4.2, 1.8 Hz, 2H), 8.21 (dd, J = 7.8, 1.8 Hz, 2H), 8.09 (d, J =
9.0 Hz, 2H), 7.72 (d, J = 8.4 Hz, 2H), 7.57 (m, 2H), 7.16 (d, J = 9.0 Hz, 2H), 4.98 (d, J = 5.4 Hz,
4H), 3.84 (quint, J = 5.4 Hz, 1H).
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C-NMR (151 MHz, CDCl3) δ 162.99, 150.05, 139.18,

136.27, 126.39, 123.86, 122.61, 114.14, 68.45, 50.75.
Synthesis of 5b-NCS. In 20-ml round-bottomed flask, 5b-S (60 mg, 0.493 mmol) was
dissolved in 6 ml of dry DMF. To the stirred solution TCDP (14.3 mg, 0.0616 mmol) along with
catalytic amount of DMAP was added. The reaction mixture was stirred for 12 h at room
temperature under Argon. The completion of the reaction was monitored with TLC [ Rf = 0.3
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(CH3OH:CH2Cl2 = 8:92 (v/v), silica gel 60 F254, EMD Millipore]. The residue was concentrated
under vacuum. Flash chromatography of the residue [silica gel, CH3OH:CH2Cl2 = 8:92: (v/v)]
yielded compound 5b-NCS (47 mg, 76 %) as a white solid. 1H-NMR (600 MHz, CDCl3) δ 6.564.48 (m, 8H), 4.45-2.65 (m, 19H), 1.82-1.29 (m, 54H).
Synthesis of 2-CP1. In 10-ml round-bottomed flask, 5a-NCS (58 mg, 0.44 mmol) was
dissolved in anhydrous pyridine (5 ml). An anhydrous pyridine solution (1 ml) of 2-CP (21.6
mg, 0.048 mmol) was added to the flask with a syringe. The reaction mixture was stirred
overnight at room temperature under N2. The reaction progress was monitored with TLC [ Rf =
0.27 (CH3OH:CH2Cl2:NH4OH = 8:92:0.8 (v/v/v), silica gel 60 F254, EMD Millipore]. The
residue was concentrated under vacuum. Flash chromatography of the residue [silica gel,
CH3OH:CH2Cl2 = 8-10:92-90 (v/v)] yielded compound 2-CP1 (32 mg, 41 %) as a white solid.
IR (KBr pellet, cm-1) 3419, 2968.17, 2936, 1702, 1605, 1498, 1369, 1262, 1155, 1026, 843. 1H
NMR (CD3OD) δ 8.93 (m, 2H), 8.28 (d, 2H, J = 7.8 Hz), 7.93 (bs, 2H), 7.35 - 7.77 (m, 6H), 7.00
- 7.24 (m, 2H), 5.43 (bs, 2H), 5.25 (d, 1H, J = 9.6 Hz), 5.01 - 5.19 (m, 3H), 4.18 - 4.42 (m, 2H),
4.02 - 4.14 (m, 1H), 3.69 - 4.01 (m, 6H), 3.59-3.68 (s, 2H), 3.41 - 3.59 (m, 6H), 2.72 - 3.01 (bs,
4H), 1.86 - 2.05 (m, 1H), 1.1 - 1.67 (m, 54H). HRMS (ESI) calcd for C83H119N12O26S2 [M+H]+ :
1763.7800, found 1763.7766.
Synthesis of 2-CP2. In 10-ml round-bottomed flask, 5b-NCS (47 mg, 0.38 mmol) was
dissolved in anhydrous pyridine (5 ml). An anhydrous pyridine solution (1 ml) of 2-CP (18.7
mg, 0.042 mmol) was added to the flask with a syringe. The reaction mixture was stirred
overnight at room temperature under N2. The reaction progress was monitored with TLC [ Rf =
0.43 (CH3OH:CH2Cl2:NH4OH = 8:92:0.8 (v/v/v), silica gel 60 F254, EMD Millipore]. The
residue was concentrated under vacuum. Flash chromatography of the residue [silica gel,
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CH3OH:CH2Cl2 = 8:92 (v/v)] yielded compound 2-CP2 (30 mg, 47 %) as a white solid. IR (KBr
pellet, cm-1) 3422, 2987, 2932, 1691, 1507, 1376, 1267, 1180, 1039, 853. 1H NMR (CD3OD) δ
8.89 (dd, 2H, J = 10.8, 3.6 Hz), 8.25 (t, 2H, J = 6.6 Hz), 8.86 (bs, 2H), 7.33-7.68 (m, 6H), 7.12
(q, 2H, J = 9 Hz), 5.78 (bs, 1H), 5.36 (bs, 2H), 4.99-5.25 (m, 3H), 4.60 (s, 1H), 4.28 - 4.51 (m,
2H), 4.19 (bs, 1H), 3.85 - 4.11 (m, 3H), 3.45 - 3.83 (m, 9H), 1.89 - 2.04 (m, 1H), 1.15 - 1.66 (m,
54H).
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C NMR (CD3OD) δ 163.94, 159.04, 159.01, 158.73, 158.62, 158.25, 158.00, 149.94,

149.84, 145.38, 145.35, 144.34, 144.30, 140.05, 138.01, 137.93, 130.41, 130.36, 127.45, 127.30,
126.05, 126.00, 124.40, 123.76, 115.65, 115.62, 113.81, 100.04, 98.65, 80.75, 80.64, 80.43,
80.32, 76.35, 75.81, 74.62, 73.22, 73.16, 73.09, 73.00, 72.41, 71.71, 69.13, 65.87, 65.39, 56.90,
54.57, 53.54, 52.52, 51.24, 49.85, 42.42, 42.02, 35.74, 29.02, 28.92, 28.84, 28.79, 28.76. HRMS
(ESI) calcd for C81H115N12O26S [M+H]+: 1703.7466, found 1703.7832.
General procedure for synthesis of AM1-9. 20-50 mg (1 equivalent) of the amine was
dissolved in 5 ml dry DCM. To the solution was added TCDP (1.5 equivalent), DMAP (catalytic
amount). The reaction mixture was stirred at room temperature for 12 h under N2 atm. Reaction
was monitored with TLC.
Compound AM1. Pale oil (52.35%, 35.8mg), The reaction was monitored with TLC [Rf
= 0.33, CH2Cl2: CH3OH = 0.45:9.55 (v/v), silica gel 60 F254, EMD Millipore]. Column
chromatography [silica gel, CH3OH:CH2Cl2 = 4.5:95.5 (v/v)]. 1H-NMR (600 MHz, CDCl3) δ
3.63 (t, J = 8Hz, 2H), 2.77 (t, J = 8 Hz, 2H), 2.50-2.62 (m, 4H), 1.74 - 1.83 (m, 4H).
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C-NMR

(151 MHz, CDCl3) δ 131.47, 55.23, 54.17, 44.68, 23.60.
Compound AM2. White oil (52.7%, 35 mg), The reaction was monitored with TLC [Rf =
0.21, CH2Cl2: CH3OH = 0.6:9.4 (v/v), silica gel 60 F254, EMD Millipore]. Column
chromatography [silica gel, CH3OH:CH2Cl2 = 6:94 (v/v)]. 1H-NMR (600 MHz, CDCl3) δ 4.00
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(t, J = 4 Hz, 2H), 2.48 - 2.63 (m, 6H), 1.91 (quint, J = 8 Hz, 2H), 1.73-1.81 (m, 4H).
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C-NMR

(151 MHz, CDCl3) δ 54.29, 53.04, 43.37, 29.11, 23.60.
Compound AM3. Slightly yellow oil (95%, 19mg), The reaction was monitored with
TLC [Rf = 0.35, CH2Cl2: CH3OH = 0.45:9.55 (v/v), silica gel 60 F254, EMD Millipore]. Column
chromatography [silica gel, CH3OH:CH2Cl2 = 4.5:95.5 (v/v)]. 1H-NMR (600 MHz, CDCl3) δ
3.63 (t, J = 8 Hz, 2H), 2.77 (t, J = 8 Hz, 2H), 2.47 - 2.63 (m, 4H), 1.64 - 1.86 (m, 4H).
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C-NMR

(151 MHz, CDCl3) δ 132.13, 58.10, 54.48, 43.18, 26.00, 24.21.
Compound AM4. Slightly yellow oil (49.2%, 31.9 mg), The reaction was monitored
with TLC [Rf = 0.425, CH2Cl2: CH3OH = 0.8:9.2 (v/v), silica gel 60 F254, EMD Millipore].
Column chromatography [silica gel, CH3OH:CH2Cl2 = 8:92 (v/v)]. 1H-NMR (600 MHz, CDCl3)
δ 3.59 (t, J = 8 Hz, 2H), 2.28 - 2.50 (m, 6H), 1.87 (quint, J = 8 Hz, 2H), 1.59 (quint, 4H), 1.38 1.48 (m, 2H).

13

C-NMR (151 MHz, CDCl3) δ 55.77, 54.74, 43.44, 27.40, 25.97, 24.42.

Compound AM5. Slightly yellow oil (51.5%, 34mg), The reaction was monitored with
TLC [Rf = 0.65, CH3OH:CH2Cl2 = 0.3:9.7 (v/v), silica gel 60 F254, EMD Millipore]. Column
chromatography [silica gel, CH3OH:CH2Cl2 = 3:97 (v/v)] yielded the desired compound. 1HNMR (600 MHz, CDCl3) δ 3.71 (t, J = 4.5 Hz, 4H), 3.58 (t, J = 6.2 Hz, 2H), 2.66 (t, J = 6.2 Hz,
2H), 2.50 (t, J = 4.1 Hz, 4H).

13

C NMR (151 MHz, CDCl3) δ 133.03, 67.02, 57.73, 53.42, 42.97.

Compound AM6. Slightly yellow oil (78.1 %, 50.4mg) The reaction was monitored with
TLC [Rf = 0.36, CH3OH:CH2Cl2 = 0.4:9.6 (v/v), silica gel 60 F254, EMD Millipore]. Column
chromatography [silica gel, CH3OH:CH2Cl2 = 4:96 (v/v)] yielded the desired compound. 1HNMR (600 MHz, CDCl3) δ 3.68 (t, J = 4.5 Hz, 4H), 3.59 (t, J = 6.5 Hz, 2H), 2.43 (t, J = 6.9 Hz,
6H), 1.82 - 1.86 (m, 2H).
26.94.

C-NMR (151 MHz, CDCl3) δ 130.15, 67.03, 55.25, 53.73, 43.10,

13
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Compound AM7. Slightly yellow oil (72.5 %, 47 mg). The reaction was monitored with
TLC [Rf = 0.146, CH3OH: (C2H5)2O = 1:9 (v/v), silica gel 60 F254, EMD Millipore]. Column
chromatography [silica gel, CH3OH: (C2H5)2O = 4:96 (v/v)] yielded the desired compound. 1HNMR (600 MHz, CDCl3) δ 3.56 (t, J = 6.2 Hz, 2H), 2.65 (t, J = 6.2 Hz, 2H), 2.31 - 2.52 (m, 8H),
2.27 (s, 3H).

13C-NMR

(151 MHz, CDCl3) δ 132.63, 57.27, 55.09, 52.96, 46.09, 43.11.

Compound AM8. Slightly yellow oil (54.6 %, 34.6 mg). The reaction was monitored
with TLC [Rf = 0.65, CH3OH:CH2Cl2 = 0.7:9.3 (v/v), silica gel 60 F254, EMD Millipore].
Column chromatography [silica gel, CH3OH:CH2Cl2 = 7:93 (v/v)] yielded the desired
compound. 1H-NMR (600 MHz, CDCl3) δ 3.56 (t, J = 6.5 Hz, 2H), 2.26 - 2.43 (m, 13H), 1.80 1.84 (m, 2H).

13

C-NMR (151 MHz, CDCl3) δ 130.02, 55.16, 54.80, 53.17, 46.09, 43.19, 27.27.

Compound AM9. Pale oil (15mg, 51.93 %). The reaction was monitored with TLC [Rf =
0.37, CH3OH:CH2Cl2:NH4OH = 5:95 (v/v)], silica gel 60 F254, EMD Millipore]. Column
chromatography [silica gel, CH3OH:CH2Cl2 = 5:95 (v/v)] yielded the desired compound. 1HNMR (600 MHz, CDCl3) δ 3.62 (t, J = 6.5 Hz, 2H), 2.63 (t, J = 6.2 Hz, 2H), 2.31 (s, 6H).

13

C-

NMR (151 MHz, CDCl3) δ 58.55, 45.42, 43.46, 131.98.
General procedure for the synthesis of 2-Clip-phen neomycin conjugates (2-CP1 and
2-CP2). To 5-8M solution of the 5a/5b-NCS in dry pyridine, 1.1 molar equivalent of the 2-Clipphen is added. The reaction mixture is stirred overnight at room temperature. The highly nonpolar boc-protected neomycin impart sufficient non-polar character to the molecule that it can be
separated from the unreacted 2-Clip-phen without a significant problem using column
chromatography.
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General procedure for the synthesis of 10-18. To the solution of 2-Clip-phen (10-25
mg in 5 ml of dry pyridine), 4 equivalents of AM1-9 was added to consume all the 2-Clip-phen.
The pyridine is removed under reduced pressure. Crude residue is rinsed with hexane to remove
most of the unreacted AM1-9. Flash chromatography of the residue yields the white solid as the
final compounds (10-18).
Compound 10. White solid (59.5%, 16mg). The reaction was monitored with TLC [Rf =
0.25, CH2Cl2: CH3OH = 0.4:9.6 (v/v), silica gel 60 F254, EMD Millipore]. Column
chromatography [silica gel, [silica gel, CH3OH:CH2Cl2:NH4OH = 4:96:0.4 (v/v/v)] yielded the
desired compound. IR (KBr, cm−1) 3270, 3065, 2957, 2936, 2877, 2794, 1608, 1592, 1451,
1554, 1451, 1417, 1394, 1344, 1221. 1H -NMR (600 MHz, CDCl3) δ 9.08 - 9.09 (m, 2H), 8.16 8.02 (2H), 7.87 (s, 2H), 7.49 - 7.59 (m, 6H), 6.98 (s, 2H), 5.46 (d, J = 4.6 Hz, 1H), 5.22 (s, 2H),
5.02 (s, 2H), 3.78 (s, 2H), 2.37 (d, J = 201.7 Hz, 6H), 1.29 (s, 4H).

13

C-NMR (151 MHz, CDCl3)

δ 182.91, 162.92, 149.63, 144.98, 143.94, 138.83, 136.17, 129.02, 126.27, 124.76, 123.66,
122.56, 114.16, 65.77, 54.68, 53.63, 43.68, 23.30.
Compound 11. White solid (52.1%, 10.7mg). The reaction was monitored with TLC [Rf
= 0.225, CH3OH:CH2Cl2:NH4OH = 10:90:1 (v/v/v)], silica gel 60 F254, EMD Millipore].
Column chromatography [silica gel, CH3OH:CH2Cl2:NH4OH = 10:90:1 (v/v/v)] yielded the
desired compound. IR (KBr, cm−1) 3451, 3070, 2955, 2877, 1607, 1592, 1503, 1453, 1348,
1264, 1223. 1H -NMR (600 MHz, CDCl3) δ 9.06 (d, J = 2.7 Hz, 2H), 8.16 (d, J = 7.6 Hz, 2H),
7.97 (s, 2H), 7.54 - 7.66 (m, 6H), 7.03 (d, J = 6.9 Hz, 2H), 5.36 (s, 1H), 5.14 (s, 2H), 4.95 (s,
2H), 3.73 (s, 2H), 2.75 - 2.24 (6H), 1.92 - 1.55 (6H).

13

C -NMR (151 MHz, CDCl3) δ 162.97,

149.67, 145.01, 143.96, 139.11, 136.42, 129.21, 126.39, 124.95, 123.88, 122.77, 114.26, 66.25,
53.94, 43.32, 29.79, 27.61, 23.44.
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Compound 12. White solid (53.2%, 15.3mg), The reaction was monitored with TLC [Rf
= 0.29, CH3OH:CH2Cl2:NH4OH = 5:95:0.5 (v/v/v)], silica gel 60 F254, EMD Millipore]. Column
chromatography [silica gel, CH3OH:CH2Cl2:NH4OH = 5:95:0.5 (v/v/v)] yielded the desired
compound. IR (KBr, cm−1) 3428, 3074, 2931, 2851, 1608, 1592, 1503, 1453, 1416, 1349, 1266,
1222. 1H-NMR (600 MHz, CDCl3) δ 9.06 (s, 2H), 8.03 (s, 2H), 7.79 (s, 2H), 7.47 (s, 6H), 6.91
(s, 2H), 5.55 - 5.36 (1H), 5.32 - 4.92 (4H), 4.04 - 3.62 (2H), 2.78 - 1.76 (m, 6H), 1.48 - 0.90 (m,
6H).

13

C-NMR (151 MHz, CDCl3) δ 182.86, 162.66, 149.42, 144.71, 143.72, 138.55, 135.96,

128.82, 126.04, 124.53, 123.46, 122.44, 113.90, 65.40, 57.16, 53.89, 41.34, 29.62, 24.89, 23.73.
Compound 13. White solid (93.4 %, 26.4 mg). The reaction was monitored with TLC
[Rf = 0.19, CH3OH:CH2Cl2:NH4OH = 6:94:0.6 (v/v/v)], silica gel 60 F254, EMD Millipore].
Column chromatography [silica gel, CH3OH:CH2Cl2:NH4OH = 6:94:0.6 (v/v/v)] yielded the
desired compound. IR (KBr, cm−1) 3436, 3065, 2933, 2853, 2805, 1608, 1592, 1560, 1546,
1558, 1452, 1417, 1395, 1349. 1H -NMR (600 MHz, CDCl3) δ 9.06 (d, J = 2.7 Hz, 2H), 8.17 (d,
J = 7.6 Hz, 2H), 7.97 (d, J = 6.2 Hz, 2H), 7.54 - 7.66 (m, 6H), 7.04 (d, J = 7.6 Hz, 2H), 5.41 (s,
1H), 5.05 (d, J = 129.2 Hz, 4H), 3.69 (s, 2H), 2.21 (s, 6H), 1.32-1.71 (m, 8H).

13

C -NMR (151

MHz, CDCl3) δ 162.99, 149.67, 145.04, 143.97, 139.09, 136.40, 129.21, 126.40, 124.95, 123.85,
122.74, 114.27, 66.01, 56.73, 54.33, 43.26, 26.30, 25.55, 24.17.
Compound 14. White solid (93.8%, 13 mg). The reaction was monitored with TLC [Rf
= 0.22, CH3OH:CH2Cl2:NH4OH = 4:96:0.4 (v/v/v)], silica gel 60 F254, EMD Millipore]. Column
chromatography [silica gel, CH3OH:CH2Cl2:NH4OH = 4:96:0.4 (v/v/v)] yielded the desired
compound. IR (KBr, cm−1) 3451, 3280, 3063, 2954, 2867, 1608, 1592, 1562, 1503, 1346, 1418,
1222, 1135, 1222. 1H-NMR (600 MHz, CDCl3) δ 9.06 (s, 2H), 7.76 (d, J = 334.7 Hz, 10H), 6.94
(s, 2H), 5.42 (s, 1H), 5.07-5.27 (m, 4H), 3.75 (s, 2H), 2.35 - 3.17 (m, 4H), 1.63 - 2.19 (m, 7H).
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C-NMR (151 MHz, CDCl3) δ 162.84, 149.50, 144.90, 143.85, 138.63, 136.11, 128.93, 126.23,

13

124.66, 123.58, 122.55, 114.12, 66.46, 65.45, 57.19, 53.52, 53.16.
Compound 15. White solid (62.6%, 20 mg). The reaction was monitored with TLC [Rf
= 0.15, CH3OH:CH2Cl2:NH4OH = 4:96:0.4 (v/v/v)], silica gel 60 F254, EMD Millipore]. Column
chromatography [silica gel, CH3OH:CH2Cl2:NH4OH = 4:96:0.4 (v/v/v)] yielded the desired
compound. 1H-NMR (600 MHz, CDCl3) δ 9.06 (d, J = 2.7 Hz, 2H), 8.16 (d, J = 7.6 Hz, 2H),
7.95 (s, 2H), 7.53-7.65 (m, 6H), 7.02 (s, 2H), 5.44 (s, 1H), 5.17 (s, 2H), 4.95 (s, 2H), 3.72 (s,
1H), 3.49 (s, 4H), 2.60 (s, 1H), 2.14 (s, 6H), 1.65 (s, 2H).

13

C-NMR (151 MHz, CDCl3) δ

163.00, 149.60, 145.03, 143.93, 139.06, 136.40, 129.18, 126.42, 124.93, 123.81, 122.70, 114.28,
66.88, 66.08, 56.38, 53.55, 43.10, 26.18.
Compound 16. White solid (72.2%, 24.5 mg). The reaction was monitored with TLC
[Rf = 0.22, CH3OH:CH2Cl2:NH4OH = 6:94:0.6 (v/v/v)], silica gel 60 F254, EMD Millipore].
Column chromatography [silica gel, CH3OH:CH2Cl2:NH4OH = 6:94:0.6 (v/v/v)] yielded the
desired compound. IR (KBr, cm−1) 3436, 3068, 2945, 2815, 1608, 1592, 1563, 1555, 1503,
1453, 1418, 1347. 1H-NMR (600 MHz, CDCl3) δ 9.03 (s, 2H), 7.40 - 8.06 (m, 10H), 6.87 (s,
2H), 5.02 - 5.42 (m, 5H), 3.75 (s, 2H), 1.74 - 2.54 (m, 13H).

13

C-NMR (151 MHz, CDCl3) δ

182.47, 162.59, 149.21, 144.64, 143.65, 138.28, 135.83, 128.69, 125.97, 124.40, 123.26, 122.37,
113.86, 64.88, 56.34, 54.14, 52.27, 50.62, 45.42, 41.50.
Compound 17. White solid (88.3%, 28.1 mg). The reaction was monitored with TLC
[Rf = 0.14, CH3OH:CH2Cl2:NH4OH = 6:94:0.6 (v/v/v)], silica gel 60 F254, EMD Millipore].
Column chromatography [silica gel, CH3OH:CH2Cl2:NH4OH = 6:94:0.6 (v/v/v)] yielded the
desired compound. IR (KBr, cm−1) 3428, 3066, 2940, 2807, 1608, 1561, 1549, 1504, 1452,
1418, 1394, 1347, 1367, 1222. 1H-NMR (600 MHz, CDCl3) δ 9.06 (d, J = 2.9 Hz, 2H), 8.18 (d,
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J = 7.4 Hz, 2H), 7.98 (s, 2H), 7.54 - 7.67 (m, 6H), 7.04 (d, J = 6.7 Hz, 2H), 5.44 (s, 1H), 5.15 (s,
2H), 4.93 (s, 2H), 3.72 (s, 2H), 2.04 - 2.75 (m, 13H), 1.65 (s, 2H). 13C-NMR (151 MHz, CDCl3)
δ 162.98, 149.87, 144.98, 143.90, 139.06, 136.41, 129.17, 126.40, 124.91, 122.69, 121.38,
114.27, 65.92, 55.99, 54.97, 52.98, 45.97, 43.44, 26.54.
Compound 18. White solid (71.5%, 12mg). The reaction was monitored with TLC [Rf =
0.202, CH3OH:CH2Cl2:NH4OH = 5:95:0.5 (v/v/v)], silica gel 60 F254, EMD Millipore]. Column
chromatography [silica gel, CH3OH:CH2Cl2:NH4OH = 5:95:0.5 (v/v/v)] yielded the desired
compound. 1H-NMR (600 MHz, CDCl3) δ 9.10 (d, J = 2.7 Hz, 2H), 8.14 (d, J = 7.6 Hz, 2H),
7.94 (s, 2H), 7.74 - 7.37 (6H), 7.05 (d, J = 8.2 Hz, 2H), 5.43 - 5.47 (m, 1H), 5.23 (s, 2H), 5.00 (s,
2H), 3.69 (s, 2H), 2.48 (s, 5H), 2.38 - 2.08 (s, 2H), 1.83 (s, 6H).

13

C-NMR (151 MHz, CDCl3) δ

150.26, 136.51, 125.05, 118.77, 112.69, 54.23, 66.17, 66.8, 46.05, 43.95, 44.17.
4.2.3. MS Analysis Procedures of Synthesized Compounds
The samples were diluted in methanol to approximately 1 M concentration. A sample
solution (1 µL) was introduced by Direct injection without a chromatographic column. High
resolution mass spectra (HRMS) were obtained on a JEOL AccuTOF time-of-flight mass
spectrometer (Peabody, MA) coupled with an ESI source or Ion sense DART open-air ionization
source (Saugus, MA). The solvent system was 1:1 methanol:water. Ions were delivered to the
mass spectrometer with an electrospray ionization (ESI) source. The capillary voltage was set to
be 4000V for the all the samples. Data were collected in the m/z range of 200-1100. Spectra
were collected at a rate of 2 spectra/s allowing for 4800 transients/spectrum.
4.2.4. Preparation of G-quadruplex DNA and Duplex DNA for CD and UV experiments
Three G-quadruplexes with different conformations were used in the study, including G1
(htelo, hybrid) 5’-AGGG(TTAGGG)3T-3’ in K+, G2 (htelo, antiparallel) 5’-
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AGGG(TTAGGG)3T-3’in Na+, and G3 (c-MYC, parallel) 5’TGGGGAGGGTGGGGAGGGTGGGGA-3’ in a mixture of Li+ and K+.
The G-quadruplex DNA strand (G1, G2 or G3, 100 M) was dissolved in a mixture (100
L) of lithium cacodylate buffer (40 mM, pH 7.1) and a corresponding salt (150 mM KCl for
G1, 150 mM NaCl for G2, and a mixture of 99 mM LiCl and 1mM KCl for G3), heated at 90 °C
for 10 min, slowly cooled to 25°C, and incubated at 4 C overnight. Duplex D1 (complementary
strands of S1 and S2, 100 M each) was dissolved in a mixture of lithium cacodylate buffer (40
mM, pH 7.1) and KCl (150 mM), heated at 90 °C for 10 min, slowly cooled to 25°C, and
incubated at 4 C overnight. All solutions were stored at 4 C for further use.
4.2.5. Preparation of G-quadruplex DNA for ESI Mass Spectrometry Experiments
G1 (100 µM) in 150 mM NH4OAc solution was heated to 95 °C for 5 min followed by
cooling slowly to room temperature and incubated at 4°C overnight.
4.2.6. Thermal Denaturation Analysis Monitored by CD
The mixture solutions (200 μL) of (G1, G2 or G3) (5 µM) in lithium cacodylate buffer
(40 mM, pH 7.1) and a corresponding salt (150 mM KCl for G1, 150 mM NaCl for G2, and a
mixture of 99 mM LiCl and 1mM KCl for G3) in the absence or presence of a ligand were
prepared. The CD spectra were recorded at a fixed wavelength (290 nm for G1 and G2, 265 nm
for G3) as a function of increasing temperature (25-85 ˚C) at a heating rate of 0.5 ˚C/min.
Melting profiles were converted into a folded fraction based on a published procedure162, and the
melting temperatures were determined at the 0.5 folded fraction.
4.2.7. CD Titration
Aliquots of a stock solution containing compounds were gradually added into a solution
(200 µL) of G1 (G2 or G3) (5 M) in lithium cacodylate (40 mM, pH 7.0) and 150 mM KCl at
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25 C. The final molar ratios of ligands to G-quadruplex were varied from 0 to 5.5. After each
addition, the solution was gently mixed and incubated for 5 min for equilibrium before collecting
the spectrum. The overall volume change during the titration was kept less than 1% of the initial
volume. CD spectra were recorded as a function of wavelength (200-400 mm, 50 nm/min scan
speed, 0.5 nm data pitch) using a 1 cm pathlength quartz cuvette. Each spectrum was averaged
over three scans.
4.3.8. G-quadruplex Induction
The solution of G1 (10 μM) in 50 mM Tris.HCl, pH 7.4 buffer was heated at 90 oC for 5
mins and immediately cooled to 0 oC using ice-water slush. The solution was kept in ice and
taken out just before CD spectra measurement. Aliquots of stock solution of the ligands were
added to vary the molar equivalents in solution from 0 to 10. After each addition, the solution
was gently mixed and incubated for 5 min for equilibrium before collecting the spectrum. CD
spectra were recorded as a function of wavelength (200-400 mm, 50 nm/min scan speed, 0.5 nm
data pitch) using a 1 cm pathlength quartz cuvette. Each spectrum was averaged over three scans
and blank subtracted.
4.2.9. Thermal Denaturation Analysis Monitored by UV
The mixture solutions (1 mL) of D1 (2 µM) in lithium cacodylate buffer (40 mM, pH 7.1)
and KCl (150 mM) in the absence or presence of a ligand (8 µM) were prepared. The UV
melting curves were recorded at 260 nm as a function of temperature (20-85 C, heating rate: 0.5
C/min). Melting profiles were converted into a folded fraction, and the melting temperatures
were determined at the 0.5 folded fraction.
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4.2.10. Fluorescent Intercalator Displacement Assay
A reaction solution containing 0.25 μM DNA (G1, G2, G3, or D1) in lithium cacodylate
(10 mM, pH 7.0) and KCl (50 mM) was incubated with 0.5 μM thiazole orange (TO) for 30 min
in the dark. Aliquots of a ligand were added to this mixture solution and equilibrated for 5 min
in the dark before measurement. The fluorescence spectra (Ex: 501 nm, slit width: 5.0 nm, scan
speed 120 nm/min) were recorded from 510-650 nm after each addition. The percent
fluorescence displacement (%F) was calculated at λmax by using the formula % FI.
displacement=100-[(FA/FA0)×100], where FA0 is the initial fluorescence intensity in the absence
of a ligand, and FA is the fluorescence intensity upon addition of a ligand.
4.2.11. Docking Procedure
The geometry optimization of the representative ligand 11 was carried out at the hybrid
density functional B3LYP level with 6-311G(d) basis set using Gaussian’09 program package.
The Natural bond order (NBO) analysis was carried out to calculate the atomic charges on the
optimized geometries. Docking simulations of 11 were carried out on the antiparallel, parallel,
and hybrid G-quadruplexes. The structures of hybrid G-quadruplex, antiparallel G-quadruplex,
and parallel G-quadruplex were modeled after the solution structures with the PDB id (the RCSB
protein data bank) of 5Z80, 2MCC, and 2L7V, respectively. Each initial solution structure is
ligand-bound, and the corresponding ligand was manually removed to obtain the G-quadruplex
structure for docking. The flexible ligand docking experiments were carried out using the
DOCK 6.9 program. Throughout the docking of all three ligands, the same receptor grid was
used. Analyses of docked structures and docked image creations were carried out using the
UCSF Chimera program.
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4.2.12. ESI-MS Analysis of the Complex Formation Between G1 and 11/13
G1 (20 µM) and compound 11/13 (80 µM) were mixed and methanol was added to make
33% methanol-water final concentration. The mixed solutions were injected into a Thermo
Scientific LTQ XL Mass Spectrometer at a rate of 5 µL/min. The ion spray voltage was set to 4500 V and ion transfer tube temperature to 300 °C. Nitrogen sheath and auxiliary gas flows
were 12 and 0 arbitrary, respectively. MS spectra were recorded in the m/z range from 1400 to
1800 with an average of 150 scans. Data were collected using Thermo Xcalibur 2.2 and
analyzed using the Thermo Xcalibur 4.0 software.
4.3. Results and Discussion
4.3.1 Synthesis of 2-Clip -phen Derivatives
The final compounds were synthesized in three steps, as shown in Schemes 1-3. 2-Clip phen was synthesized based on a published procedure206. We used 2-bromo-1,10-phenanthroline
instead of 2-chloro-1,10-phenanthroline as the starting material because it is readily available
and cost-effective. Reaction of 2-bromo-1,10-phenanthroline with serinol in the presence of
NaH in anhydrous DMF followed by recrystallization yielded pure 2-Clip-phen (Scheme 4.1). It
is noteworthy that 2-Clip-phen streaks in the silica gel column so that it cannot be easily purified
using column chromatography. In separated reactions, amines 5a-L, 5b-S and AN1-9 were
converted into the corresponding isothiocyanates by reacting with 1,1’-thiocarbonyldi-2(1H)pyridone (TCDP) in dry dichloromethane/dimethylformamide. In the final step, 2-Clip-phen
react with isothiocyanates to yield the target products via the thiourea linkage formation in good
yields. The target compounds had very similar mobility to 2-Clip-phen on the silica gel column;
therefore, purification with column chromatography was very time-consuming. Using a large
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excess (4-5 molar equivalents) of isocyanates to consume most 2-Clip-phen in the coupling
reaction greatly helped the purification step.

Scheme 4.1. Synthesis of 2-Clip-phen.

Scheme 4.2. Synthesis of 2-Clip-neomycin derivatives.
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Scheme 4.3. Synthesis of isothiocyanate (AM1-9) from primary amines (AN1-9). (TCDP is 11’-thiocarbonyldi-2(1H)-pyridone).

Scheme 4.4. Coupling of isothiocyanates and 2-Clip-phen moieties.
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4.3.2. 2-Clip-phen Derivatives Stabilize the Human Telomeric Antiparallel G-quadruplexes
Over Other G-quadruplexes
The stabilization of G-quadruplex DNA by 2-Clip-phen derivatives was determined by
thermal denaturation studies monitored by circular dichroism (CD). CD spectroscopy is a
common technique that is used to analyze the conformation of proteins and DNA. DNA Gquadruplexes can adopt three major conformations, characterized by unique signature peaks in
circular dichroism. A typical parallel G-quadruplex topology exhibits a maximum peak (+)
around 260 nm and a peak (-) with a maximum around 240 nm216. A hybrid G-quadruplex
topology188 typically shows a maximum (+) around 290 nm, a shoulder (+) centered around 260
nm, a weak band (+) with a maximum around 250 nm, and a band (-) with a maximum around
240 nm. An antiparallel G-quadruplex topology shows a maximum (+) around 290 nm and a
band (-) with a maximum around 260 nm. CD signals of G-quadruplexes depend on the sugarphosphate backbone strand orientation, loops composition, helical handedness, and nucleobase
orientations217,186. For instance, the positive CD peak at 260 nm indicates the parallel strand
orientation or anti-anti base steps, and the CD peak at 290 nm most likely shows the antiparallel
strand orientation or syn-anti, anti-syn base steps. Hybrid G-quadruplex DNA can have more
than one conformation. Its CD peaks at 290 nm and 260 nm come from a combination of
nucleobase orientations. The relative intensity of the signals at 290 nm and 260 nm reflects the
percentage of nucleobase orientations contributed to the conformation(s). For example, human
telomeric DNA and BCL-2 proto-oncogene G-quadruplexes both adopt hybrid conformation(s)
under physiological conditions, but their CD signals are slightly different. The CD spectrum of
the BCL-2 G-quadruplex is contributed from anti-anti base steps, and that of the human
telomeric G-quadruplex is contributed from syn-anti or anti-syn base steps200.
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In the present study, three G-quadruplexes were chosen for thermal denaturation
monitored by CD. A hybrid human telomeric G-quadruplex (G1) was formed in the presence of
150 mM K+. The same sequence was used to create an antiparallel G-quadruplex in the presence
of 150 mM Na+. To form a parallel G-quadruplex (G3) conformation, we used a 27mer c-MYC
DNA sequence annealed in a mixture of 99 mM Li+ with 1 mM K+. The conformations of three
G-quadruplexes were confirmed using circular dichroism (Figure 4.4).

Figure 4.4. The CD spectra of htelo hybrid (G1), htelo antiparallel (G2) and c-MYC parallel
(G3) G-quadruplex conformations.
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Figure 4.5. Effect of compound 13 on the Tm of htelo hybrid (G1) (left), and antiparallel Gquadruplex conformation (G2) (right).

Figure 4.6. Effect of compound 13 on the Tm of c-MYC parallel (G3) G-quadruplex.

Thermal stability of G-quadruplex DNA can be probed by analyzing CD ellipticity at 290
nm or 265 nm as a function of increasing temperature. The intensity of the ellipticity decreases
as a G-quadruplex dissociates into random coils at high temperatures. The temperature at which
50% of the G-quadruplex dissociates into random coils is defined as melting temperature (Tm).
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A melting profile is normally converted into a folded fraction as a function of increasing
temperature. The melting temperature can be determined at the folded fraction of 0.5.
The thermal denaturation experiments were conducted with a DNA: ligand ratio of 1:4.
All the experiments were duplicated. The representative normalized melting profiles of
compound 13 with three G-quadruplex conformations are shown in figure 4.5 and 4.6. The
melting curves for all the compounds are presented in the appendix C.
All 2-Clip-phen derivatives showed a more significant stabilization effect (Table 4.1) on
the antiparallel telomeric G-quadruplex (G2) than the other two G-quadruplexes (G1 and G3).
2-Clip-phen had a minor effect on the stabilization of three G-quadruplexes, which increased the
Tms of G1, G2, and G3 by 0.8, 2.3, and 2.9 °C, respectively. Amongst all the derivatives,
compounds 11 and 13 had the best stabilization effect, which increased the Tm of G2 by more
than 10 °C. All the derivatives slightly increased the Tms of G1 and G3 (1-3 °C in most cases),
suggest that they preferentially bind to the antiparallel telomeric G-quadruplex. The effect of
amino-containing side chains of the derivatives was determined by comparing the ΔTms of the
derivatives with that of 2-Clip-phen for each G-quadruplex (ΔΔTm in Table 4.1). Conjugation of
amino-containing side chains to 2-Clip-phen could not enhance its binding to the parallel c-MYC
G-quadruplex (G3) because the ΔΔTm values were within the experimental errors. The aminocontaining side chains drastically increased the binding of 2-Clip-phen to the antiparallel
telomeric G-quadruplex (G1) and slightly increased its binding to the hybrid telomeric Gquadruplex (G2). The positively charged alicyclic bases or (aliphatic amine) make favorable
interactions with the N-H of G-tetrads in the grooves or with negatively charged phosphate
backbones. The alicyclic rings pyrrolidine and piperidine showed the most stabilizing effect
followed by piperazine and morpholine. The morpholine ring contains an oxygen atom which
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may cause electrostatic repulsive interactions with the phosphate backbones and thus decrease
the ligand binding to G-quadruplexes176. The N-methyl group of the piperazine ring might be
involved in some steric interactions within the groove, which renders the stacking interaction
with the G-tetrads. The length of the linker seems to play an important role in thermal
stabilization. The derivatives with a longer linker showed a slightly better stabilization effect
when comparing the corresponding Tm values.

Table 4.1
G-quadruplex Stabilization Potential (ΔTm) of the 2-Clip-phen (2-CP) Derivatives by CD
Thermal Denaturation Study.
Hybrid G-quadruplex
Antiparallel G-quadruplex
Parallel G-quadruplex
(G1)
(G2)
(G3)
Tm
ΔTm ΔΔTm
Tm
ΔTm ΔΔTm
Tm
ΔTm ΔΔTm
C
67.4 ± 0.4
53.3 ± 0.3
60.3 ± 0.6
2-CP 68.2 ± 1.2 0.8
55.6 ± .5
2.3
63.2 ± 0.3 2.9
10 71.6 ±0.4
4.2
3.4
63.3 ± 1
10
7.7
64.2 ± 0.7 3.9
1.0
11 72.7 ± 0.01 5.3
4.5
63.4 ± 1
10.1 7.8
62.3 ± 0.1 2.0
-0.9
12 71.2 ± 0.4
3.8
3.0
62.9 ± 0.8
9.6
7.3
65.2 ± 1.6 4.9
2.0
13 72.8 ± 0.4
5.4
4.6
64.7 ± 0.5
11.4 8.1
63.2 ± 0.6 2.9
0
14 68.6 ± 0.6
1.2
0.4
58.4 ± 1
5.1
2.8
62.1 ± 0.1 1.8
-0.9
15 70.3 ± 0.4
2.9
2.1
60.4 ± 0.8
7.1
4.8
62.5 ± 0.7 2.2
-0.7
16 70.7 ± 0.7
3.3
2.5
61.4 ± 0.01 8.1
5.8
62.9 ± 1.7 2.6
-0.3
17 70.5 ± 0.1
3.1
2.3
60.5 ± 1
7.2
4.9
62.1 ± 0.5 1.8
-1.1
18 71.1 ± 0.6
3.7
2.9
61.3 ± 1
8.0
5.7
65.5 ± 0.3 5.2
2.3
ΔTm = melting temperature (Tm) of G-quadruplex with the 4 molar equivalents of compound –
melting temperature of G-quadruplex without ligand (C). ΔΔTm = melting temperature (Tm) of
G-quadruplex with the 4 molar equivalents of compound – melting temperature of Gquadruplex 2-CP. C= control

All 2-Clip-phen derivatives showed the binding selectivity for G-quadruplexes over
duplex DNA as none of them could stabilize an oligonucleotide duplex DNA (D1) (Figure 4.7).
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Figure 4.7. Melting of the dsDNA (26 mer) with 2-Clip-phen derivatives.

4.3.3. Binding of 2-Clip-phen Derivatives With G-quadruplex DNA Investigated Using the
FID Assay
The binding to 2-Clip-phen derivatives was further investigated with the fluorescent
intercalator displacement (FID) assay. The nature of the FID assay has been discussed in
Chapter 3. FID assay is a well-established assay to complement the results of thermal
denaturation studies182. In our study, thiazole orange (TO) was first incubated with Gquadruplex DNA for equilibrium binding. The pre-bound TO was gradually displaced from
DNA by the addition of a ligand. The displacement of TO from the bound state leads to a
dramatic loss of its quantum yield. The concentration of a ligand required to displace 50% of
pre-bound TO from G-quadruplex DNA is defined as G4DC50 (Figure 4.8).
As shown in Table 4.2, the G4GC50 value of 2-Clip-phen is much higher than those of 2Clip-phen derivatives for each G-quadruplex, suggesting that tethering an amino side chain to 2Clip-phen can greatly enhance its binding to G-quadruplex DNA. All the 2-Clip -phen
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derivatives showed stronger affinities to the antiparallel G-quadruplex (G2) than the hybrid Gquadruplex (G1). This result is in accordance with the thermal denaturation results mentioned
above. The G4GC50 value of each 2-Clip-phen derivative for G3 is much higher than those for
G1 and G2, indicating relatively weaker affinities of these ligands towards parallel c-MYC Gquadruplex.
For G1, the compounds 11, 13, 15, 17 containing a 3-carbon linker between an alicyclic
base and 2-Clip-phen showed lower G4DC50 as compared to their analogs 10, 12, 14, 16 with a 2carbon linker, respectively. The compounds 14 and 15 containing a 2-carbon and 3-carbon
linker with the morpholine moiety showed a negligible difference in the G4DC50 for the G1. The
2-Clip-phen showed a G4DC50 value of 33.3 µM, which is around ~18 times weaker than the least
potent derivative 12 for G1, suggesting the effect of side chains on increasing the binding
affinity of 2-Clip-phen. The alicyclic base moiety may provide additional ionic interactions with
G-quadruplexes in the grooves. The following trend was found in terms of the alicyclic base
moiety in the FID assay for G2: pyrrolidine > piperidine > morpholine > n-methyl
piperazine which is also the trend of the pKa of the alicyclic bases218,219.
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Figure 4.8. Displacement of thiazole orange (TO) by 2-Clip-phen derivatives from a) G1, b) G2
c) G3 in Fluorescent Intercalator displacement (FID) assay.

G-quadruplex DNA in Na+ folds into the antiparallel conformation (G2). The compounds
11 and 13 with a pyrrolidine and piperidine alicyclic base showed no significant difference in
G4

DC50 values for G2, which is in accordance with the thermal denaturation studies. The 2-

carbon linker containing derivatives of 2-Clip-phen overall showed better G4DC50 than the three
carbon linker analogues except for morpholine derivatives. One possible reason could be the
ligand induced G-quadruplex conformation has different groove features in K+ and Na+ salt
conditions. The exact reason for this reversal of trend is not known yet. 2-Clip-phen showed a
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high G4DC50 value of 22.90 µM, which is in accordance with a small thermal stabilization
observed.

Table 4.2
G4
DC50 Values of 2-Clip-phen Derivatives Against G1, G2 and G3.
G4DC of 2-Clip-phen derivatives against different G4 conformations in µM
50
Compounds
G1
G2
G3
10
1.3 ± 0.1
0.6± 0.03
5.81 ± 0.78
11
01 ± 0.1
0.6 ± 0.02
9.67 ± 0.47
12
1.8 ± 0.3
0.4 ± 0.07
3.94 ± 0.16
13
1.0 ± 0.1
0.7 ± 0.02
5.13 ± 0.26
14
1.3 ± 0.1
1.3 ± 0.10
23.2 ± 2.5
15
1.4 ± 0.1
0.8 ± 0.08
10.76 ± 0.46
16
1.8 ± 0.2
0.7 ± 0.04
9.49 ± 0.73
17
1.4 ± 0.1
0.7 ± 0.02
10.23 ± 0.63
18
1.4 ± 0.1
0.4 ± 0.03
7.25 ± 1.07
2-CP
33.3 ± 2.9
22.9 ± 0.7
19.9 ± 2.2
2-CP = 2-Clip-phen

2-Clip-phen derivatives showed the least affinity towards parallel stranded c-MYC
conformation. Out of all the derivatives, the piperidine-containing derivatives were the most
potent, followed by pyrrolidine, N-methyl piperazine and morpholine which is in accordance
with thermal denaturation studies. Derivatives with C-2 linker performed better than the ligands
with C-3 linker except morpholine containing derivatives. The trend is again in line with the
thermal denaturation studies.
The binding of the 2-Clip derivatives to dsDNA was also evaluated using the FID assay.
As shown in Table 4.3, none of the derivatives showed the 50% displacement of the at 20 µM
concentration. Both 11 and 13 showed the highest displacement of TO at 20 µM, which is 34.3
± 2.4 % and 34.5 ± 3.0 %, respectively. Using a rough estimate, 11 and 13 are at least 28 times
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more selective to G2 than the duplex DNA. The corresponding selectivity to G1 is at least 20
times over duplex DNA. Compounds showed better selectivity for G2/G1 over duplex DNA
than Phen-DC6. The selectivity profile is equivalent or better than Phen-DC3, one of the best Gquadruplex ligand220.

Table 4.3
Percentage Displacement of the TO from the Duplex DNA at 20 µM Ligand Concentration.
Compound
10
11
12
13
14
15
16
17
18
2-CP

TO displacement at 20 µM concentration
23.3 ± 3.0
34.3 ± 2.4
16.7 ± 1.2
34.5 ± 3.0
24.0 ± 2.1
34.8 ± 2.5
27.4 ± 4.8
28.3 ± 2.90
19.8 ±1.7
16.2 ± 1.1

4.3.4. 2-Clip-phen Derivatives Induced Conformational Change in a Hybrid Telomeric Gquadruplex
CD titrations were performed to study the conformation preference of the ligands to three
G-quadruplex conformations mentioned above. As shown in figure 4.4, the CD spectrum of the
htelo hybrid G-quadruplex (G1) showed a maximum at 293 nm, a shoulder peak at 270 nm, and
a negative band at 235 nm, which signifies a hybrid conformation. The addition of ligand 11 and
13 to the DNA solution led to the increase in the intensity of the peak at 293 nm with a
concomitant blue shift of the maximum (287.5 nm at 5.5 molar equivalents of ligand). There is a
clear emergence of a new peak at 263 nm (negative band), which intensifies as more ligand stock
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is added to the G-quadruplex solution. This observation suggested a ligand-induced transition
from the hybrid conformation to the antiparallel conformation in solution. As a representative
example, an isoelliptic point at 273 nm when titrating a ligand (11 or 13) to G1 was observed,
showing the clear transition to the antiparallel conformation117. In addition, titrating the hybrid
conformation G-quadruplex (G1) with 11 or 13, the intensity of the peak at ~293 nm increased
as a function of increasing ligand concentrations in solution, signifying the conformation
transition to the antiparallel conformation (Figure 4.9a and 4.9c). It is known that a concomitant
increase in the peak at 295 nm (+) with a blue shift at this wavelength and an increase in the peak
at 265 (-) are a signature feature of the antiparallel conformation, resulting from the syn-anti and
anti-syn base steps186. The change in conformation of hybrid htelo (G1) to antiparallel
conformation (G2) has also been observed with other ligands such as 1,10-phenanthroline
scaffold214,221, natural product Telomestatin222, metal porphyrins117 and bis quinolinium
derivative of pyridine221.
Previous studies suggested that the G1 sequence in K+ can form an ensemble of different
conformations in rapid equilibrium, with the hybrid conformation being the most stable62,223.
Therefore, the CD spectrum of a hybrid G-quadruplex could be the weighted average spectrum
of all conformers present in solution. The shoulder peak at 270 nm results from a minor 2-tetrad
antiparallel G-quadruplex136, in which guanines stack in exclusively alternating orientations and
a triplet of guanines stacks on one terminal G-tetrad136,223. Two-tetrad G-quadruplex also called
hybrid-3 is well characterized and is found to exist in equilibrium with hybrid conformations in
the solution223,224. The presence of 5’-flanking sequences is required for its stabilization in
solution223. The disappearance of the shoulder peak at 270 nm upon addition of 11 or 13 (Figure
4.9b and 4.9d) indicates the interaction of the ligand with this 2-tetrad G-quadruplex. This

183
disappearance was observed at a low ligand concentration (0.5 equivalent of Compound 11),
suggesting that the percentage of this 2-tetrad G-quadruplex in solution is small. A previous
study reported a less than 10% contribution226 of the 2-tetrad G-quadruplex to the CD spectrum
of the hybrid G-quadruplex, which is consistent with our result. The disappearance of the peak
at 270 nm also suggests that 11 or 13 could stack on top of the end G-tetrad in the 2-tetrad Gquadruplex and consequently disrupt the stacking of the guanine triplet at this location. The
ligand ability to induce the hybrid to antiparallel conformational change is weaker for 2-Clipphen (without any side chains) because higher ligand concentrations are needed. 2-Clip-phen
derivatives with an amino side chain can bind to antiparallel G-quadruplexes more tightly than 2Clip-phen, facilitates the transformation. At this point, it is inconclusive whether the hybrid Gquadruplex transforms into the 3-tetrad or 2-tetrad antiparallel G-quadruplex or both in solution.
More characterization will be discussed in the later section when we discuss the results of ESI
mass spectrometry.
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Figure 4.9. CD titrations of compound 11 with 13 to G1 in 150 mM KCl. a) Ligand 11 to G1.
b) Disappearance of shoulder peak at 270 nm with 0.5 equivalent of 11 in solution. c) Ligand 13
to G1. d) Disappearance of shoulder peak at 270 nm at 0.5 equivalent of 13 in solution.

By contrast, the addition of 2-Clip-phen derivatives to the c-MYC parallel G-quadruplex
did not show any conformational changes even in the presence of more than 5.5 equivalents of
ligands (Figure 4.10). This G-quadruplex is very stable, so the transformation from parallel to
antiparallel could be thermodynamically unfavorable. The weak binding of 2-Clip-phen
derivatives cannot promote the transformation as well.
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Figure 4.10. c-MYC G-quadruplex (black line) with 5.5 equivalents of 2-Clip-phen derivatives.

4.3.5. 2-Clip-phen Derivatives Can Even Induce Antiparallel G-quadruplex Formation in
the Salt (K+) Free Conditions
The ability of the ligands to induce the G-quadruplex formation from random coils in a
salt-deficient condition was studied. Compound 11 and 13 were chosen as a representative
example. Monovalent alkali metal ions like Na+ and K+ are necessary to stabilize G-quadruplex
structures by sitting in/near the center cavity of G-tetrads and coordinating with O6 of guanines.
The energy of this coordination almost entirely drives the folding of G-quadruplex with little or
no contribution from other weak interactions225. The ligands were analyzed for their ability to
induce the folding of G-quadruplex DNA from random coils in the absence of K+/Na+. The htelo
DNA (10 µM) in 50mM Tris•HCl (K+ free buffer) was heated to 90oC for 5 mins and then
rapidly cooled in ice water to ensure the random coil of the DNA, characterized by the positive
maximum at 255 nm and negative maximum ~240 nm (red line in figure 4.11). The addition of
0.5 equivalent of 11 and 13 followed by 5 min equilibrium time leads to induction of antiparallel
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G-quadruplex characterized by the appearance of peak (positive) at 295 nm along with the peak
(negative) at 265 nm. The addition of stoichiometric amounts of the ligand leads to further
amplification of the peaks at 295 nm and 265 nm. The transition from random coils to folded Gquadruplex DNA is fast and takes only a few mins. The presence of the isoelliptic point at 272
nm suggests a clean transition to the antiparallel G-quadruplex upon the addition of 11. A
similar but much weaker effect was reported by Balasubramanian group117 on a
tetramethylpyridiniumporphyrazines class of G-quadruplex ligands,
To determine the effect of the side chain in 11 and 13, the ability of the 2-Clip-phen for
the induction of G-quadruplex from random coils was analyzed (Figure 4.12).

Figure 4.11. CD spectrum of non-annealed 10µM htelo DNA in a K+ /Na+ free Tris.HCl buffer,
pH 7.4 (black) and in the increasing stoichiometric amounts of ligands a) 11 and (b) 13.

The comparable CD spectrum of 2-Clip-phen was weaker at all the concentrations as
seen from the intensity of the peak at 295 nm (due to antiparallel G-quadruplex) and the peak at
255 nm (due to random coil), which is due to the antiparallel G-quadruplex and random coils of
DNA, respectively. The peak at 255 nm at 10 equivalents of 2-Clip-phen has relatively the same
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amplitude as peak at 295 nm, signifying much weaker influence of 2-Clip-phen scaffold alone on
the induction of G-quadruplex from random coil.
Compound 11 and 13 were able to induce the formation of G-quadruplex from random
coils even at a very low ligand to DNA molar ratio (0.5). There is not much change in intensity
at 295 nm when th ligand to DNA molar ratio is over 6, as shown in figure 4.9. All the 2-Clipphen derivatives were tested for their ability to induce G-quadruplex formation in K+/Na+ free
buffer at both 0.5 and 6 molar equivalents for comparison (Figure 4.13a and Figure 4.13b). It is
evident that 11 and 13 are the most potent ligands based on the intensity changes of peaks at 295
nm at both 0.5 and 6 molar equivalents of ligand concentrations. This data supports the thermal
denaturation studies.

Figure 4.12. CD spectrum of random coil in a K+ free buffer (black). The addition of aliquots of
2-Clip-phen to the solution lead to the appearance of the peaks at 295 nm (+ ve), 260 nm (- ve)
with concomitant decrease in intensity at 255 nm. There is no significant increase in the
amplitude of the peak at 295 nm after addition of 6 molar equivalents of 2-Clip-phen.
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Figure 4.13. CD spectrum of the random coil in a K+ free buffer (black). a) Addition of the 0.5
molar equivalents of 2-Clip-phen derivatives lead to appearance of peaks at 295 nm (+ve), 260
nm (-ve) with concomitant decrease in intensity at 255 nm. b) CD spectra of the mixture
solutions with 6 molar equivalents of ligands.

The G-quadruplex (the G1 sequence) induced by both 11 and 13 in a salt-free condition
are stable, which can be readily observed by thermal denaturation. The melting temperature (Tm)
of the induced G-quadruplex in the presence of both 11 and 13 (a 4:1 ligand to DNA ratio) is 60
o

C (Figure 4.14). By contrast, without 11 or 13, this sequence is random coils in solution. No

melting transitions were observed.
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Figure 4.14. CD thermal denaturation of induced G-quadruplex.

4.3.6. Compound 11 Binds the Antiparallel Htelo G-quadruplex With 2:1 Binding
Stoichiometry
The changes in ellipticity in CD spectrum were plotted against the ligand/DNA ratio226.
As shown in the previous section, 11 can induce the formation of the antiparallel G-quadruplex
in the absence of salts but has a little effect on the antiparallel G-quadruplex in 150 mM NaCl.
Therefore, the CD spectra for the induction of G-quadruplex from random coils in a salt-free
buffer and in 150 mM KCl were used to investigate the binding stoichiometry. The ellipticity at
292 nm was plotted against the ligand to DNA molar ratios. The graphs are shown in figure
4.15. The intersection point in the graphs corresponds to an approximately 2:1 ligand to DNA
binding ratio, suggesting that two ligand molecules bind to one G-quadruplex molecule. UV/Vis
titrations were not used for this study because the ligands have a UV λmax at 270 nm, which
interferes with the absorption of DNA in the same region.
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Figure 4.15. CD Job plot of 11 against G1 random coil in 50mM Tris.HCl buffer, pH7.4 (left)
and against folded G1 in 150 mM KCl and 40 mM LiCaco buffer (right).

4.3.7. 2-Clip-phen Derivatives Induced a Two-tetrad G-quadruplex Conformation in
Solution
The binding stoichiometry of the ligands to DNA and the nature of bound complexes
were further investigated with electrospray ionization (ESI) mass spectrometry. As explained in
Chapter 3, the number of ammonium ions complexed with a G-quadruplex DNA provides the
nature of the G-quadruplex under study. If the G-quadruplex complex contains only one NH4+, it
is a two-tetrad structure because two G-tetrads can only sandwich one NH4+ ion. If the Gquadruplex complex contains two NH4+ ions, it is composed of three G-tetrads. Previous CD
studies suggested that 2-Clip-phen derivatives can induce the transformation of G1 (hybrid) into
antiparallel G-quadruplex(es) although the identity of the antiparallel G-quadruplex (2-tetrad or
3-tetrad) is uncertain.
In the study, compounds 11 and 13 were analyzed using an ESI-LTQ mass spectrometer
for their binding stoichiometry and relative binding affinity for G-quadruplex DNA. A solution
of G-quadruplex sequence (Gseq) annealed in 150 mM NH4+ was used as a control (G1) (Figure
4.16a). The ion at m/z 1460.36 corresponds to the G1 [Gseq + 2NH4+ - 7H+]5- anion.
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The inclusion of two NH4+ ions suggests the formation of a 3-tetrad G-quadruplex (G1) in
solution. Previous CD result shows this sequence folds into a hybrid G-quadruplex in NH4+,
which is preserved in the gas phase227. The addition of 4 equivalents of ligand 11 to the Gquadruplex solution leads to the complexation of nearly all the G-quadruplex in solution. Only a
small peak representing the free G1 was observed (Figure 4.16a and b). Two new ion peaks at
m/z 1432.64 and 1719.18 emerge, representing the [Gseq + NH4++DMF + 2x(11))]6- and [Gseq +
NH4++ DMF + 2x(11)]5- ions, respectively, suggesting the formation of a 2:1 ligand to DNA
complex with only one ammonium ion associated with the complex ion peaks. It shows that the
G-quadruplex folds into a two-tetrad conformation (Q1) as only one NH4+ ion is associated with
the ligand-DNA complex. We also observed the peaks at m/z 1435.91 and 1723.36, [Gseq +
2NH4++DMF + 2x(11))]6- and [Gseq + 2NH4+ + DMF + 2x(11))]5- respectively which showed the
inclusion of two NH4+ ions in the complex ion peak along with two molecules of 11 in the
complex ion peak (Figure 4.16b). Q1 and G1 were calculated according to the formula, Q1 or
G1 = [(Gseq) + (NH4+)y - x(H+)]-x+y, where Gseq is a unfolded DNA sequence. The ligands do not
contribute to the overall charge of the complex ion peak in our case.
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a

b

Figure 4.16. Mass spectrometry analysis of the G-quadruplex. a) G1 without ligand. b) Mixture
solution of G1 and 11 ([G1]:[11] = 1:4). The peak with maximum intensity is set as the base
peak (100%).

To confirm the result is not due to the experimental condition, an ESI experiment on the
complexation of a phenanthroline-neomycin conjugate (Chapter 3, 7b) with G1 was carried out.
As expected, this ligand forms a 1:1 ligand and G1 complex with the inclusion of two NH4+ ions,
indicating the presence of a 3-tetrad G-quadruplex (Figure 4.17a). It is noteworthy that our
previous studies (Chapter 3) showed no change in conformation of the hybrid G-quadruplex
occur on the addition of 7b to G1227.
The relative intensities of Q1 and G1 in the mass spectra changed when we prolonged the
incubation time (from 30 minutes to 3 days) of the ligand (11 or 13) with G1. As shown in
figure 4.15b and 4.16b, after a 3-day incubation time, the intensities of complex ions
representing 2-tetrad G-quadruplex (Q1) increased, suggesting that 2-Clip-phen derivatives
could bind more preferentially to the 2-tetrad antiparallel G-quadruplex over the 3-tetrad Gquadruplex (antiparallel or hybrid).
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Overall, both 11 and 13 binds with the 2-tetrad and 3-tetrad G-quadruplexes in a 2:1 ligand to
DNA stoichiometry. The mass spectral data is consistent with the results of CD studies.

a

b

Figure 4.17. Mass spectrum of the mixture solution of a) G1 and 7b ([G1]:[7b] =1:2) and b) G1
and 13 ([G1]:[13] =1:4) mixture solution on the right.

4.3.8. Docking Studies
The binding interactions of 2-Clip-phen derivatives with three G-quadruplexes were
further studied with docking simulations. Compound 11 was chosen as a representative ligand.
The Grid score and energy attribution of compound 11 with antiparallel, parallel, and hybrid Gquadruplexes are shown in Table 4.5. Relative binding interactions involved in stabilization of
the ligand are primarily non-polar in nature due to the large contribution of the van der Waals
interactions to the binding (Table 4.5).
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Table 4.4
DOCK 6 Grid Score and Energy Attribution of Ligand 11 With Three Different G-quadruplexes.
G-quadruplex conformation
Receptor
Antiparallel Parallel
Hybrid
van der Waals -50.3
-58.0
-48.9
Electrostatic
-12.1
-10.0
-15.2

Ligand 11 binds with a relatively higher electrostatic contribution to hybrid G-quadruplex
(Figure 4.18a). The two nitrogen atoms at the 1 and 10 positions of phenanthroline are probably
interacting with the N-H of the guanines (G10, G18 in the top and G11, G17 in the middle tetrad)
in the grooves. The amino-containing side chains point up, making no bonding contribution in
this state. For the antiparallel G-quadruplex (Figure 4.18b), ligand 11 binds with the top Gtetrad through favorable π- π interactions, and One of the phenanthroline rings interacts with the
lateral loop nucleobases with the ligand side chain pointing into the groove. We previously
observed that 2-Clip-phen stabilizes G2 poorly; therefore, the strong polar interactions in the
groove between the basic nitrogen of the side chain are a plausible explanation for the effect of
side chains on antiparallel G-quadruplex (G2) stabilization. The docking results indicate more
contacting points of 11 with antiparallel G-quadruplex (G2), clearly showing that the binding of
11 to antiparallel G-quadruplex is better than that to hybrid G-quadruplex. This result is
consistent with our CD and thermal denaturation studies. Parallel c-MYC G-quadruplex used in
the study has propeller loops, which might be hampering the binding of the side chain in the
groove. One of the phenanthroline rings and the side chain interact with flanking sequences
(Figure 4.18c). The binding to the c-MYC G-quadruplex is governed mainly by the van der
Waals interactions means that the side chain is not able to make favorable electrostatic
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interactions. It is necessary to point out that the docking studies on the 2-tetrad G-quadruplex
cannot be carried out at this moment due to the lack of reliable PDB structures.

Figure 4.18. Docked structure of ligand 11 to different G-quadruplex conformations. The Gquadruplex is represented as surface colored by electrostatic potential and ligand 11 is
represented as a ball and stick. a) Ligand interactions with the hybrid conformation, the two
rings are involved in stacking and groove interactions. b) Ligand 11 interacting with antiparallel
conformation and c) 11 is interacting with the parallel G-quadruplex preferably through π-π
interactions.
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4.4. Conclusion
The 2-Clip-phen derivatives show a remarkable preference to G-quadruplexes. They can
induce antiparallel G-quadruplex from the random coils in a Na+/K+ free buffer and stabilize it to
a great extent (Tm = 60 °C). In addition, the ligands can induce the formation of antiparallel
conformation from the already folded hybrid conformation under the conditions suitable for the
formation of hybrid conformation. A plausible mode of action is shown in figure 4.19. The 2Clip-phen derivatives could bind to both 2-tetrad and 3-tetrad antiparallel G-quadruplexes. The
binding of a 2-Clip-phen derivative to the 2-tetrad G-quadruplex disrupts its guanine triplet
capping. When binding to the antiparallel G-quadruplex conformation, two phenanthroline
moieties of 2-Clip-phen derivatives can interact individually with the loops nucleotides as
observed in the docking study. The inability to be in a plane also greatly affects its ability to
interact with c-MYC parallel G-quadruplex. The additional specificity could result from steric
interactions between the side chain and edge reversal loop in the groove, which forces the side
chain interacts with the flanking sequence rather than being in the groove (Figure 4.18c).
The discovery of 2-Clip-phen preferentially binding to antiparallel G-quadruplex DNA is
encouraging. 2-Clip-phen derivatives are capable of coordinating with Cu2+, which makes a
fixed planar aromatic surface. The resulting metal complexes should have even better Gquadruplex binding affinities. In addition, The Cu2+-2-Clip-phen complexes have the ability to
cleave DNA; therefore, our 2-Clip-phen derivatives could be used as G-quadruplex specific
cleaving agents. The evaluation will be reported in due course.

197

Figure 4.19. Proposed model to explain the different extent of thermal stabilization observed in
NaCl and KCl salt solutions.
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APPENDIX C: CD MELTING AND CD TITRATIONS SPECTRA OF G1 AND G2 WITH
2-CLIP-PHEN DERIVATIVES

Figure C.1. CD Titrations curves for G1 with 2-Clip-phen derivatives.
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Figure C.2. CD Titrations curves for G2 with 2-Clip-phen derivatives (10-15).

285

Figure C.3. CD Titrations curves for G2 with 2-Clip-phen derivatives (16-18).

286

Figure C.4. CD melting curves of G1 (top-left), (G2) (top-right) and (G3) (bottom right) with 2Clip-phen derivatives. The temperature at 0.5 folded fraction is called the melting temperature.

287

Figure C.5. Stabilizing effect of the compound 13 on the G1 (left) and (G2) under different salt
conditions. The two transitions are clearly visible at low salt concentration (25 mM, biphasic
curves).

Figure C.6. Stabilizing effect of the compound 11 on the G1 (left) and (G2) under different salt
conditions. The two transitions are clearly visible at low salt concentration (25 mM, biphasic
curves).
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Figure C.7. Effect of KCl and NaCl concentration on the melting temperature (Tm) of the G1
(left) and G2 (right) respectively.
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APPENDIX D: MIC DETERMINATION OF NEOMYCIN AND NUCEOBASE-NEOMYCIN
CONJUGATES
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Figure D.1. MIC determination: The OD600 values for each bacterial strain in the presence of
neomycin and compound 6a-6d at various concentrations.

